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Preface 
In the last century, the strong demand for new compounds pushed organic chemists to 
develop new synthetic strategies for the easy and fast generation of compounds libraries. 
In particular, in the field of diversity oriented synthesis (DOS), convergent synthetic 
methods, such as the multicomponent reactions (MCRs), have been considered powerful 
strategies toward this aim. More recently, the pursuit of highly functionalized MCR 
products as biological probes, drug candidates and synthetic intermediates has resulted in 
an intensified effort to find catalysts for asymmetric MCR transformations. Because of 
various reasons, including that of air and moisture tolerance, chiral organocatalysts are 
emerging as efficient and environmentally friendly synthetic alternatives to chiral metal 
complexes. 
In this context, my research was aimed to the synthesis of oxindole-based libraries, 
exploiting protocols at the cutting edge of synthetic chemistry, such as MCRs and 
organocatalysis. 
2-Oxindoles, especially those 3,3-disubstituted or spiro-fused to other cyclic frameworks, 
continue to be recognized as valuable compounds for drug discovery since they are 
present in a lot of natural compounds and medicinal drugs.  
The employment of auxiliary chiral components or, alternatively, organocatalysis, 
allowed me to address the hot issue of asymmetry, achieving the generation of various 
families of 3,3-disubstituted and spiro-oxindoles. 
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I. Introduction 
Indoline-2,3-dione, commonly known as isatin, was first discovered by Erdmann
1
 
and Laurent
2
 in the early 19
th
 century as a product arising from the oxidation of 
indigo using a mixture of nitric and chromic acids (Figure 1). The compound was 
considered synthetic for almost 140 years until it was found to be present in 
plants from the Isatis genus and in fruits of the cannon ball tree, Couropita 
guianancis aubl.
3
 More recently, it was found in the secretions of the Bufo frog,
4
 
and isolated as a metabolic derivative of adrenaline in humans.
5
 Currently, isatin 
itself and many substituted isatins are commercially available at easily affordable 
prices. 
Isatin, whose current structure was proposed by Kekulé,
6
 has revealed many 
interesting aspects of organic reactions and mechanisms. It undergoes electrophilic 
aromatic substitution at positions C-5 and C-7 of the phenyl ring, N-substitutions 
with different electrophiles, nucleophilic additions at the C-3 carbonyl group, 
chemoselective reductions, ring-expansions, spiro-annulations and many others. 
The unique potential of indoline-2,3-diones to be used both as an electrophile 
and nucleophile and their easy availability have made them valuable building 
blocks in organic synthesis. 
 
 
Figure 1. Isatin structure and its production from renewable source 
and synthetic production. 
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The most fascinating application of isatins in organic synthesis is undoubtedly due 
to the highly reactive C-3 carbonyl group that is a prostereogenic center as well. 
The reactions of the C-3 carbonyl group of isatins, mostly by nucleophilic 
additions or spiroannulation, transform it into 2-oxindole derivatives. These 
compounds, especially those which are spiro-fused to other cyclic frameworks, 
have drawn tremendous interest of researchers in the area of synthetic organic 
chemistry and medicinal chemistry worldwide. In fact, they occur in many 
natural products such as spirotryprostatins, horsfiline, rhynchophylline, and 
elacomine, etc. and have been reported to have various types of bioactivity,
7
 
such as progesterone receptor modulation,
8
 anti-HIV,
9
 anticancer,
10
 
antitubercular,
11
 antimalarial,
12
 and MDM2 inhibition (Figure 2).
13 
The architecture of a spiro-cyclic framework has always been a challenging 
endeavour for synthetic organic chemists because it often requires synthetic 
design based on specific strategies. Due to steric strain, the presence of a spiro 
carbon atom induces easy rearrangements that can lead to different cyclic 
compounds. 
Under such a complex scenario, isatins constitute perhaps the single class of 
heterocyclic compounds which has been employed so extensively, either directly 
or via 3- substituted 2-oxindoles, in design and synthesis of spiro-cyclic 
frameworks, both carbocyclic and heterocyclic. 
Although the isatins were well-known by the middle of the 19
th
 century and their 
chemistry investigated extensively for over 100 years thereafter, only a few 
convincing reports were available on the formation of spiro-cyclic compounds 
from isatins until the middle of the 20th century. 
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Figure 2. Selected example of natural products and bioactive compounds containing 3,3-
disubstituted or spiro-fused oxindole moiety. 
 
The investigations, in fact, were not focused on the synthesis of spiro-cyclic 
frameworks, because of little or no knowledge about the significance of 
compounds with such frameworks.  
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The research on isatin-based spiro-cycles received increasingly more attention 
during the last quarter of the 20th century when investigations on 
phytochemistry of some bioactive natural resources led to isolation and structure 
elucidation of some natural products that contained this motif. The landmark 
achievements in the area of phytochemistry, combined with discovery of 
potential anticancer activity in some synthetic analogues of horsfiline, gave 
impetus to studies aimed toward the synthesis of spiro-cyclic oxindoles 
employing isatins as starting materials. 
Most of these studies were, however, focused on development of appropriate 
methodologies for the synthesis of natural products and only in few cases non- 
natural spirocyclic compounds were faced. With further development in the area 
of medicinal chemistry and with the achievement that only a particular isomer 
was bioactive in many cases, researchers were encouraged to develop 
stereoselective methodologies. Furthermore, the biological evaluation of 
structure’s analogues and synthetic precursors of such biological active 
compounds, sometimes found even more active, required an extensive 
investigation of new synthetic methodologies, also favoring the development of 
asymmetric versions.  
With the strong demand for new compounds, it appeared obvious that a 
traditional step-by-step synthesis was not sufficient to provide a large number of 
compounds in a brief period. For this reason, in the early 1990s, with the advent 
of combinatorial chemistry and diversity oriented synthesis (DOS), new 
convergent synthetic strategies have been developed, as the multicomponent 
reactions (MCRs).
14
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MCRs use three or more reactants in one vessel under a set of fixed conditions, 
to provide products that contain a structure or substructure of all reactants. With 
respect to a traditional linear synthesis, these reactions offer different advantages 
as a higher overall yield and atom-economy, a reduction of synthetic and 
purification steps allowing to obtain the desired product in shorter times (Figure 
3). This type of reactions is uniquely powerful in accessing products of high 
complexity and diversity from simple starting materials with easy operation. 
These important advantages made it an important tool in organic chemistry for 
the synthesis of functional molecular libraries
15
 and natural products'
16
 families. 
The use of MCRs for the preparation of diverse libraries carries the potential 
liability of having one core structure that is over-represented within a collection. 
The diversity of a library of MCR products is, on some level, limited by the 
 
 
Figure 3. Comparison between a stepwise linear synthesis and multicomponent 
reaction (Ref. 14a). 
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Figure 4. Unification of MCRs. Schematic representation of unifying two MCRs via (a) 
intermediate generation for a successive MCR, or (b) combination of MCRs with 
orthogonal functionalities (Ref. 14a). 
 
structure of the appendages that emanate from the components. This liability is 
addressed by new variants of traditional MCRs that result in fundamentally 
different structures. Furthermore, the use of MCRs as a starting point for 
subsequent reactions that define the core connectivity of the components is a 
powerful approach to achieving further efficiency and diversity (Figure 4). 
The pursuit of MCR products as biological probes, drug candidates and as 
synthetic intermediates has resulted in an intensified effort to find catalysts for 
MCRs. MCRs are striking in their ability to resist catalysis, as exemplified by the 
fact that more than a century elapsed between the discovery of the Hantzsch
17
 
and Biginelli
18
 MCRs and their first catalysed versions.
19,20
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If the catalysed MCRs is an underdeveloped branch in catalysis field, asymmetric 
MCRs are even more rare,
21
 and one of the reasons is the low compatibility of 
well-known metal-based catalysts with typical MCR experimental conditions. 
MCRs often proceed via imine intermediates, formed from condensation of 
carbonyls and amines. This results in the concomitant generation of water that 
deactivates some Lewis acid catalysts and ends the reaction prematurely. Thus, to 
catalyse a MCR, catalysts are mostly required to be water-moisture compatible. 
With the advent of organocatalysis in the last decade, an attractive tool was 
introduced in the organic chemistry’s field.22 The term ‘organocatalysis’ was 
coined in 2000 by MacMillan
23 
and it is defined as the employment of organic 
molecules with low molecular weight as catalysts in organic reactions. In the case 
of asymmetric transformations, chiral organocatalysts usually activate the 
electrophile or the nucleophile (or both in the case of bifunctional catalysis) 
creating an asymmetric environment that drives the stereochemistry of the 
product (Figure 5). 
This type of catalysis offers multiple advantages compared with metal-based and 
enzymatic catalysis: in general, organocatalysts are non-toxic and robust 
compounds, and a large number of them are commercially available and/or 
easily synthesized. Moreover, they are usually stable under aerobic conditions, 
and reactions do not require extremely dry conditions, and thus, inert-equipment 
such as vacuum lines or gloveboxes are not necessary. Frequently, the reactions 
are conducted under mild conditions and in high concentrations avoiding the use 
of large amounts of solvents and minimizing waste. 
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Figure 5. Selected examples of principal classes of organocatalysts. 
 
Furthermore, organocatalysts are tolerant of numerous functional groups and 
avoid time-consuming and protecting-group manipulations. 
Considering all these advantages, the organocatalysis field has grown 
exponentially from a handful of publications in 2001 to more than 2500 in 2015, 
and in parallel, the number of citations has also increased up. 
In particular, during the ‘‘golden-age’’24 and the ‘‘gold-rush’’25 of organocatalysis, 
many researchers from academia and chemical industry were involved in this 
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field, with most of the efforts focused on the development of new reactivities 
and asymmetric methodologies. 
Currently, asymmetric organocatalysis is recognized as an independent synthetic 
toolbox besides asymmetric metal-based catalysis and bio-enzymatic catalysis for 
the synthesis of chiral organic molecules, and its application to MCRs has 
emerged quite recently as a robust synthetic tool. Major examples of these 
combined approaches were reported by Terada
26 
and
 
Akiyama
27
 that established 
chiral Brønsted acid BINOL-based phosphoric acid as a privileged class of 
organocatalysts for asymmetric MCRs to access optically pure nitrogenous 
heterocycles in structural diversity. 
Concluding with an overview on last years' literature, oxindoles have been 
increasingly investigated as privileged targets in medicinal chemistry (Graph 1a). 
Instead, MCRs can be considered a sort of ‘evergreen’ field since from the early 
1990s. However, the number of publications on this topic are in continuous 
increment, demonstrating the great interest for this synthetic tool capable of 
creating great diversity in the chemical space (Graph 1b). 
Since 2000, organocatalysis became an important emerging field (Graph 1c). 
Organocatalysts reported in the last decade fully demonstrate their suitability for 
the replacement of more classical metal-based catalysts in many different 
reactions. 
As a natural consequence of above considerations, the idea of combining 
organocatalysis and MCRs appears as a valuable strategy for the efficient 
preparation of oxindole-based libraries, sharing isatin-derived ketimines as 
common starting materials. 
 
Introduction 
- 10 - 
 
 
 
 
 
 
Graph 1. Number of publications per year containing the term (a) ‘oxindole’ in orange, (b) 
‘multicomponent’ in blue, (c) ‘organocatalysis’ in green searched on SciFinder®.28 
 
c) Organocatalysis 
b) Multicomponent 
a) Oxindole 
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II. 3-Aminooxindole Butenolides: 
Vinylogous Mannich-type Reactions 
 
A family of chiral quaternary 3-aminooxindole butenolides have been 
synthesized, by BINOL-derived phosphoric acid-catalyzed addition of 
trimethylsiloxyfuran to isatin-derived ketimines. Such vinylogous Mannich-type 
reaction was found to produce the diastereoisomeric butenolides in good yields 
and in most cases high enantiomeric excesses. The configurational assignment of 
the obtained products was safely performed by chemical correlation. A 
computational study of the transition state allowed to rationalize the obtained 
stereochemical outcome, highlighting the possible binding modes of the catalyst-
imine-nucleophile transition complex.  
 
 
 
 
 
 
 
 
 
 
 
 
Published in Org. Biomol. Chem. 2016, 14, 7768-7776. 
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II.1 Introduction 
Optically active -amino--unsaturated carbonyl compounds, particularly those 
bearing the -butenolide skeleton, are receiving considerable attention due to 
their broad application in the synthesis of biologically active compounds. The 
butenolide ring is in fact one of the most ubiquitous structures found in natural 
products and its incorporation into more complex heterocyclic architectures has 
continuously attracted the attention from a pharmaceutical point of view (Figure 
1).
1
  
The vinylogous Mannich-type reaction of imines with a dienolate equivalent, 
such as trimethylsiloxyfuran (TMSOF), is a useful mean to prepare butenolide 
derivatives bearing an amine functionality.
2
 Metal complexes and organocatalysts 
efficiently promote asymmetric vinylogous Mannich (AVM) reactions of 
aldimines, affording optically active -amino--unsaturated carbonyl 
compounds in high yields and enantiomeric excesses. With regard to catalytic 
methods, a milestone was placed in 2006 by Hoveyda,
3,4
 who reported the first 
highly diastereo- and enantioselective protocol for such reaction. The AVM was 
catalyzed by a silver salt and an easily accessible chiral phosphine, and only 
 
 
Figure 1. Examples of products containing the butenolide moiety. 
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aromatic aldimines were employed. More recently, a new Ag(I)-monophosphine 
complex was developed by Xu, displaying wide aldimine versatility, excellent 
yield and diastereoselectivity, and moderate enantioselectivity.
5
 Among 
organocatalytic, metal-free methods, an iodine-substituted chiral phosphoric acid 
was demonstrated by Akiyama to efficiently catalysed the AVM of aliphatic as 
well as aromatic aldimines.
6
 
Application of the vinylogous Mannich-type reaction to ketimines is more 
challenging, due to the lower reactivity of ketimines compared with aldimines 
and to the steric challenge inherent in the stereocontrolled formation of a 
quaternary stereocenter consecutive with a bulky tertiary one. To date, there are 
only few reports on the AVM of TMSOF with ketimines, to give chiral -amino-
-unsaturated carbonyl compounds having a quaternary carbon center. Besides 
the successful Ag-catalyzed process, applied by Hoveyda
7
 also to -ketimine 
esters, relevant is the contribution from Nakamura,
8
 who reported a Cinchona 
alkaloid amide/copper (II) catalyzed diastereo- and enantioselective Mannich 
reaction of ketimines. Quite recently, the closely related Cinchona alkaloid 
amide/zinc (II) system was also developed by the same author,
9
 and applied to 
the similar Mannich reaction employing -butenolide instead of TMSOF as 
nucleophile. Given the relevance of chiral -amino--unsaturated carbonyl 
compounds having a quaternary carbon center, the development of novel 
stereoselective methods for the construction of this attractive framework in an 
asymmetric manner is highly desirable. 
As part of our interest in the asymmetric synthesis of 3,3-disubstituted oxindole 
derivatives and related spiro-compounds,
10
 we recently turned our attention to 
BINOL-derived phosphoric acids that recently emerged as a new class of  
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Scheme 1. Previous works of AVM on isatin-derived imines. 
 
environmentally benign chiral catalysts for different enantioselective reactions.
11
 
Herein, our ongoing interest was extended to the asymmetric preparation of 
quaternary 3-aminooxindole butenolides, which can be considered an intriguing 
combination of pharmacologically interesting -butenolide and oxindole motifs. 
A racemic preparation of such compounds in excellent yields and 
diastereoselectivities was realized by Deng,
12
 employing AgOAc as the catalyst. A 
highly practical, sulfinyl amine chiral auxiliary-based approach was also recently 
developed,
13
 based on a simple Lewis acid mediated diastereoselective vinylogous 
Mannich process (Scheme 1). 
At the best of our knowledge, no organocatalytic methods employing TMSOF 
have been reported for the preparation of such scaffolds. Only a related AVM 
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was recently realized, based on a bifunctional quinidine-derived catalyst and 3,4-
dichlorofuran-2(5H)-one as the nucleophile.
14
 
Herein, we report the BINOL-derived phosphoric acid-catalyzed asymmetric 
synthesis of quaternary 3-aminooxindole butenolides via a vinylogous Mannich-
type reaction, consisting in the enantioselective addition of TMSOF to isatin-
derived ketimines. 
 
II.2 Results and Discussion 
We began our investigation using N-diphenylmethyl ketimine II∙1a, obtained as 
the only product in the reaction between C,C-diphenyl-methanamine and N-
benzyl-isatin (Scheme 2), and two well-known isatin-derived ketimines, II∙2 and 
II∙3. 
Reaction of II∙1a, II∙2 and II∙3 with TMSOF, initially carried out at room 
temperature, using THF as the solvent and 10 mol % of catalyst II∙4a, proved to 
be completely ineffective. Reasoning that the addition of a protic co-solvent to 
the reaction mixture could be essential for the onset of the catalytic cycle, we 
repeated the reaction by adding MeOH (1% vol). In such conditions, all three 
ketimines proved to be reactive, affording the corresponding 3-aminooxindole 
butenolides with variable yields, up to 84% (Table 1, entries 1-3). 
 
 
Scheme 2. Synthesis of isatin-based N-benzydryl ketimines II∙1. 
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Table 1. Optimization of the asymmetric AVM reaction.a 
 
 
 
a Reaction conditions: ketimine II∙1a-3 (0.12 mmol), TMSOF (0.14 mmol) in solvent (1.2 
mL); MeOH was used as additive (1% vol). b Isolated yield. c II·5a:II·5b determined by 1H 
NMR from integration of olefinic protons. d Determined by chiral HPLC analysis. e Ketimine 
II·2 was used. f Ketimine II·3 was used. g Toluene was used as solvent. h Dichloromethane 
was used as solvent. nr = no reaction.  
Entry Catalyst T [°C], time 
Yield 
(%)
b
 
dr
c
 
ee (%)
d
 
II∙5a  II∙5b 
1 II∙4a rt, 10min 84 75:25 0 25 
2
e
 II∙4a rt, 20min 60 61:39 2 10 
3
f
 II∙4a rt, 8h 15 51:49 5 7 
4 II∙4a 0 °C, 40min 87 69:31 1 31 
5 II∙4a -20 °C, 1h 85 57:43 47 69 
6 II∙4a -40 °C, 7h 80 52:48 90 92 
7 II∙4a -78 °C, 48h 68 51:49 90 92 
8
g
 II∙4a -40 °C, 48h 35 53:47 89 93 
9
h
 II∙4a -40 °C, 48h 27 55:45 90 93 
10 II∙4b -40 °C  48h 50 57:43 57 66 
11 II∙4c -40 °C, 48h nr - - - 
12 II∙4d -40 °C, 48h nr - - - 
13 II∙4e -40 °C, 48h nr - - - 
14 II∙4f -40 °C, 48h 41 50:50 67 78 
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We assumed that probably the protic co-solvent suppresses the undesired 
retroaddition reaction by rapidly converting the silylated butenolide ring into the 
final product, while also enabling the isolation of the adduct formed under 
conditions of kinetic control.
15
 In addition, we can also suppose that, in absence 
of a protic source, the catalytic BINOL-derived phosphoric acid might be 
converted to the corresponding O-silylated BINOL-phosphate, evidently not able 
to promote the AVM reaction as the phosphoric acid form.
16 
Ketimine II∙1a, performing best, was then chosen for subsequent conditions and 
catalyst screening, also in the light of 
the potential greater versatility of the obtained products, due to the easy 
removal of the benzhydryl protective group. The temperature proved to be a 
key parameter for the asymmetric induction of this reaction. At room 
temperature (entry 1), the reaction proceeds to give II∙5 as a 75:25 mixture of the 
II∙5a and II∙5b diastereoisomers, each of which with a negligible enantiomeric 
excess. Upon lowering the reaction temperature (entries 4-7), we noticed a 
substantial maintenance of the obtained yields, with a collapse of 
diastereoselectivity (Figure 2) and an overall improvement of the 
enantioselectivity for both II∙5a and II∙5b diastereoisomers. In particular, carrying 
out the reaction at -40 °C, both diastereoisomers could be recovered in almost 
equal quantities (80% overall yield, II∙5a: II∙5b 52:48), showing excellent 
enantioselectivities (ee II∙5a 90%, ee II∙5b 92%). 
Changing the solvent to toluene (entry 8) or dichloromethane (entry 9) entailed 
a significant negative effect on the chemical conversion, demonstrating that the 
originally chosen THF was the optimal solvent for this reaction. Screening of 
more hindered catalysts II∙4b-e, aimed to evaluate the impact of the 3,3'- 
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Figure 2. 1H NMR spectra (400MHz, CDCl3) of compound II∙5a,b performing the reaction 
at different temperature. 
 
substitution, and of octahydro-BINOL-based II∙4f was performed (entries 10-14). 
Increasing the size of the 3,3'-substitents on the phosphoric acid proved 
detrimental for the chemical conversion, with only catalysts II∙4b and II∙4f able to 
produce product II∙5, with maintenance of the same level of diastereo- and lower 
enantioselectivity with respect to catalyst II∙4a, and in definitely decreased yields. 
After having established II∙4a as the catalyst of choice and to work in THF at -40 
°C as the optimal conditions, the substrate scope of the AVM reaction was 
surveyed, by evaluating differently N-substituted isatins and the presence of 
substituents at 5- or 6-position of the isatin nucleus (Scheme 3). 
In general, all isatins readily undergo this reaction, to afford the desired products 
II∙5-13 in moderate to high yields, with a good degree of enantioselectivity 
(entries 1-5). The presence of a halogen substituent on the oxindole (entries 6-9) 
results in a lower yield and enantiomeric excess, with a slight increase of 
T: -78 °C dr: 51:49 
T: -40 °C dr: 52:48 
T: -20 °C dr: 
57:43 
T: 0 °C dr: 69:31 
T: 20 °C dr: 75:25 
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Scheme 3. Substrate scope of the asymmetric AVM reaction catalysed by II∙4a.a 
 
 
 
a Reaction conditions: ketimine II∙1a-i (0.12 mmol), TMSOF (0.14 mmol), catalyst (R)-II·4a 
(0.012 mmol) in THF (1.2 mL) at -40 °C using MeOH as additive (1% vol).  Isolated yields 
are reported. dr determined by 1H NMR from integration of olefinic protons; for both 
relative and absolute configurational assignment of diastereoisomeric products, see below. 
ee was determined by chiral HPLC analysis. PMB = p-Methoxy benzyl. Trt = trityl. 
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diastereoselectivity. Since diastereoisomers II∙7a and II∙7b (entry 3) proved to be 
readily separable by flash chromatography, we selected them for the 
determination of absolute and relative stereochemistry. However, neither of 
them proved to be suitable for X-ray analysis. Thus, starting from the major II∙7a, 
we performed a chemical correlation based on the literature compound II∙14, as 
depicted in Scheme 4. From NMR and []D comparison of compound II∙15, 
derived from II∙14, and compound II∙15', derived from II∙7a, the (R,R) anti 
configuration could be safely assigned to II∙7a. 
For the configurational assignment of minor diastereoisomer II∙7b, still we relied 
on a chemical correlation, performing on both II∙7a and II∙7b the same reaction 
to give the silyl enol ether derivative II∙16. Since II∙16 was obtained as opposite 
 
Scheme 4. Chemical correlations for the configurational assignment of II∙7a and II∙7b. 
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enantiomer starting from II∙7a and II∙7b, we could assign the (S,R) syn 
configuration to II∙7b. 
In order to propose a possible explanation of the stereochemical outcome, a 
preliminary investigation of the transition state organization was performed by 
means of computational tools. The theoretical study of this reaction is 
complicated by a number of factors, namely, the size of the system, the possible 
approach endo or exo of the nucleophile, with respect to both the re and si face 
of the imine and the several competing H-bonding possibilities in the assembly of 
the transition state. We were aware that also the E/Z geometry of the imine 
might play an important role in the enantioselection. However, since NMR 
analysis of starting imine II∙1c showed the presence of a major isomer (9:1) and 
theoretical DFT calculations indicated the Z-II∙1c imine more stable than the 
corresponding E isomer by 4.38 kcal/mol, we decided to consider only the Z 
geometry in our further studies. 
In accordance with the enantioselectivity of the reaction, in the proposed 
model
17
 the major enantiomer (3R,2’R)-II∙7a is achieved through TS-A, whereas 
TS-C would lead to the diastereoisomeric (3S,2’R)-II∙7b. To support this 
hypothesis, we calculated the energy for TS-C and TS-D at the B3LYP/6-31G(d) 
level.
18
 TS-C resulted to be lower in energy for 0.6 kcal/mol at -40 °C, with 
respect to TS-D, in agreement with the measured 68% ee. In such favored TS-C, 
the 2-hydroxyfuran is coordinated to the catalyst II∙4a through the OH hydrogen 
and it prefers to assume the endo orientation with respect to the imine as the 
third component (the opposite exo orientation is present in TS-D). The same 
considerations apply to TS-A (favored) and TS-B (Figure 3). 
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Figure 3. Possible binding modes of the catalyst II∙4a - 2-hydroxyfuran - imine II∙1c 
transition complex. 
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The orientation of the imine is less significant, probably due to the great steric 
hindrance around both faces of the imine double bond. 
 
II.3 Conclusions 
In summary, an organocatalytic approach for the asymmetric synthesis of 
quaternary 3-aminooxindole butenolides has been developed. The method 
exploits the vinylogous Mannich reaction of TMSOF with various isatin-derived 
benzhydryl-ketimines, affording diastereoisomeric products in good yields and in 
most cases high enantiomeric excesses. 
The obtained products, containing a quaternary stereocenter consecutive with a 
bulky tertiary one, are suitable for further transformations, as demonstrated in 
the performed chemical correlation study. The stereochemical outcome was also 
rationalized by means of a computational study, which allowed to propose the 
most favoured binding modes of reaction components in the transition state. 
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II.4 Experimental section 
All commercial materials (Aldrich, Fluka) were used without further purification. 
All solvents were of reagent grade or HPLC grade. All reactions were carried out 
under a nitrogen atmosphere unless otherwise noted. All reactions were 
monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254; 
spots were visualized with UV light or by treatment with ninhydrin solution in 
ethanol. Products were purified by flash chromatography (FC) on silica gel 60 
(230–400 mesh). 1H NMR spectra and 13C NMR spectra were recorded on 300 
and 400 MHz spectrometers. Chemical shifts are reported in parts per million 
relative to the residual solvent. 
13
C NMR spectra have been recorded using the 
APT pulse sequence. Multiplicities in 
1
H NMR are reported as follows: s = singlet, 
d = doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution MS 
spectra were recorded with a Waters Micromass Q-ToF micro TM mass 
spectrometer, equipped with an ESI source. Chiral HPLC analysis was performed 
on Jasco PU-2080 (UV Detector and binary HPLC pump) at 254 nm. Chiralcel 
ODH and AD columns were purchased from Daicel Chemical Industries®. 
Optical rotator power [α]TD was measured with a Jasco P-1030 polarimeter, 
endowed with a cell of 1 dm pathlength and 1 mL capacity. The light used has a 
wavelength of 589 nm (Sodium D line). All the N-substituted isatins
20
 and 
BINOL-derived phosphoric acids
21
 were synthetized according to reported 
literature. 
 
General procedure A (GP-A) for the synthesis of isatins-derived benzhydryl imines 
II∙1a-i. To a suspension of appropriate substituted isatin (1.5 mmol) in absolute 
EtOH (5 mL), under a nitrogen atmosphere, benzhydryl amine (1.5 mmol) was 
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added in one portion and the mixture was refluxed for 24 hours. The reaction 
was cooled to room temperature and stirred for 2 hours. 
3-(Benzhydrylimino)-1-benzylindolin-2-one (II∙1a). Prepared according to GP-A 
using 1-benzyl isatin. The desired product was collected by filtration; yield: 494 
mg, 82%; yellow foam; 
1
H NMR (300 MHz, CDCl3, 9:1 mixture of imine 
isomers)
 δ 7.87 (s, 0.9H), 7.77 (d, J = 7.5 Hz, 0.9H), 7.61-7.46 (m, 4H), 7.45-
7.14 (m, 12.1H), 7.05 (t, J = 7.5 Hz, 0.9H), 6.98 (t, J = 7.5 Hz, 0.1H), 6.75 (d, J 
= 7.8 Hz, 0.1H), 6.66 (d, J = 7.8 Hz, 0.9H), 6.56 (s, 0.1H), 4.97 (s, 0.2H), 4.89 
(s, 1.8H);
 13
C NMR (75 MHz, CDCl3) δ 158.9, 151.8, 144.6 and 143.0 (1C), 144.2 
(2C), 135.3, 133.3 and 132.7 (1C), 128.9-127.1 (15C), 123.2, 122.9 and 122.5 (1C), 
122.0, 110.3 and 109.3 (1C), 69.9 and 65.5 (1C), 43.9 and 43.5 (1C); HRMS (ESI) 
calcd for C28H22N2NaO
+ 
[MNa]
+
 425.1624, found 425.1632. 
3-(Benzhydrylimino)indolin-2-one (II∙1b). Prepared according to GP-A using 
isatin. The desired product was collected by filtration; yield: 407 mg, 87%; 
yellow foam; 
1
H NMR (300 MHz, CDCl3, 4:1 mixture of imine isomers) δ 8.83 
(m, br, 0.2H), 7.98 (m, br,  0.8H), 7.83-7.69 (m, 2H), 7.52 (d, br, J = 7.8 Hz, 
3.2H), 7.46 (d, br, J = 7.7 Hz, 0.8H), 7.38-7.13 (m, 7H), 7.06 (t, J = 7.5 Hz, 
0.8H), 7.00 (t, J = 7.5 Hz, 0.2H), 6.92 (d, J = 7.6 Hz, 0.2H), 6.78 (d, J = 7.6 
Hz, 0.8H), 6.53 (s, br, 0.2H);
 13
C NMR (75 MHz, CD2Cl2+1%DMSO-d6)
 δ 160.9, 
153.6, 144.8 (2C), 143.8, 133.8 and 133.2 (1C), 128.9-127.2 (10C), 122.8, 122.7, 
122.5, 111.8 and 110.8 (1C), 69.9 and 65.1 (1C); HRMS (ESI) calcd for 
C21H16N2NaO
+ 
[MNa]
+
 335.1155, found 335.1144. 
3-(Benzhydrylimino)-1-methylindolin-2-one (II∙1c). Prepared according to GP-A 
using 1-methyl isatin. The desired product was collected by filtration; yield: 367 
mg, 75%; yellow foam; 
1
H NMR (400 MHz, CD2Cl2, 9:1 mixture of imine 
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isomers)
 δ 7.83 (s, 0.9H), 7.78 (d, br,  J = 7.5 Hz, 0.9H), 7.76 (d, br,  J = 7.5 
Hz, 0.1H), 7.57 (d, br, J = 7.7 Hz, 3.6H), 7.52 (d, br, J = 7.8 Hz, 0.4H), 7.47 
(dt, J = 7.8 and 1.5  Hz, 0.9H), 7.46 (dt, J = 7.7 and 1.5  Hz, 0.1H),  7.41-7.24 
(m, 6H), 7.16 (dt, J = 7.6, 1.0 Hz, 0.9H), 7.06 (dt, J = 7.8, 1.0 Hz, 0.1H), 6.92 
(d, br, J = 7.8 Hz, 0.1H), 6.86 (d, br,  J = 7.8 Hz, 0.9H), 6.57 (s, 0.1H), 3.27 (s, 
0.3H), 3.22 (s, 2.7H);
 13
C NMR (101 MHz, CD2Cl2) δ 158.9, 152.3, 145.7 and 
143.3 (1C), 144.4 (2C), 133.5 and 132.9 (1C), 128.6-127.3 (10C), 122.9, 122.5, 
121.7, 109.2 and 108.4 (1C), 69.7 and 65.4 (1C), 26.0 and 25.5 (1C); HRMS (ESI) 
calcd for C22H18N2NaO
+ 
[MNa]
+
 349.1311, found 349.1322. 
3-(Benzhydrylimino)-1-(4-methoxybenzyl)indolin-2-one (II∙1d). Prepared 
according to GP-A using 1-4-methoxybenzyl isatin. The desired product was 
collected by filtration; yield: 486 mg, 75%; yellow foam; 
1
H NMR (400 MHz, 
CD2Cl2, 9:1 mixture of imine isomers) δ 7.88 (s, br, 0.9H), 7.79 (d, br,  J = 7.6 
Hz, 0.9H), 7.76 (d, br,  J = 7.7 Hz, 0.1H), 7.59 (d, br,  J = 7.4 Hz, 3.6H), 7.54 
(d, br,  J = 7.4 Hz, 0.4H), 7.44-7.23 (m, 9H), 7.12 (t, J = 7.6, 0.9H), 7.03 (t, J 
= 7.7, 0.1H), 6.88 (d, br, J = 8.0, 2H),  6.84 (d, br, J = 7.8, 0.1H), 6.78 (d, br, 
J = 7.8, 0.9H), 6.57 (s, br, 0.1H), 4.93 (s, 0.2H), 4.87 (s, 1.8H), 3.80 (s, 3H). 
13
C 
NMR (101 MHz, CD2Cl2) δ 159.9, 159.4, 152.9, 145.5, 145.0 (2C), 144.0, 134.0 
and 133.4 (1C), 129.4-127.6 (12C), 123.7 and 123.3 (1C), 122.6, 122.7, 114.8 (2C), 
110.9 and 110.0 (1C), 70.5 and 66.1 (1C), 55.9, 43.9 and 43.5 (1C); HRMS (ESI) 
calcd for C29H24N2NaO2
+
 [MNa]
+
 455.1730, found 455.1742. 
3-(Benzhydrylimino)-1-tritylindolin-2-one (II∙1e). Prepared according to GP-A 
using 1-trityl isatin. The desired product was collected by filtration; yield: 498 
mg, 60%; pale yellow foam; 
1
H NMR (300 MHz, CDCl3, 9:1 mixture of imine 
isomers)
 δ 7.82-7.69 (m, 1.9H), 7.61-7.37 (m, 10H), 7.35-7.17 (m, 15H), 7.04-
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6.83 (m, 2H), 6.50 (s, br, 0.1H), 6.38 (d, J = 7.8 Hz, 0.1H), 6.16 (d, J = 7.8 Hz, 
0.9H);
 13
C NMR (101 MHz, CDCl3)
 δ 160.3, 151.8, 145.3, 144.5 (2C), 141.9 (3C), 
131.6 and 131.2 (1C), 129.6-126.9 (25C), 123.4, 122.6, 122.2 and 122.8 (1C), 117.2 
and 115.7 (1C), 74.7, 69.7 and 64.4 (1C); HRMS (ESI) calcd for C40H30N2NaO
+ 
[MNa]
+
 577.2250, found 577.2239. 
3-(Benzhydrylimino)-1-benzyl-5-fluoroindolin-2-one (II∙1f). Prepared according to 
GP-A using 5-fluoro-1-benzyl isatin. The desired product was collected by 
filtration; yield: 428 mg, 68%; yellow foam; 
1
H NMR (400 MHz, CD2Cl2, 9:1 
mixture of imine isomers)
 δ 7.88 (s, 0.9H), 7.63-7.50 (m, 4H), 7.47-7.26 (m, 
11H), 7.07 (dt, J = 8.0, 2.8 Hz, 1H), 6.75 (dd, J = 8.0, 4.2 Hz, 0.1H), 6.68 (dd, 
J = 8.0, 3.9 Hz, 0.9H), 6.50 (s, 0.1H), 4.99 (s, 0.2H), 4.93 (s, 1.9H).
 13
C NMR 
(101 MHz, CD2Cl2)
 δ 160.1 (d, J = 241.6Hz, 1C), 159.4, 152.4, 144.8 (2C), 143.7 
and 141.5 (1C), 135.9, 131.0-127.8 (15C), 123.8 (d, J = 8.5Hz, 1C), 120.3 (d, J = 
24.0Hz) and 119.6 (d, J = 24.0Hz) (1C), 116.0 (d, J = 24.0Hz) and 110.3 (d, J = 
24.0Hz) (1C), 111.6 (d, J = 7.1Hz) and 111.0 (d, J = 7.1Hz) (1C), 70.6 and 66.4 
(1C), 44.5 and 44.2 (1C); HRMS (ESI) calcd for C28H21FN2NaO
+ 
[MNa]
+
 
443.1530, found 443.1515. 
3-(Benzhydrylimino)-1-benzyl-5-chloroindolin-2-one (II∙1g). Prepared according 
to GP-A using 5-chloro-1-benzyl isatin. The desired product was collected by 
filtration; yield: 458 mg, 70%; yellow foam; 
1
H NMR (400 MHz, CD2Cl2, 19:1 
mixture of imine isomers)
 δ 7.86 (s, br, 0.95H), 7.81 (d, br, J = 1.6 Hz, 0.95H), 
7.78 (d, br, J = 1.6 Hz, 0.05H), 7.60 (d, br, J = 7.5 Hz, 3.8H), 7.55 (d, br, J = 
7.5 Hz, 0.2H), 7.46-7.26 (m, 12H), 6.76 (d, J = 8.5 Hz, 0.05H), 6.69 (d, J = 
8.5 Hz, 0.95H), 6.53 (s, br, 0.05H), 5.00 (s, 0.1H), 4.93 (s, 1.9H);
 13
C NMR (101 
MHz, CD2Cl2)
 δ 158.4, 151.2, 144.1 (2C), 143.3, 135.1, 132.9 and 132.3 (1C), 
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130.4-127.1 (16C), 123.3, 122.4, 111.3 and 110.6 (1C), 70.0 and 65.9 (1C), 43.9 
and 43.6 (1C); HRMS (ESI) calcd for C28H21ClN2NaO
+ 
[MNa]
+
 459.1234, found 
459.1245. 
3-(Benzhydrylimino)-1-benzyl-6-bromoindolin-2-one (II∙1h). Prepared according 
to GP-A using 6-bromo-1-benzyl isatin. The desired product was collected by 
filtration; yield: 562 mg, 78%; yellow foam; 
1
H NMR (400 MHz, CD2Cl2, 85:15 
mixture of imine isomers)
 δ 7.83 (s, 0.85H), 7.68 (d, J = 7.7 Hz, 0.85H), 7.66-
7.50 (m, 4.15H),  7.47-7.25 (m, 11.85H), 7.19 (dd, J = 7.8 and 1.2 Hz, 0.15H), 
6.99 (d, J = 1.2 Hz, 0.15H), 6.93 (s, br, 0.85H), 6.51 (s, br, 0.15H), 4.98 (s, 
0.3H), 4.91 (s, 1.7H);
 13
C NMR (101 MHz, CD2Cl2) δ 158.6, 151.2, 145.9, 144.1 
(2C), 135.0, 128.9-125.7 (17C), 123.4, 120.9, 113.5 and 112.7 (1C), 70.1 and 65.8 
(1C), 43.9 and 43.6 (1C); HRMS (ESI) calcd for C28H21BrN2NaO
+ 
[MNa]
+
 
503.0729, found 503.0713. 
3-(Benzhydrylimino)-6-bromo-1-methylindolin-2-one (II∙1i). Prepared according 
to GP-A using 6-bromo-1-methyl isatin. The desired product was collected by 
filtration; yield: 424 mg, 70%; yellow foam; 
1
H NMR (400 MHz, CD2Cl2, 85:15 
mixture of imine isomers) δ 7.78 (s, br, 0.85H), 7.66 (d, J = 7.8 Hz, 0.85H),  
7.61-7.46 (m, 4.15H), 7.44-7.19 (m, 7H),  7.10 (s, br, 0.15H), 7.03 (s, br,  
0.85H), 6.48 (s, br, 0.15H), 3.25 (s, 0.45H), 3.20 (s, 2.55H); 
13
C NMR (101 
MHz, CD2Cl2) δ 159.2, 152.1, 147.3, 144.8 (2C), 131.1-123.9 (13C), 121.3, 113.5 
and 112.7 (1C), 70.6 and 66.3 (1C), 26.9 and 26.4 (1C); HRMS (ESI) calcd for 
C22H17BrN2NaO
+ 
[MNa]
+
 427.0416, found 427.0411. 
 
General procedure B (GP-B) for the asymmetric organocatalyzed synthesis of 
compounds II∙5-13. To a solution of isatin-derived imine II∙1a-i (0.12 mmol, 1 eq) 
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and trimethylsilyloxyfuran (TMSOF) (0.14 mmol, 1.16 eq) in tetrahydrofuran (1 
mL) cooled to -40 °C, a solution of catalyst (R)-II∙4a (10% mol) in MeOH (25 µL) 
and tetrahydrofuran (200 µL) was slowly added. The resulting mixture was 
stirred at the same temperature for 7 hours. The reaction was quenched by 
adding NaHCO3 saturated aq. (1 mL) and the product was extracted with EtOAc 
(2 x 5 mL). The combined organic layer was dried over anhydrous Na2SO4 and 
the solvent was evaporated under reduced pressure. The residue was purified by 
FC, as indicated below. 
3-(Benzhydrylamino)-1-benzyl-3-(5-oxo-2,5-dihydrofuran-2-yl)indolin-2-one 
(II∙5a,b). Prepared according to GP-B using 3-(benzhydrylimino)-1-benzylindolin-
2-one (II∙1a); FC: n-Hexane:EtOAc, 7:3; yield: 47 mg, 80%; pale orange solid; 1H 
NMR (300 MHz, CDCl3, mixture of diasteroisomers syn:anti, 48:52) δ 7.83 (dd, 
J = 5.8 and 1.7 Hz, 0.52H), 7.43-7.13 (m, 15H), 7.10 (dd, J = 5.9 and 1.5 Hz, 
0.48H), 7.08-6.91 (m, 2.48H), 6.87 (td, J = 7.6 and 1.0 Hz, 0.52H), 6.65 (d, J 
= 7.8 Hz, 0.48H), 6.59 (d, J = 7.8 Hz, 0.52H), 6.25 (dd, J = 5.8, 1.9 Hz, 
0.52H), 5.97 (dd, J = 5.9, 2.2 Hz, 0.48H), 5.48 (t, br, J = 1.8 Hz, 0.48H), 5.26 
(t, br, J = 1.7 Hz, 0.52H), 4.81 (d, J = 15.9 Hz, 0.52H), 4.73 (s, br, 0.48H), 4.72 
(s, br, 0.52H), 4.65 (d, J = 15.4 Hz, 0.48H), 4.25 (d, J = 15.9 Hz, 0.52H), 4.10 
(d, J = 15.4 Hz, 0.48H), 3.03-2.41 (m, br, 1H); 
13
C NMR (101 MHz, CDCl3, 
mixture of diasteroisomers syn:anti, 48:52) δ 176.0 and 174.3 (1C), 165.0 and 
163.2 (1C), 152.4 and 151.1 (1C), 143.6 and 143.3 (2C), 142.2 and 141.8 (1C), 
135.5 and 135.3 (1C), 130.1 and 129.9 (1C), 128.8-1258(17C), 124.2 and 123.9 
(1C), 122.9 and 122.1 (1C), 109.6 and 109.5 (1C), 86.1 and 85.2 (1C), 68.1 and 
67.3 (1C), 63.0 and 62.3 (1C), 43.9; HRMS (ESI) calcd for C32H26N2NaO3
+ 
[MNa]
+
 509.1836, found 509.1828; enantiomeric excess: syn 92%, anti 90%, 
Vinylogous Mannich Reaction 
- 34 - 
 
determined by HPLC (Chiracel-AD, n-Hexane:iPrOH = 1:1, flow rate 0.6 
mL/min): tR = 10.33 min (anti, minor), tR = 11.75 min (syn, major); tR = 14.27 
min (syn, minor), tR = 66.85 min (anti, major). 
3-(Benzhydrylamino)-3-(5-oxo-2,5-dihydrofuran-2-yl)indolin-2-one (II∙6a,b). 
Prepared according to GP-B using 3-(benzhydrylimino)indolin-2-one (II∙1b); FC: 
CH2Cl2:MeOH, 99:1; yield: 37 mg, 78%; pale yellow solid; 
1
H NMR (300 MHz, 
CDCl3+1% CD3OD, mixture of diasteroisomers syn:anti, 37:63) δ 7.73 (d, br, J = 
5.8 Hz, 0.63H), 7.32-6.82 (m, 15H), 6.81-6.62 (m, 1.37H), 6.16 (dd, J = 5.9 and 
1.9 Hz, 0.63H), 5.92 (dd, J = 5.8 and 1.9 Hz, 0.37H), 5.34 (t, br,  J = 1.8 Hz, 
0.37H), 5.16 (t, br,  J = 1.8 Hz, 0.63H), 4.64 (s, 0.37H), 4.62 (s, 0.63H); 
13
C 
NMR (75 MHz, CDCl3+1% CD3OD, mixture of diasteroisomers syn:anti, 37:63)
 δ 
178.1, 172.6 and 172.3 (1C), 153.1 and 151.7 (1C), 143.6 and 143.4 (2C), 142.6 
and 142.0 (1C), 129.9-121.6 (15C), 110.3, 86.0 and 85.2 (1C), 66.0 and 64.8 (1C), 
62.9 and 62.2 (1C); HRMS (ESI) calcd for C25H20N2NaO3
+ 
[MNa]
+
 419.1366, 
found 419.1354; enantiomeric excess: syn 88%, anti 80%, determined by HPLC 
(Chiracel-AD, n-Hexane:iPrOH = 4:1, flow rate 0.7 mL/min): tR = 10.58 min 
(syn, minor), tR = 11.38 min (syn, major), tR = 13.61 min (anti, minor), tR = 
63.13 min (anti, major). 
3-(Benzhydrylamino)-1-methyl-3-(5-oxo-2,5-dihydrofuran-2-yl)indolin-2-one 
(II∙7a) and (II∙7b). Prepared according to GP-B using 3-(benzhydrylimino)-1-
methylindolin-2-one (II∙1c); FC: n-Hexane:EtOAc, 7:3. 
(II∙7a) yield: 22 mg, 45%; orange foam; [α]20D –24.6 (c 0.2, CHCl3); 1H NMR 
(400 MHz, CDCl3, anti diasteroisomer) δ 7.88 (dd, J = 5.6 and 1.5 Hz, 1H), 
7.43-7.13 (m, 10H), 6.97 (t, J = 7.6 Hz, 1H), 6.87- 6.80 (m, 2H), 6.70 (d, J = 
7.6 Hz, 1H), 6.27 (dd, J = 5.6 and 1.5 Hz, 1H), 5.16 (t, J = 1.5 Hz, 1H), 4.68 (s, 
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br, 1H), 2.81 (s, 3H), 2.71-2.45 (m, br, 1H); 
13
C NMR (101 MHz, CDCl3)
 δ 175.7, 
171.8, 152.6, 144.5, 143.3, 141.9, 130.2, 128.5-126.8 (11C), 124.0, 123.1, 122.1, 
108.5, 85.1, 67.0, 62.2, 26.1; HRMS (ESI) calcd for C26H22N2NaO3
+ 
[MNa]
+
 
433.1523, found 433.1529; enantiomeric excess: 91%, determined by HPLC 
(Chiracel-ODH, n-Hexane:iPrOH = 4:1, flow rate 0.7 mL/min): tR = 5.51 min 
(minor), tR = 15.34 min (major). 
(II∙7b) yield: 19 mg, 36%; orange foam; [α]20D + 115.2 (c 0.3, CHCl3); 1H NMR 
(300 MHz, CDCl3, syn diasteroisomer)
 δ 7.42-7.07 (m, 11H), 7.03 (t, br,  J = 7.8 
Hz, 1H),  6.94-6.86 (m, 2H), 6.64 (d, br, J = 7.8 Hz, 1H), 5.93 (dd, J = 5.9, 2.0 
Hz, 1H), 5.41 (s, 1H), 4.64 (s, 1H), 3.21-2.74 (m, br, 1H),  2.68 (s, 3H). 
13
C NMR 
(75 MHz, CDCl3) δ 174.2, 172.1, 151.2, 143.6, 143.5, 141.4, 130.0, 128.4-127.1 
(10C), 125.7, 123.9, 123.7, 122.9, 108.6, 86.0, 67.9, 63.1, 25.9; HRMS (ESI) calcd 
for C26H22N2NaO3
+ 
[MNa]
+
 433.1523, found 433.1531; enantiomeric excess: 
68%, determined by HPLC (Chiracel-AD, n-Hexane:iPrOH = 4:1, flow rate 0.7 
mL/min): tR = 11.28 min (major), tR = 13.51 min (minor). 
3-(Benzhydrylamino)-1-(4-methoxybenzyl)-3-(5-oxo-2,5-dihydrofuran-2-
yl)indolin-2-one (II∙8a,b). Prepared according to GP-B using 3-(benzhydrylimino)-
1-(4-methoxybenzyl)indolin-2-one (II∙1d); FC: n-Hexane:EtOAc, 7:3; yield: 51 
mg, 79%; 
1
H NMR (300 MHz, CDCl3, mixture of diasteroisomers syn:anti, 
45:55) δ 7.73 (d, J = 4.9 Hz, 0.55H), 7.32-6.74 (m, 17.45H), 6.63 (d, br, J = 
7.8 Hz, 0.45H), 6.58 (d, br, J = 7.8 Hz, 0.55H), 6.20 (d, br, J = 5.8 Hz, 
0.55H), 5.93 (d, br, J = 5.9 Hz, 0.45H), 5.45 (s, br, 0.45H), 5.31 (s, br, 0.55H), 
4.80-4.64 (m, 1.55H), 4.56 (d, J = 14.7 Hz, 0.45H), 4.15 (d, J = 15.8 Hz, 
0.55H), 3.99 (d, J = 14.7 Hz, 0.45H), 3.75 (s, 3H), 3.34-2.47 (m, br, 1H); 
13
C 
NMR (75 MHz, CDCl3, mixture of diasteroisomers syn:anti, 45:55)
 δ 175.2 and 
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174.0 (1C), 172.0 and 171.6 (1C), 159.2, 152.2 and 151.1 (1C) , 143.5 and 143.4 
(1C), 142.9, 141.6, 130.2 and 129.9 (1C), 128.8-127.2 (14C), 125.7 and 124.2 (1C), 
122.8 and 122.2 (1C), 122.4, 114.2, 111.3, 109.6 and 109.5 (1C),   86.0 and 84.8 
(1C), 68.0 and 67.3 (1C), 63.0 and 62.6 (1C), 55.3, 43.4 and 43.3 (1C); HRMS 
(ESI) calcd for C33H28N2NaO4
+ 
[MNa]
+
 539.1941, found 539.1950; enantiomeric 
excess: syn 89%, anti 84%, determined by HPLC (Chiracel-AD, n-Hexane:iPrOH 
= 9:1, flow rate 1.0 mL/min): tR = 30.00 min (anti minor), tR = 40.25 min (syn 
major), tR = 42.46 min (syn minor), tR = 112.89 min (anti major). 
3-(Benzhydrylamino)-3-(5-oxo-2,5-dihydrofuran-2-yl)-1-tritylindolin-2-one 
(II∙9a,b). Prepared according to GP-B using 3-(benzhydrylimino)-1-tritylindolin-2-
one (II∙1e); FC: n-Hexane:EtOAc, 4:1; yield: 64mg, 81%; pale orange solid; 1H 
NMR (400 MHz, CDCl3, mixture of diasteroisomers syn:anti, 53:47) δ 7.81 (dd, J 
= 5.9 and 1.5 Hz, 0.47H), 7.67-6.99 (m, 23H), 6.95 (d, br, J = 7.7 Hz, 0.47H), 
6.88 (t, br, J = 7.7 Hz, 0.47H), 6.81-6.86 (m, 3.06H), 6.55 (dd, J = 5.9 and 1.5 
Hz, 0.53H), 6.41-6.27 (m, 2H), 6.22 (dd, J = 5.8 and 1.9 Hz, 0.47H), 5.83 (dd, 
J = 5.9 and 2.2 Hz, 0.53H), 5.35 (t, br, J = 1.7 Hz,  0.53H), 5.24 (t, br, J = 1.7 
Hz,  0.47H), 4.60 (s, br,  0.53H), 4.17 (s, br, 0.47H), 3.47-2.32 (m, br, 1H);
 13
C 
NMR (101 MHz, CDCl3, mixture of diasteroisomers  syn:anti, 53:47)
 δ 178.6 and 
175.6 (1C), 172.0 and 171.4 (1C), 153.0 and 151.7 (1C), 144.1 and 144.0 (1C), 
143.5 and 143.4 (1C), 143.3 and 143.2 (1C), 142.2 and 141.9 (3C), 129.2, 129.3-
126.9 (26C), 126.5 and 125.4 (1C), 125.2, 123.9 and 123.2 (1C), 122.4 and 121.0 
(1C), 116.0 and 115.8 (1C), 86.5 and 85.2 (1C), 75.4 and 75.2 (1C), 68.8 and 68.4 
(1C), 62.9 and 62.6 (1C); HRMS (ESI) calcd for C44H34N2NaO3
+ 
[MNa]
+
 
661.2462, found 661.2455; enantiomeric excess: syn 96%, anti 4%, determined 
by HPLC (Chiracel-AD, n-Hexane:iPrOH = 17:1, flow rate 0.7 mL/min): tR = 
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15.85 min (anti minor), tR = 24.13 min (syn minor), tR = 27.90 min (anti major), 
tR = 33.83 min (syn major). 
3-(Benzhydrylamino)-1-benzyl-5-fluoro-3-(5-oxo-2,5-dihydrofuran-2-yl)indolin-2-
one (II∙10a,b). Prepared according to GP-B using 3-(benzhydrylimino)-1-benzyl-5-
fluoroindolin-2-one (II∙1f); FC: n-Hexane:EtOAc, 7:3; 29 mg, yield: 45%; pale 
orange solid; 
1
H NMR (300 MHz, CDCl3, mixture of diasteroisomers syn:anti, 
28:72) δ 7.81 (d, br, J = 4.9 Hz, 0.72H), 7.52-6.76 (m, 16.56H), 6.69 (d, br, J 
= 7.8 Hz, 0.72H), 6.57-6.42 (m, 1H), 6.25 (d, br, J = 5.8 Hz, 0.72H), 5.99 (d, 
br, J = 5.8 Hz, 0.28H), 5.42 (s, br, 0.28H), 5.21 (s, br, 0.72H), 4.81 (d, J = 15.7 
Hz, 0.72H), 4.72-4.60 (m, 1.28H), 4.30 (d, J = 15.7 Hz, 0.72H), 4.11 (d, J = 
15.7 Hz, 0.28H), 3.01-2.66 (m, br, 1H); 
13
C NMR (75 MHz, CDCl3, mixture of 
diasteroisomers syn:anti, 28:72)
 δ 175.8 and 174.1 (1C), 158.9 (d, J = 239.9Hz) 
and 158.1 (d, J = 244.0Hz) (1C),  152.1 and 150.8 (1C), 143.3 and 142.9 (1C), 
142.1 and 141.8 (1C), 139.3 and 138.7 (1C), 135.1 and 134.9 (1C), 128.9- 127.1 
(16C), 125.3 and 124.6 (1C), 124.4 and 124.0 (1C), 116.6-116.1 (m, 1C), 114.9 (d, J 
= 26.2Hz) and 113.8 (d, J = 22.8Hz) (1C), 110.0 (d, J = 8.7Hz) (1C), 85.8 and 
84.8 (1C), 68.3 and 67.7 (1C), 63.1 and 62.5 (1C), 44.0; HRMS (ESI) calcd for 
C32H25FN2NaO3
+ 
[MNa]
+
 527.1741, found 527.1752; enantiomeric excess: syn 
15%, anti 1%, determined by HPLC (Chiracel-ODH, n-Hexane:iPrOH = 4:1, flow 
rate 0.7 mL/min): tR = 25.91 min (syn major), tR = 32.60 min (syn minor), tR = 
35.53 min (anti major), tR = 57.56 min (anti minor). 
3-(Benzhydrylamino)-1-benzyl-5-chloro-3-(5-oxo-2,5-dihydrofuran-2-yl)indolin-2-
one (II∙11a,b). Prepared according to GP-B using 3-(benzhydrylimino)-1-benzyl-5-
chloroindolin-2-one (II∙1g); FC: n-Hexane:EtOAc, 7:3; yield: 27 mg, 42%; pale 
orange solid; 
1
H NMR (400 MHz, CDCl3, mixture of diasteroisomers syn:anti, 
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3:7) δ 7.83 (dd, J = 5.8, 1.2 Hz, 0.7H), 7.46-6.98 (m, 16.6H), 6.92 (d, , J = 2.0 
Hz, 0.7H) 6.54 (d, J = 8.4 Hz, 0.3H), 6.50 (d, J = 8.4 Hz, 0.7H), 6.29 (dd, J = 
5.8, 1.7 Hz, 0.7H), 6.06 (dd, J = 5.8, 1.9 Hz, 0.3H), 5.44 (t, J = 1.5 Hz, 0.3H), 
5.24 (t, J = 1.5 Hz, 0.7H), 4.84 (d, J = 15.8 Hz, 0.7H), 4.76-4.62 (m, 1.3H), 
4.34 (d, J = 15.8 Hz, 0.7H), 4.14 (d, J = 15.8 Hz, 0.3H), 3.11-2.68 (m, br, 1H); 
13
C NMR (101 MHz, CDCl3, mixture of diasteroisomers syn:anti, 3:7)
 δ 176.4 and 
174.7 (1C), 172.2 and 172.0 (1C), 152.7 and 151.5 (1C), 143.8-142.1 (3C), 135.7 
and 135.6 (1C), 130.7 and 130.5 (1C), 129.6 to 126.8 (17C), 126.6 and 125.2 (1C), 
125.1 and 124.8 (1C), 111.1, 86.5 and 85.4 (1C), 68.9 and 68.3 (1C), 63.8 and 
63.3 (1C), 44.8 and 44.7 (1C); HRMS (ESI) calcd for C32H25ClN2NaO3
+ 
[MNa]
+
 
543.1446, found 543.1454; enantiomeric excess: syn 74%, anti 26%, determined 
by HPLC (Chiracel-AD, n-Hexane:iPrOH = 9:1 to 3:7, flow rate 1.0 mL/min): tR 
= 18.02 min (syn major), tR = 19.84 min (anti major), tR = 37.38 min (syn 
minor), tR = 57.02 min (anti minor). 
3-(Benzhydrylamino)-1-benzyl-6-bromo-3-(5-oxo-2,5-dihydrofuran-2-yl)indolin-
2-one (II∙12a,b). Prepared according to GP-B using 3-(benzhydrylimino)-1-benzyl-
6-bromoindolin-2-one (II∙1h); FC: n-Hexane:EtOAc, 7:3; yield: 44 mg, 65%; 
orange solid; 
1
H NMR (400 MHz, CDCl3, mixture of diasteroisomers 3:7)
 δ 7.83 
(d, br, J = 5.6 Hz, 0.7H), 7.46-7.02 (m, 14.6H), 7.01-6.94 (m, 2H), 6.86 (d, br, 
J = 7.9 Hz, 0.7H ), 6.79 (s, br 0.3H), 6.74 (s, br, 0.7H), 6.26 (dd, J = 5.6, 1.5 
Hz, 0.7H), 6.00 (dd, J = 5.8, 1.9 Hz, 0.3H), 5.44 (s, br, 0.3H), 5.22 (s, br, 
0.7H), 4.79 (d, J = 15.8 Hz, 0.7H), 4.72- 4.58 (m, 1.3H), 4.25 (d, J = 15.8 Hz, 
0.7H), 4.08 (d, J = 15.8 Hz, 0.3H), 3.10-2.69 (m, br, 1H). 
13
C NMR (101 MHz, 
CDCl3, mixture of diasteroisomers syn:anti, 3:7)
 δ 176.6 and 174.9 (1C), 172.3 
and 172.0 (1C), 152.8 and 151.4 (1C), 145.5-142.2 (4C), 135.6 and 135.4 (1C), 
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129.7 to 127.6 (15C), 126.5 and 125.7 (1C), 125.0 and 124.9 (1C), 124.6 and 
124.4 (1C), 123.6 and 123.5 (1C), 113.5, 86.4 and 85.4 (1C), 68.5 and 67.9 (1C), 
63.8 and 63.1 (1C), 44.7; HRMS (ESI) calcd for C32H25BrN2NaO3
+ 
[MNa]
+
 
587.0941 found 587.0944. enantiomeric excess: syn 42%, anti 31%, determined 
by HPLC (C-AD, n-Hexane:iPrOH = 9:1, flow rate 1.0 mL/min): tR = 16.04 min 
(anti minor), tR = 17.91 min (syn major), tR = 24.31 min (syn minor), tR = 63.35 
min (anti major). 
3-(Benzhydrylamino)-6-bromo-1-methyl-3-(5-oxo-2,5-dihydrofuran-2-yl)indolin-
2-one (II∙13a) and (II∙13b). Prepared according to GP-B using 3-
(benzhydrylimino)-6-bromo-1-methylindolin-2-one (II∙1i); FC: n-Hexane:EtOAc, 
7:3. (II∙13a) yield: 25 mg, 42%; orange foam; [α]20D – 18.4 (c 0.3, CHCl3); 1H 
NMR (300 MHz, CDCl3, anti diasteroisomer)
 δ 7.84 (dd, J = 5.8, 1.9 Hz, 1H), 
7.24-7.10 (m, 8H), 7.06 (d, br, J = 7.8 Hz, 1H), 6.98 (d, J = 7.8 Hz, 1H), 6.88-
6.80 (m, 3H),  6.25 (dd, J = 5.8, 1.9 Hz, 1H), 5.12 (s, br, 1H), 4.61 (s, 1H), 2.78 
(s, 3H), 2.72-2.06 (m, br, 1H); 
13
C NMR (75 MHz, CDCl3)
 δ 175.5, 171.6, 152.3, 
145.7, 142.8, 141.6, 128.3-127.1 (11C), 125.0, 124.3, 124.1, 121.9, 112.1, 84.6, 
66.9, 62.3, 26.2; HRMS (ESI) calcd for C26H21BrN2NaO3
+ 
[MNa]
+
 511.0628, 
found 511.0637; enantiomeric excess: anti 32%, determined by HPLC (Chiracel-
ODH, n-Hexane:iPrOH = 4:1, flow rate 0.7 mL/min): tR =  23.33 min (major), 
tR = 75.68 min (minor). 
(II∙13b) yield: 15 mg, 26%; orange foam; [α]20D – 2.82 (c 0.3, CHCl3); 1H NMR 
(300 MHz, CDCl3, syn diasteroisomer)
 δ 7.44-7.03 (m, 11H), 7.01-6.90 (m, 2H), 
6.80 (d, J = 1.4 Hz, 1H), 5.97 (dd, J = 5.8, 2.0 Hz, 1H), 5.39 (s, br, 1H), 4.62 (s, 
1H), 2.68 (s, 3H), 2.16-1.77 (m, br, 1H); 
13
C NMR (75 MHz, CDCl3) δ 173.8, 
171.7, 150.9, 144.9, 142.8, 140.9, 128.3-126.9 (11C), 125.8, 124.2, 123.9, 122.5, 
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112.2, 85.5, 67.8, 63.4, 26.1; HRMS (ESI) calcd for C26H21BrN2NaO3
+ 
[MNa]
+
 
511.0628, found 511.0633; enantiomeric excess: syn 31%, determined by  HPLC 
(Chiracel-ODH, n-Hexane:iPrOH = 4:1, flow rate 0.7 mL/min): tR = 14.81 min 
(major), tR = 23.13 min (minor). 
 
Post-transformation reactions 
3-Amino-1-methyl-3-(5-oxotetrahydrofuran-2-yl)indolin-2-one (II∙15). To a 
solution of Mannich adduct II∙14 (100 mg, 0.29 mmol) in EtOAc (3 mL), 10% 
Pd/C (10% w/w) was added. The reaction mixture was degassed in vacuo, placed 
under an atmosphere of H2 (g), stirred at rt and the conversion was monitored 
by TLC. The mixture was filtered through a pad of Celite eluting with EtOAc (10 
mL) and the solvent was concentrated in vacuo. The crude residue was dissolved 
in dry MeOH (1 mL) followed by the dropwise addition of HCl solution (0.5 mL, 
4M HCl in dioxane) and the resulting mixture was stirred at room temperature 
for 4h. After quenching with saturated aq NaHCO3 (2 mL), and dilution with 
CH2Cl2 (2 mL), the aqueous phase was extracted with CH2Cl2 (3 x 5 mL). The 
combined organic layer was washed with saturated aq. NaHCO3, dried over 
anhydrous Na2SO4 and the solvent was removed under reduce pressure. The 
crude was subjected to FC (CH2Cl2:MeOH, 95:5) giving the desired product II∙15, 
as a white foam (65 mg, 91% overall yield). 
[α]20D – 83.3 (c 1.0, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.46 (d, br, J = 7.8 
Hz, 1H), 7.36 (t, br, J = 7.6 Hz, 1H), 7.09 (t, br, J = 7.7 Hz, 1H), 6.86 (d, br, J 
= 7.8 Hz, 1H), 4.62 (dd, br, J = 7.8 and 5.9 Hz, 1H), 3.21 (s, 3H), 2.58-2.33 (m, 
4H), 1.88 (m, br, 2H); 
13
C NMR (75 MHz, CDCl3)
 δ 177.7, 176.6, 143.7, 130.1, 
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128.2, 124.8, 123.2, 108.7, 82.4, 62.1, 28.0, 26.5, 21.7; HRMS (ESI) calcd for 
C13H14N2NaO3
+ 
[MNa]
+
 269.0897, found 269.0908. 
3-Amino-1-methyl-3-(5-oxotetrahydrofuran-2-yl)indolin-2-one (II∙15’) 
Palladium hydroxide (20 wt.% on carbon, 12 mg) was added to a solution of 
vinylogous Mannich-adduct II∙7a (82 mg, 0.20 mmol) in MeOH (1 mL). The 
reaction mixture was degassed in vacuo, placed under an atmosphere of H2 (g), 
stirred at rt and the conversion was monitored by TLC. The mixture was filtered 
through a pad of Celite eluting with MeOH (10 mL), and the solvent was 
concentrated in vacuo. The crude was subjected to FC (CH2Cl2:MeOH, 95:5) to 
give II∙15' as a white foam (47 mg, 96%). [α]20D – 90.6 (c 1.3, CHCl3); 1H NMR 
(300 MHz, CDCl3) and 
13
C NMR (75 MHz, CDCl3) were identical to those of 
compound II∙15. HRMS (ESI) calcd for C13H14N2NaO3+ [MNa]+ 269.0897, found 
269.0879. 
3-(Benzhydrylamino)-1-methyl-3-(5-((triisopropylsilyl)oxy)furan-2-yl)indolin-2-
one (II∙16). To a solution of 3-(benzhydrylamino)-1-methyl-3-(5-oxo-2,5-
dihydrofuran-2-yl)indolin-2-one (II∙7a or II∙7b) (60 mg, 0.15 mmol) in anhydrous 
CH2Cl2 (1.5 mL) cooled to 0 °C, anhydrous trimethylamine (0.15 mmol, 1eq) and 
TIPSOTf (0.17 mmol, 1.1 eq) were added. The solution was stirred at the same 
temperature for 1 hour (monitored by TLC). The reaction was quenched by 
adding water (1.5 mL). The organic phase was separated, dried over anhydrous 
Na2SO4 and the solvent was evaporated in vacuo to give II∙16 as a viscous oil. 
Compound (R)- II∙16 from II∙7a: Yield: 72 mg, 98%; [α]20D – 33.2 (c 1.0, CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 7.33-7.10 (m, 12H), 6.90 (t, J = 7.4 Hz, 1H), 6.69 
(d, J = 7.7 Hz, 1H), 6.13 (d, br,  J = 2.9 Hz, 1H), 5.04 (d, br, J = 2.9 Hz, 1H), 
4.79 (s, 1H), 3.07-2.95 (m, br, 1H), 2.72 (s, 3H), 1.22 (hept, J = 7.8 Hz, 3H), 
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1.04 (d, J = 7.8 Hz,18H); 
13
C NMR (75 MHz, CDCl3)
 δ 175.7, 157.1, 144.2, 
143.4, 142.5, 141.1, 128.1-126.9 (12C), 123.1, 122.2, 109.7, 109.0, 84.3, 71.7, 
62.6, 25.2, 17.5 (6C), 12.2 (3C); HRMS (ESI) calcd for C35H42N2NaO3Si
+ 
[MNa]
+
 
589.2857, found 589.2866. 
Compound (S)- II∙16 from II∙7b: Yield: 69 mg, 95%; [α]20D + 31.8 (c 0.9, CHCl3); 
1
H NMR (300 MHz, CDCl3) and 
13
C NMR (75 MHz, CDCl3) were identical to 
those of compound (R)-16; HRMS (ESI) calcd for C35H42N2NaO3Si
+ 
[MNa]
+
 
589.2857, found 589.2869. 
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III. Spiro[Indoline-Pyrimidine]-Diones Derivatives: 
Biginelli Reaction 
 
The first asymmetric, Brønsted acid-catalyzed Biginelli-like reaction of a ketone 
has been developed, employing N-substituted isatins as carbonyl substrates, and 
urea and alkyl acetoacetates as further components. BINOL-derived phosphoric 
acid catalysts have been used to achieve the synthesis of a small library of chiral, 
enantioenriched spiro(indoline-pyrimidine)-diones derivatives. The absolute 
configuration of the new spiro stereocenter was assessed on diastereoisomeric 
derivatives through computer-assisted NMR spectroscopy. X-Ray diffractometry 
allowed to disclose the overall molecular conformation in the solid state and to 
characterize the crystal packing of a Br-substituted Biginelli-like derivative, while 
computational studies on the reaction transition state allowed to rationalize the 
stereochemical outcome. 
 
 
 
 
 
 
 
 
 
 
Published in J. Org. Chem., 2016, 81, 1877-1884 
 
Biginelli Reaction 
- 47 - 
 
III.1 Introduction 
Simple heterocyclic compounds, such as pyrimidin-2(1H)-ones, are well known 
because of their important natural representatives, namely, the uracil, thymine, 
and cytosine nucleobases, which are essential components of DNA and RNA 
molecules.
1
 Moreover, such heterocyclic scaffolds have found increasing 
applications in medicinal chemistry, because of their important pharmacological 
and biological properties (Figure 1).
2 
As part of our interest in the asymmetric synthesis of 3,3-disubstituted oxindole 
derivatives and related spiro-compounds,
3
 we focused on the Biginelli reaction 
(Scheme 1), one of the well-established MCRs, mainly employed for the synthesis 
of 3,4-dihydropyrimidine-2(1H)-ones (DHPMs). 
Only few examples are reported on enantioselective organocatalytic Biginelli 
reactions, all involving aromatic aldehydes as carbonyl components.
4
 The 
milestone was placed by Gong,
7
 who disclosed the first highly enantioselective 
 
 
Figure 1. Example of biologically important pyrimidin-2(1H)-one-based compounds. 
 
 
Biginelli Reaction 
- 48 - 
 
 
Scheme 1. Most accepted Biginelli reaction mechanism. 
 
protocol, based on BINOL-derived chiral phosphoric acids as organocatalysts. 
Also dual-activation routes have been developed,by using combined catalysts 
consisting of a Brønsted acid and a chiral secondary amine
8,9
 or, alternatively, a 
chiral bifunctional primary amine-thiourea.
10
  
At the best of our knowledge, only two examples of the multicomponent 
preparation of racemic DHPMs derivatives starting from isatin are reported.
11,12
 In 
general, application of organocatalysis to the Biginelli-like reaction, employing a 
ketone as the carbonyl component, is even now quite unexplored. Herein, we 
report the Brønsted acid-catalyzed asymmetric synthesis of spiro(indoline-
pyrimidine)-diones derivatives via a Biginelli-like reaction, consisting of a three 
component cyclocondensation of alkyl acetoacetates, urea and isatin derivatives 
instead of aldehydes (Scheme 2). 
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Scheme 2. Strategy used for the asymmetric construction of the spiro(indoline-pyrimidine)-
dione scaffold. 
 
III.2 Results and Discussion 
Our initial studies were performed taking into account the Brønsted acid-catalytic 
enantioselective protocol reported by Gong for the true, aldehyde-involving, 
Biginelli reaction. Isatin III·1a, urea III·2a, ethyl acetoacetate III·3a and (R)-
BINOL-derived phosphoric acid III·4a were chosen for preliminary experiments 
(Table 1).  
At room temperature, the reaction proceeds with difficulty both in CH2Cl2 and in 
toluene (entries 1 and 2) and, after 96 hours, only trace amounts of the desired 
compound III·5a could be detected by 
1
H NMR of the crude reaction mixture. 
The lower reactivity of C-3 carbonyl group of isatin compared to aldehydes, 
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along with its higher steric demand, appears to be the key factor hindering the 
reaction from successfully proceeding at room temperature. 
To our delight, increasing the temperature to 50 °C (entries 3 and 4) entailed a 
significant effect on the chemical conversion. Toluene proved to be the solvent of 
choice, affording product III·5a in acceptable yield and with a good level of 
enantioselectivity. Screening of more hindered catalysts III·4b-f, aimed to 
evaluate the impact of the 3,3'-substitution, and of octahydro-BINOL-based III·4g 
was performed (entries 5-10). Increasing the size of the 3,3'-substitents on the 
phosphoric acid proved detrimental for the chemical conversion, with only 
catalysts III·4c and III·4d able to afford product III·5a, with maintenance of the 
same level of enantioselectivity as III·4a, but in definitely decreased yields. 
After that, we established III·4a as the catalyst of choice, and further screening of 
the reaction conditions were performed. Some yield improvement without 
sacrificing the stereoselectivity could be achieved by prolonging the reaction time 
until 96 hours (entry 11). 
More prolonged times are not convenient for the balance of yield vs ee (entry 
12). Increasing the reaction temperature deeply eroded the enantioselectivity, 
albeit with better yield (entry 13). The same happened when the reaction was 
conducted in more concentrated conditions (entry 14). Lowering the reactant 
concentration or the catalyst loading led to a significant decrease in yield.  
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Table 1. Optimization of the asymmetric Biginelli-like reaction.a 
 
 
 
Entry Catalyst Solvent 
Conc. 
[mol/L] 
T [°C], 
t [h] 
Yield
b 
[%] 
ee
c
 
[%] 
1 III·4a CH2Cl2 0.2 rt, 96 trace - 
2 III·4a Toluene 0.2 rt, 96 trace - 
3 III·4a CH2Cl2 0.2 50, 48 32 75 
4 III·4a Toluene 0.2 50, 48 51 80 
5 III·4b Toluene 0.2 50, 48 trace - 
6 III·4c Toluene 0.2 50, 48 30 79 
7 III·4d Toluene 0.2 50, 48 31 81 
8 III·4e Toluene 0.2 50, 48 trace - 
9 III·4f Toluene 0.2 50, 48 trace - 
10 III·4g Toluene 0.2 50, 48 26 79 
11 III·4a Toluene 0.2 50, 96 60 80 
12 III·4a Toluene 0.2 50, 240 66 77 
13 III·4a Toluene 0.2 70, 96 65 48 
14 III·4a Toluene 0.4 50, 96 62 66 
a Reaction conditions: isatin III·1a (0.16 mmol), urea III·2a (0.19 mmol), acetoacetate III·3a 
(0.48 mmol) and catalyst (R)-III·4 (0.032 mmol) in different solvent. b Isolated yield. c 
Determined by chiral HPLC analysis.  
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After establishing the optimal conditions, the Biginelli-like reaction of a isatins 
series was examined, using (R)-III·4a as catalyst, in toluene at 50 °C for 96 h 
(Scheme 3). The substrate scope was surveyed, by evaluating differently N-
substituted isatins and the presence of substituents at 5- or 6-position of the isatin 
nucleus. In general, all isatins readily undergo this reaction, to afford the desired 
products III·5a-h in moderate to high yields, with a good degree of 
enantioselectivity. Only the sterically demanding N-trityl isatin failed to 
participate in the reaction and the corresponding Biginelli-like adduct could not 
be detected. The N-Me isatin gave a better result than the corresponding N-
Benzyl, N-p-Nitrobenzyl and N-p-Methoxybenzyl ones in terms of yield (93% in 
comparison to up to 63%), but suffering a drop in ee (50% in comparison to up 
to 80%).  
The presence of various halogen substituents at the aryl ring has almost no effect 
on both yield and ee. Variations at the ester moiety of the β-ketoester 
component were also evaluated. Methyl and benzyl acetoacetates participated at 
the reaction efficiently to provide adducts III·5i-j in good yields and moderate 
ee's. In this kind of reaction, surprisingly, neither thiourea in place of urea, nor 
various linear or cyclic β-diketones in place of alkyl acetoacetates, showed to be 
suitable, together with N-benzyl- isatin.  
With thiourea no reaction occurred, while with -diketones a complex mixture of 
products could be detected. 
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Scheme 3. Substrate scope of the Biginelli-like reaction catalyzed by (R)-III·4a.a 
 
 
 a Reaction conditions: isatin III·1a-h (0.16 mmol), urea III·2a (0.19 mmol), acetoacetate 
III·3a-c (0.48 mmol) and catalyst (R)-III·4a (0.032 mmol) in toluene (0.8 mL).  Isolated 
yields are reported.  ee were determined by chiral HPLC analysis. 
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Scheme 4. Synthetic transformations on compounds III·5a and III·5j. 
 
 
 
Then, we examined some products transformations, first of all the facile 
regioselective mono-N-alkylation of the dihydropyrimidin-2-one ring. Starting 
from the Biginelli-like compound III·5a, the corresponding N-benzyl derivative 
III·6 was achieved in high yield and regioselectivity, by reaction with benzyl 
bromide and cesium carbonate, in DMF at room temperature (Scheme 4). 
Further, catalytic hydrogenolysis of the benzyl ester moiety of compound III·5j 
allowed to easily obtain the carboxylic acid derivative III·7, that can be regarded 
as a useful key intermediate toward the synthesis of peptidomimetic compounds. 
The carboxylic acid functional group of III·7 can also be quantitatively removed 
to give III·8, by heating in acidic conditions. 
In order to demonstrate the reactivity of acid III·7 and aiming at the same time 
to gain information on the absolute configuration of the major enantiomer III·5j 
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(vide infra), obtained in the (R)-III·4a-catalyzed Biginelli-like reaction, we pursued 
the transformation depicted in Scheme 5. 
By reaction with (S)-1-phenylethanamine in the presence of the condensing agent 
HATU, acid III·7 was cleanly converted into diastereoisomeric amides III·9a and 
III·9b, which could be efficiently separated by flash chromatography, establishing 
the possible application of III·7 in peptidomimetic chemistry.  
Confiding at first on X-ray diffractometry in order to determine the C3 absolute 
configuration of compounds III·5, we planned to perform the crystallographic 
analysis on III·5h. This molecule was selected as a suitable derivative, due to the 
presence of the bromine atom as anomalous dispersor. Initially, III·5h disclosed a 
recalcitrant crystallization behavior in yielding single crystals and, only after many 
attempts, well diffracting crystals were obtained. The X-ray data revealed that the 
12:88 molar mixture of enantiomers crystallized in a centrosymmetric space 
group, showing the more favored crystallization of the racemate instead of the 
major enantiomer. 
 
Scheme 5. Synthesis of diastereoisomeric compounds III·9a and III·9b, starting from acid 
III·7. 
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In the solid state, the overall molecular conformation is determined by the 
spiro(indoline-pyrimidine)-dione system, with the dihydropyrimidin-2-one ring, 
having an almost planar conformation, perpendicularly oriented with respect to 
oxindole (Figure 2a). The conformation of the benzyl group shows the phenyl 
ring pointing in the same direction of the dihydropyrimidin-2-one carbonyl 
moiety. The crystal packing is characterized by strong centrosymmetric N-H...O 
hydrogen bonds, leading to the formation of dimers, that are in turns stabilized 
by Cp-H...O contacts, as depicted in Figure 2b.  
This interactions pattern can be employed for rationalizing the preferential 
crystallization of the racemate, which is indeed consistent with the close packing 
found in the crystal environment, dominated by unique characteristics of 
hydrogen bonds involved in dimers formation.  
 
 
 
Figure 2. (a) ORTEP13 drawing of III·5h, showing the arbitrary atomic numbering 
(displacement ellipsoids at 40% probability). (b) Intermolecular interactions viewed along c 
axis. 
a) b)a) b) 
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This easier racemate crystallization is in agreement with previous literature data,
14
 
showing the tendency for several racemic crystals to be more stable and denser 
than their chiral counterparts.Although it was not possible to obtain suitable 
crystals for X-ray-based determination of the prevailing enantiomer III·5h, we 
were able to determine the C3 stereochemistry through ab initio calculation of 
NMR shifts, a technique pioneered by Bifulco.
15
 We considered the differences in 
both 
1
H and 
13
C NMR spectra for compounds III·9a and III·9b and then 
performed a theoretical conformational search on both (3S,1’S) and (3R,1’S) 
possible diastereoisomers, employing the Monte Carlo algorithm and molecular 
mechanics (MMFF force field). After DFT optimization, we calculated 
1
H and 
13
C 
NMR chemical shifts, by subjecting the shielding constants to Boltzmann 
averaging over the conformers, followed by linear regression, as reported by 
Pierens.
16
 From comparison of experimental and calculated data, the (3S,1'S) 
absolute configuration could be confidently assigned to the major 
diastereoisomer III·9a and, consequently, the (3R,1'S) one to the minor III·9b. To 
make this assignment safe beyond any doubt, we also calculated the comparison 
parameter (CP3), especially designed
17
 for the computer-assisted assignment of 
the stereochemistry of diastereoisomers pairs, in which only the configuration of 
one stereocenter is unknown. By this way, our stereochemical assignment could 
be made quite secure also from a quantitative point of view.  
These results allowed us to disclose the C3-S favoring enantioselectivity of the 
described organocatalyzed reaction and prompted us to perform theoretical 
calculations on the stereogenic centre forming step. The mechanism of the 
Biginelli reaction has been previously investigated by means of computational 
tools,
18
 also in the presence of tartaric acid as catalyst.
19
 Results indicated the 
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iminium path as the most favorable, in accordance with previously proposed 
mechanism.
20
 Therefore, we decided to investigate the initial addition of the enol 
form of ethyl acetoacetate on the imine formed between isatin III·1a and urea 
III·2a, in the presence of (R)-III·4a, since in this step the final configuration of 
III·5a is determined. DFT study at the B3LYP/6-31G(d,p) level of theory were 
performed taking into account the two possible spatial arrangement of the more 
stable Z-imine in the reagents-catalyst complex,
21
 leading to the diastereoisomeric 
transition state models TS-A and TS-B (Figure 3).  
All the calculations were performed with the Spartan ’08 22 suite. The energy 
profiles clearly indicate a strong preference for TS-A, with a ΔΔG‡ = 1.47 
Kcal/mol with respect to TS-B, at T = 323K, from which an expected 85% ee 
could be calculated.  
These results are in satisfactory agreement with the experimentally observed ee's, 
and once again support the previously predicted (S)-configuration for major 
diastereoisomer III·9a. Looking at the transition state 3D structures, the steric 
hindrance between one phenyl substituent of (R)-III·4a and the ureidic residue 
could explain the higher activation energy of TS-B and the resulting favored 
nucleophilic attack on the si-face of the imine (TS-A). Moreover, in TS-A a 
hydrogen bond between the ureidic NH of the imine and the carbonyl oxygen of 
the acetoacetate ester is established, thus further stabilizing this structure. 
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Figure 3. Proposed transition states TS-A and TS-B (and the corresponding 3D structures) of 
the BINOL-derived phosphoric acid catalyzed Biginelli-like reaction to give III·5a. 
In 3D TS-B red lines highlight the steric hindrance between one phenyl substituent of (R)-
III·4a and the ureidic residue. 
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III.3 Conclusion 
In conclusion, we developed the first enantioselective organocatalyzed Biginelli-
like reaction applied to a ketone, namely isatin, with good yields and 
enantioselectivity. By employing BINOL-based phosphoric acids as catalysts and 
different isatins and alkyl acetoacetates as substrates, together with urea, a small 
library of enantioenriched spiro[indoline-pyrimidine]-dione derivatives could be 
obtained. Post-condensation reactions have been performed, increasing the 
number of potentially useful compounds. 
The solid state conformation of a Br-containing Biginelli-like compound was 
investigated, putting in evidence its crystallization behaviour leading to the more 
favored racemate, instead of the major enantiomer. The absolute configuration 
at the oxindole C3 quaternary stereocenter was assessed to be (S) for the major 
enantiomer, by means of quantum mechanical methods and NMR spectroscopy 
on diastereoisomeric derivatives. Computational studies on the reaction 
transition state (TS) allowed us to explain the experimentally observed 
enantioselectivity and stereochemical outcome. 
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III.4 Experimental section 
All commercial materials were used without further purification. All solvents 
were of reagent grade or HPLC grade. All reactions were carried out under a 
nitrogen atmosphere unless otherwise noted. All reactions were monitored by 
thin layer chromatography (TLC) on precoated silica gel 60 F254; spots were 
visualized with UV light or by treatment with a 1% aqueous KMnO4 solution. 
Products were purified by flash chromatography on silica gel 60 (230–400 
mesh). 
1
H NMR spectra and 
13
C NMR spectra were recorded on 300 and 400 
MHz spectrometers. Chemical shifts are reported in parts per million relative to 
the residual solvent. 
13
C NMR spectra have been recorded using the APT pulse 
sequence. Multiplicities in 
1
H NMR are reported as follows: s = singlet, d = 
doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution MS 
spectra were recorded with a Q-ToF mass spectrometer, equipped with an ESI 
source. Chiral HPLC analysis was performed with UV Detector and binary HPLC 
pump at 254 nm. Chiralcel OD column was used. Specific optical rotation [α]TD 
was measured with a cell of 1 dm pathlength and 1 mL capacity. The light used 
has a wavelength of 589 nm (Sodium D line). N-substituted isatins
23
 and BINOL-
phosphoric acids
24
 were synthetized according to reported literature. 
 
General procedure for the asymmetric organocatalyzed synthesis of 
compounds III·5a-j. Substituted isatin III·1a-h (0.16 mmol, 1 eq), urea III·2a (0.19 
mmol, 1.2 eq), alkyl acetoacetate III·3a-c (0.48 mmol, 3 eq) and (R)-III·4a 
catalyst (0.03 mmol, 0.2 eq) were dissolved in toluene (0.800 mL, 0.2 M). The 
reaction was stirrer at 50 °C for 96 hours. The resulting mixture was then 
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concentrated under reduced pressure, to give a residue which was purified by 
flash chromatography (FC) as indicated below. 
(S)-ethyl 1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-
pyrimidine]-5'-carboxylate (III·5a). Prepared according to general procedure 
starting from N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 60%; white solid; mp 223-224 
o
C; 
[α]20D – 45.5 (c 0.2, CHCl3); 1H NMR (400 MHz, CDCl3) δ 8.50 (br s, 1H), 7.42 
(d, J = 7.4 Hz, 2H), 7.38 – 7.24 (m, 4H), 7.21 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 
7.5 Hz, 1H), 6.76 (d, J = 7.8 Hz, 1H), 5.69 (br s, 1H), 4.99 (d, J = 15.5 Hz, 1H), 
4.80 (d, J = 15.5 Hz, 1H), 3.99 – 3.86 (m, 1H), 3.70 – 3.55 (m, 1H), 2.38 (s, 
3H), 0.71 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ 176.5, 165.2, 151.9, 
149.9, 143.2, 136.3, 132.9, 130.5, 129.5 (2C), 128.5 (3C), 124.6, 124.0, 109.9, 
99.4, 64.2, 60.6, 45.0, 20.1, 14.1; HRMS (ESI) calcd for C22H21N3NaO4
+ 
[MNa]
+
 
414.1434, found 414.1442; enantiomeric excess: 80%, determined by chiral HPLC 
(n-hexane:isopropanol = 80:20, flow rate 1.0 mL/min): tR = 14.98 min (major), 
tR = 33.78 min (minor). 
(S)-ethyl 1-(4-methoxybenzyl)-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-
spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (III·5b). Prepared according to 
general procedure starting from N-(4-methoxybenzyl) isatin and ethyl 
acetoacetate; FC: dichlorometane:methanol, 97.5:2.5; yield: 63%; white solid; 
mp 193-194 
o
C; [α]20D + 4.5 (c 0.35, CHCl3); 1H NMR (300 MHz, CDCl3, mixture 
of conformers 6:1) δ 8.87 (br s, 0.15H), 8.74 (br s, 0.85H), 7.33 (d, J = 8.7 Hz, 
2H), 7.26 (d, J = 8.2 Hz, 1H), 7.17 (t, J = 7.7 Hz, 1H), 6.98 (t, J = 7.3 Hz, 1H), 
6.88 – 6.70 (m, 3H), 6.01 (br s, 0.86H), 5.81 (br s, 0.14H), 4.85 (d, J = 15.3 Hz, 
1H), 4.71 (d, J = 15.3 Hz, 1H), 3.96 – 3.78 (m, 1H), 3.74 (s, 0.43H), 3.71 (s, 
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2.57H), 3.64 – 3.43 (m, 1H), 2.33 (s, 0.44H), 2.27 (s, 2.56H), 0.64 (t, J = 7.1 
Hz, 3H). 
13
C NMR (75 MHz, CDCl3, mixture of conformers 6:1) δ 175.9, 164.6, 
159.1, 152.1, 149.5, 142.6, 132.5, 129.7, 129.2 (2C), 127.8, 123.9, 123.2, 114.1 
(2C), 109.2, 98.5, 63.4, 59.8, 55.2, 43.7, 19.1, 13.5; HRMS (ESI) calcd for 
C23H23N3NaO5
+ 
[MNa]
+
 444.1530, found 444.1519; enantiomeric excess: 75%, 
determined by chiral HPLC (n-hexane:isopropanol = 65:35, flow rate 1.0 
mL/min): tR = 9.85 min (major), tR = 27.96 min (minor). 
(S)-ethyl 6'-methyl-1-(4-nitrobenzyl)-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-
3,4'-pyrimidine]-5'-carboxylate (III·5c). Prepared according to general procedure 
starting from N-(4-nitrobenzyl) isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 49%; white solid; mp 201-202 
o
C; 
[α]20D – 8.2 (c 0.3, CHCl3); 1H NMR (300 MHz, CDCl3, mixture of conformers 
5:1) δ 8.48 (br s, 0.17H), 8.40 (br s, 0.83H), 8.21 – 8.08 (m, 2H), 7.65 – 7.54 
(m, 2H), 7.30 (d, J = 7.3 Hz, 1H), 7.19 (t, J = 7.3 Hz, 1H), 7.03 (t, J = 7.5 Hz, 
1H), 6.62 (d, J = 7.6 Hz, 1H), 6.28 (br s, 0.84H), 6.12 (br s, 0.16H), 5.09 – 4.87 
(m, 2H), 4.07 – 3.89 (m, 1H), 3.86 – 3.68 (m, 1H), 2.34 (s, 0.5H), 2.30 (s, 
2.5H), 0.88 (m, 3H). 
13
C NMR (75 MHz, CDCl3, mixture of conformers 5:1) δ 
176.0, 164.6, 151.8, 149.0, 147.5, 143.0, 141.9, 132.2, 130.0, 128.4 (2C), 124.1, 
124.0 (2C), 123.8, 109.0, 98.9, 63.51, 60.3, 43.7, 19.5, 13.8; HRMS (ESI) calcd 
for C22H20N4NaO6
+ 
[MNa]
+
 459.1275, found 459.1268; enantiomeric excess: 
70%, determined by chiral HPLC (n-hexane:isopropanol = 50:50, flow rate 1.0 
mL/min): tR = 10.05 min (major), tR = 45.50 min (minor). 
(S)-ethyl 1,6'-dimethyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-
pyrimidine]-5'-carboxylate (III·5d). Prepared according to general procedure 
starting from N-methyl isatin and ethyl acetoacetate; FC: 
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dichlorometane:methanol, 95:5; yield: 93%; white solid; mp 228-229 
o
C; [α]20D 
– 1.6 (c 0.35, CHCl3); 1H NMR (400 MHz, DMSO-d6) δ 9.45 (br s, 1H), 7.75 (br 
s, 1H), 7.30 (t, J = 7.7 Hz, 1H), 7.18 (d, J = 7.3 Hz, 1H), 7.01 (t, J = 7.4 Hz, 
1H), 6.97 (d, J = 7.8 Hz, 1H), 3.68 (q, J = 7.1 Hz, 2H), 3.10 (s, 3H), 2.26 (s, 
3H), 0.75 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, DMSO-d6) δ 176.2, 164.8, 
150.9 (2C), 144.0, 134.0, 129.6, 123.4, 122.8, 108.7, 97.1, 63.1, 59.5, 26.6, 18.7, 
13.8; HRMS (ESI) calcd for C16H17N3NaO4
+ 
[MNa]
+
 338.1111, found 338.1123; 
enantiomeric excess: 50%, determined by chiral HPLC (n-hexane:isopropanol = 
65:35, flow rate 1.0 mL/min): tR = 7.25 min (major), tR = 38.20 min (minor). 
(S)-ethyl 1-benzyl-5-fluoro-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-
3,4'-pyrimidine]-5'-carboxylate  (III·5e). Prepared according to general procedure 
starting from 5-fluoro-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 51%; white solid; mp 135-136 
o
C; 
[α]20D + 3.8 (c 0.3, CHCl3); 1H NMR (300 MHz, CDCl3, mixture of conformers 
5:1) δ 8.76 – 8.49 (br, m, 1H), 7.38 (d, J = 7.2 Hz, 2H), 7.34 – 7.16 (m, 3H), 
7.03 (dd, J = 7.3, 2.5 Hz, 1H), 6.88 (td, J = 8.8, 2.4 Hz, 1H), 6.67 (dd, J = 8.5, 
3.8 Hz, 1H), 6.13 – 5.88 (br, m, 1H), 4.92 (d, J = 15.5 Hz, 1H), 4.76 (d, J = 15.5 
Hz, 1H), 4.04 – 3.83 (m, 1H), 3.74 – 3.52 (m, 1H), 2.35 (s, 0.5H), 2.30 (s, 
2.5H), 0.83 – 0.68 (m, 3H). 13C NMR (75 MHz, CDCl3, mixture of conformers 
5:1) δ 175.7, 164.4, 161.1, 157.9, 151.80, 149.75, 138.42, 135.34, 128.77 (2C), 
127.81, 127.74 (2C), 116.17 and 115.86 (1C), 112.19 and 111.9 (1C), 110.0 and 
109.9 (1C), 98.2, 63.6, 60.1, 44.4, 19.3, 13.6; HRMS (ESI) calcd for 
C22H20FN3NaO4
+ 
[MNa]
+
 432.1330, found 432.1326; enantiomeric excess: 75%, 
determined by chiral HPLC (n-hexane:isopropanol = 70:30, flow rate 1.0 
mL/min): tR = 8.15 min (major), tR = 16.35 min (minor). 
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(S)-ethyl 1-benzyl-5-chloro-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-
3,4'-pyrimidine]-5'-carboxylate (III·5f). Prepared according to general procedure 
starting from 5-chloro-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 66%; white solid; mp 126-127 
o
C; 
[α]20D + 33.6 (c 0.2, CHCl3); 1H NMR (300 MHz, CDCl3, mixture of conformers 
5:1) δ 8.76 (br s, 0.16H), 8.69 (br s, 0.84H), 7.37 (d, J = 7.1 Hz, 2H), 7.33 – 
7.18 (m, 4H), 7.14 (d, J = 8.3, 1H), 6.67 (d, J = 8.3 Hz, 1H), 6.24 (br s, 0.83H), 
6.18 (br s, 0.17H), 4.90 (d, J = 15.6 Hz, 1H), 4.77 (d, J = 15.7 Hz, 1H), 4.01 – 
3.84 (m, 1H), 3.75 – 3.56 (m, 1H), 2.34 (s, 0.5H), 2.29 (s, 2.5H), 0.83 – 0.68 
(m, 3H). 
13
C NMR (75 MHz, CDCl3) δ 175.5, 164.4, 151.9, 149.8, 141.1, 135.2, 
134.0, 129.7, 128.8 (2C), 128.5, 127.8, 127.7 (2C), 124.3, 110.3, 98.1, 63.4, 60.1, 
44.4, 19.3, 13.6; HRMS (ESI) calcd for C22H20ClN3NaO4
+
 [MNa]
+
 448.1035, 
found 448.1049; enantiomeric excess: 74%, determined by chiral HPLC (n-
hexane:isopropanol = 70:30, flow rate 1.0 mL/min): tR = 9.05 min (major), tR = 
16.45 min (minor). 
(S)-ethyl 1-benzyl-6-chloro-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-
3,4'-pyrimidine]-5'-carboxylate (III·5g). Prepared according to general procedure 
starting from 6-chloro-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 62%; white solid; mp 213-214 
o
C; 
[α]20D – 1.0 (c 0.3, CHCl3); 1H NMR (300 MHz, CDCl3) δ 8.44 (br s, 1H), 7.39 (d, 
J = 7.0 Hz, 2H), 7.35 – 7.22 (m, 3H), 7.19 (d, J = 7.7 Hz, 1H), 6.98 (d, J = 7.6 
Hz, 1H), 6.79 (s, 1H), 6.14 (br s, 1H), 4.90 (d, J = 15.5 Hz, 1H), 4.75 (d, J = 15.5 
Hz, 1H), 3.90 (m, 1H), 3.60 (m, 1H), 2.29 (s, 3H), 0.74 (t, J = 6.8 Hz, 3H). 
13
C 
NMR (75 MHz, CDCl3) δ 175.8, 164.4, 151.9, 149.4, 143.9, 135.6, 135.1, 130.7, 
128.8 (2C), 127.9, 127.8 (2C), 124.8, 123.1, 109.9, 98.4, 63.0, 60.1, 44.4, 19.2, 
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13.6; HRMS (ESI) calcd for C22H20ClN3NaO4
+
 [MNa]
+
 448.1035, found 
448.1039; enantiomeric excess: 77%, determined by chiral HPLC (n-
hexane:isopropanol = 65:35, flow rate 1.0 mL/min): tR = 8.65 min (major), tR = 
15.35 min (minor). 
(S)-ethyl 1-benzyl-6-bromo-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-
3,4'-pyrimidine]-5'-carboxylate (III·5h). Prepared according to general procedure 
starting from 6-bromo-N-benzyl isatin and ethyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 63%; white solid; mp 221-222 
o
C; 
[α]20D + 7.6 (c 0.55, CHCl3); 1H NMR (300 MHz, CDCl3) δ 8.52 (br s, 1H), 7.39 
(d, J = 7.3 Hz, 2H), 7.26 (m, 3H), 7.18 – 7.06 (m, 2H), 6.95 (s, 1H), 6.22 (br s, 
1H), 4.87 (d, J = 15.6 Hz, 1H), 4.75 (d, J = 15.6 Hz, 1H), 4.00 – 3.77 (m, 1H), 
3.70 – 3.49 (m, 1H), 2.27 (s, 3H), 0.72 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 
CDCl3) δ 175.7, 164.4, 152.0, 149.5, 144.0, 135.1, 131.3, 128.8 (2C), 127.9, 127.8 
(2C), 126.1, 125.2, 123.4, 112.6, 98.3, 63.1, 60.1, 44.1, 19.2, 13.6; HRMS (ESI) 
calcd for C22H20BrN3NaO4
+ 
[MNa]
+
 492.0529, found 492.0518; enantiomeric 
excess: 75%, determined by chiral HPLC (n-hexane:isopropanol = 70:30, flow 
rate 1.0 mL/min): tR = 9.35 min (major), tR = 16.50 min (minor). 
(S)-methyl 1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-
pyrimidine]-5'-carboxylate (III·5i). Prepared according to general procedure 
starting from N-benzyl isatin and methyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 65%; white solid; mp 143-144 
o
C; 
[α]20D – 6.8 (c 0.35, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.77 (br s, 1H), 7.40 
(d, J = 7.7 Hz, 2H), 7.36 – 7.23 (m, 4H), 7.20 (td, J = 7.8, 1.2 Hz, 1H), 7.01 (t, 
J = 7.5 Hz, 1H), 6.75 (d, J = 7.7 Hz, 1H), 5.29 (br s, 1H), 4.94 (d, J = 15.5 Hz, 
1H), 4.83 (d, J = 15.4 Hz, 1H), 3.20 (s, 3H), 2.37 (s, 3H). 
13
C NMR (75 MHz, 
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CDCl3) δ 175.8, 165.0, 151.3, 149.2, 142.3, 135.6, 132.1, 129.9, 128.8 (2C), 127.9 
(2C), 127.8, 123.8, 123.3, 109.2, 98.7, 63.5, 51.0, 44.3, 19.4; HRMS (ESI) calcd 
for C21H19N3NaO4
+
 [MNa]
+
 400.1268, found 400.1257; enantiomeric excess: 
61%, determined by chiral HPLC (n-hexane:isopropanol = 70:30, flow rate 1.0 
mL/min): tR = 9.15 min (major), tR = 18.30 min (minor). 
(S)-benzyl 1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-spiro[indoline-3,4'-
pyrimidine]-5'-carboxylate (III·5j). Prepared according to general procedure 
starting from N-benzyl isatin and benzyl acetoacetate; FC: 
dichlorometane:methanol, 97.5:2.5; yield: 55%; white solid; mp 147-148 
o
C; 
[α]20D +17.2 (c 0.5, dioxane); 1H NMR (300 MHz, CDCl3) δ 8.15 (br s, 1H), 7.41 – 
7.17 (m, 10H), 7.18 – 7.09 (m, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.85 (d, J = 6.5 
Hz, 1H), 6.44 (d, J = 7.8 Hz, 1H), 5.39 (br s, 1H), 4.85 – 4.70 (m, 2H), 4.63 (d, 
J = 12.0 Hz, 1H), 3.81 (d, J = 15.6 Hz, 1H), 2.39 (s, 3H). 
13
C NMR (75 MHz, 
CDCl3) δ 175.8, 164.4, 162.2, 150.2, 142.3, 135.8, 132.2, 129.9, 128.9 (4C), 128.6 
(2C), 128.3, 127.8, 127.7 (2C), 124.0, 123.4, 109.8, 66.5, 43.8, 19.6 (3 
quaternary carbons are missed); HRMS (ESI) calcd for C27H23N3NaO4
+
 [MNa]
+
 
476.1581, found 476.1589; enantiomeric excess: 74%, determined by chiral 
HPLC (n-hexane:isopropanol = 80:20, flow rate 1.0 mL/min): tR = 13.50 min 
(major), tR = 28.20 min (minor). 
 
Post-transformations 
Procedure for the synthesis of ethyl (S)-1,1'-dibenzyl-6'-methyl-2,2'-dioxo-2',3'-
dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxylate (III·6). To a solution of 
compound III·5a (0.25 mmol, 1 eq) in anhydrous dimethylformamide (0.830 mL, 
0.3 M), CsCO3 (0.33 mmol, 1.3 eq) was added, then the mixture was stirred for 1 
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hour at room temperature. Benzyl bromide (0.38 mmol, 1.5 eq) was slowly 
added and the mixture was stirred overnight. After the completion of reaction 
(monitored by TLC), saturated aq. NaCl (1 mL) was added. The reaction mixture 
was extracted with ethyl acetate (3 x 2 mL). The combined organic layer was 
washed with water (2 x 6 mL), followed by brine (2 x 6 mL). the organic phase 
was dried over anhydrous Na2SO4 and concentrated in vacuo to afford the crude 
product, which was purified by FC (n-hexane:ethyl acetate, 7:3), affording the 
desired product III·6 (115 mg, 96%) as a white solid; mp 91-92 
o
C; [α]20D – 32.4 
(c 0.5, CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 7.51 – 7.24 (m, 11H), 7.21 (d, J = 
7.7 Hz, 1H), 7.02 (t, J = 7.4 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 5.32 (d, J = 17.0 
Hz, 1H), 5.16 (br s, 1H), 5.00-4.78 (m, 3H), 3.91 – 3.73 (m, 1H), 3.57 – 3.42 (m, 
1H), 2.40 (s, 3H), 0.52 (t, J = 7.1 Hz, 3H);
 13
C NMR (75 MHz, CDCl3) δ 175.9, 
165.1, 152.2, 150.7, 142.9, 137.7, 135.6, 131.7, 129.8, 128.9 (2C), 128.7 (2C), 
127.8 (3C), 127.1, 126.0 (2C), 123.9, 123.2, 109.1, 101.9, 62.3, 60.0, 46.0, 44.2, 
16.8, 13.2; HRMS (ESI) calcd for C29H27N3NaO4
+
 [MNa]
+
 504.1894, found 
504.1898. 
Procedure for the synthesis of (S)-1-benzyl-6'-methyl-2,2'-dioxo-2',3'-dihydro-1'H-
spiro[indoline-3,4'-pyrimidine]-5'-carboxylic acid (III·7). Palladium (10 wt.% on 
carbon, 0.025 mmol, 0.05 eq) was added to a solution of Biginelli-adduct III·5j 
(0.50 mmol, 1 eq) and Et3N (0.50 mmol, 1 eq) in 7.5 mL of dioxane/methanol 
(2:1). The reaction mixture was degassed in vacuo, placed under an atmosphere 
of H2 (g), and stirred in the dark at rt for 3h. The mixture was filtered through a 
pad of Celite eluting with methanol (10 mL), and the combined organic layers 
were concentrated in vacuo to give the crude carboxylic acid derivative III·7 (173 
mg, 95%) as a white solid, sufficiently pure to be directly used in the next step; 
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mp not misured (decomposition); [α]20D – 19.2 (c 0.25, CHCl3);  1H NMR (300 
MHz, DMSO-d6) δ 11.97 (br s, 1H), 9.39 (br s, 1H), 7.89 (br s, 1H), 7.47 (d, J = 
6.7 Hz, 2H), 7.39 – 7.25 (m, 3H), 7.23 (d, J = 7.2 Hz, 1H), 7.16 (t, J = 7.7 Hz, 
1H), 6.98 (t, J = 7.4 Hz, 1H), 6.62 (d, J = 7.7 Hz, 1H), 4.96 (d, J = 16.3 Hz, 
1H), 4.70 (d, J = 16.3 Hz, 1H), 2.29 (s, 3H); 
13
C NMR (75 MHz, DMSO-d6) δ 
176.1, 166.4, 150.7, 149.4, 142.7, 136.3, 133.9, 128.8, 128.3 (2C), 127.1 (2C), 
127.0, 123.0, 122.3, 108.9, 97.8, 63.0, 43.4, 18.5; HRMS (ESI) calcd for 
C20H17N3NaO4
+
 [MNa]
+
 386.1111, found 386.1121. 
Procedure for the synthesis of (R)-1-benzyl-6'-methyl-1'H-spiro[indoline-3,4'-
pyrimidine]-2,2'(3'H)-dione (III·8). To a solution of the carboxylic acid derivative 
III·7 (0.1 mmol, 1 eq) in 1 mL of dioxane/methanol (1:1), hydrochloric acid in 
dioxane (4 M, 0.4 mmol, 4 eq) was added, and the reaction was stirred at 90 °C 
for 0.5h. The solvent was removed under reduced pressure to afford compound 
III·8 (31 mg, 98%) in high purity as a white solid, with no need for further 
purifications; mp 95-96 
o
C; [α]20D – 25.6 (c 0.5, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.82 (br s, 1H), 7.40 (d, J = 7.3 Hz, 1H), 7.37 – 7.23 (m, 5H), 7.18 (t, J 
= 7.7 Hz, 1H), 7.06 (t, J = 7.5 Hz, 1H), 6.71 (d, J = 7.8 Hz, 1H), 5.72 (br s, 1H), 
4.93 (d, J = 15.6 Hz, 1H), 4.79 (d, J = 15.6 Hz, 1H), 4.24 (s, 1H), 1.86 (s, 3H). 
13
C NMR (100 MHz, CDCl3) δ 177.2, 154.4, 142.0, 136.4, 136.1, 132.6, 130.5, 
129.5 (2C), 128.4, 128.0 (2C), 125.7, 124.2, 110.2, 95.4, 64.3, 44.7, 19.4; HRMS 
(ESI) calcd for C19H17N3NaO2
+
 [MNa]
+
 342.1213, found 342.1206. 
Procedure for the synthesis of diastereoisomers (S)-1-benzyl-6'-methyl-2,2'-dioxo-
N-((S)-1-phenylethyl)-2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-
carboxamide (III·9a) and (R)-1-benzyl-6'-methyl-2,2'-dioxo-N-((S)-1-phenylethyl)-
2',3'-dihydro-1'H-spiro[indoline-3,4'-pyrimidine]-5'-carboxamide (III·9b).  To a 
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solution of carboxylic acid derivative III·8 (0.9 mmol, 1 eq) and DIPEA (1.8 
mmol, 2 eq) in 9.4 mL of anhydrous dimethylformamide, HATU (1.4 mmol, 1.5 
eq) was added. After 5 min, (S)-(−)-α-methylbenzylamine (0.9 mmol, 1 eq) and 
DIPEA (1.8 mmol, 2 eq) were added, and the reaction was stirred at room 
temperature for 24 hours. The resulting mixture was partitioned between ethyl 
acetate (20 mL) and water (20 mL). The organic phase was washed with brine (6 
x 10 mL), dried over Na2SO4 and concentrated in vacuo to afford the crude 
diastereoisomeric mixture III·9, which was purified by flash chromatography 
(ethyl acetate:n-hexane, 95:5), obtaining the two isolated stereoisomers III·9a 
(358 mg, 86%) and III·9b (54 mg, 12%). 
III·9a: white solid; mp 149-150 
o
C; [α]20D   +16.5 (c 0.9, CHCl3); 1H NMR (400 
MHz, DMSO-d6) δ 8.79 (br s, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.62 (br s, 1H), 7.46 
(d, J = 7.3 Hz, 2H), 7.33 (d, J = 7.4 Hz, 1H), 7.32 – 7.22 (m, 7H), 7.18 (q, J = 
8.4, 7.8 Hz, 2H), 7.00 (t, J = 7.5 Hz, 1H), 6.63 (d, J = 7.8 Hz, 1H), 4.78 (s, 
2H), 4.71 – 4.59 (m, 1H), 1.91 (s, 3H), 1.04 (d, J = 7.0 Hz, 3H). 13C NMR (100 
MHz, DMSO-d6) δ 177.4, 165.6, 153.2, 145.3, 144.4, 138.0, 137.3, 132.4, 130.2, 
129.4 (2C), 129.3 (2C), 128.3 (2C), 128.1, 127.6, 127.2 (2C), 125.3, 123.0, 109.9, 
105.1, 64.3, 48.6, 44.2, 23.0, 18.3. HRMS (ESI) calcd for C28H26N4NaO3
+
 [MNa]
+ 
489.1897, found 489.1905. 
III·9b: white solid; mp 138-139 
o
C; [α]20D – 89.5 (c 1, CHCl3); 1H NMR (400 MHz, 
DMSO-d6) δ 8.81 (br s, 1H), 8.13 (d, J = 8.3 Hz, 1H), 7.62 (br s, 1H), 7.42 (d, J 
= 6.4 Hz, 2H), 7.31 (d, J = 7.2 Hz, 1H), 7.29 – 7.19 (m, 3H), 7.17 (t, J = 7.6 
Hz, 1H), 7.11 (m, 3H), 7.00 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 7.4 Hz, 2H), 6.57 
(d, J = 7.8 Hz, 1H), 4.88 – 4.67 (m, 3H), 2.01 (s, 3H), 1.32 (d, J = 7.0 Hz, 3H). 
13
C NMR (100 MHz, DMSO-d6) δ 177.4, 165.6, 153.0, 144.9, 144.32, 138.3, 
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137.3, 132.7, 130.1, 129.4 (2C), 128.9 (2C), 128.2 (2C), 128.07, 127.1, 126.8 (2C), 
125.3, 123.2, 110.0, 105.12, 64.4, 48.1, 44.2, 22.5, 18.4. HRMS (ESI) calcd for 
C28H26N4NaO3
+
 [MNa]
+ 
489.1897, found 489.1909. 
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IV. Spirooxindole-fused 3-Thiazoline Compounds: 
Asinger-Type Reaction 
 
A one-pot, three-component reaction has been developed and successfully 
employed for the synthesis of biologically relevant, highly functionalized 
spirooxindole-fused 3-thiazoline derivatives. Starting from ammonia, three 
different mercapto carbonyl components and a series of differently substituted 
isatins, products were obtained in good yields (24 examples), by means of a 
simple and rapid protocol. The obtained thiazolines proved to be optimal 
substrates for further transformations, including the three-component Ugi-Joullié 
reaction.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Published in Synlett, 2016, 27, 2831-2836. 
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IV.1 Introduction 
Thiazoline heterocycles are privileged motifs found in an array of biologically 
active natural products. For instance, they represent a relevant structural 
fragment of various cyclopeptide alkaloids extracted from different marine 
organisms and endowed with a promising cytotoxic activity (Figure 1).
1
 
Compounds bearing thiazoline moieties have also been reported to exhibit a 
wide spectrum of different biological effects, including anti-tubercular,
2
 anti-
inflammatory
3,4
 and antimicrobial
5
 activity, boosting numerous synthetic and 
medicinal chemistry investigations.
6,7
 Recently, many research groups have paid 
attention to the anticancer properties of thiazoline-based compounds, ranging 
from cytotoxicity against various cell lines
8
 to histone deacetylase inhibitory 
activity
9
 and MDM2-p53 protein-protein interaction modulation.
10
 As part of our 
interest in the synthesis of spirooxindoles,
11
 we looked into the biological 
significance of the thiazoline ring, aiming to introduce it as a spiro-fused 
heterocycle in our oxindole-based drug discovery programs.
12
 It is well known as  
the conjugation of privileged heterocycles into spiro structures is of special 
interest, being able to provide compounds with great three-dimensionality, often 
 
 
Figure 1. Examples of products containing thiazoline and 3,3’-disubstituted oxindole motifs. 
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improved properties in their interaction with biological systems and overall more 
likely to be successfully developed as drugs.
13
 Spirocyclic oxindoles have recently 
emerged as attractive targets, since they seem to be promising candidates for their 
anticancer potentials.
14
 Among the class, there are natural products like 
Spirotryprostatins A and B
15
 and synthetic spirooxindoles such as MI-888, 
currently in preclinical research for the treatment of human cancers.
16
 The 
common characteristic of such bioactive compounds is the presence of various 
heterocyclic motifs, jointed at the C-3 position of the oxindole core. This key 
structural element is the focus of a huge interest to develop rapid and efficient 
synthetic methods providing access to such spiro building blocks. 
In the context of sulfur-containing compounds' synthesis, a number of methods 
have been carried out for the preparation of spirooxindole-based 4-
thiazolidinones, by reacting amines with isatins and mercaptoacetic acid under 
different conditions.
17
 At the best of our knowledge, no efforts have been made 
yet in synthesizing spiro oxindole-fused 3-thiazolines, which would represent 
more versatile intermediates, thanks to the presence of the reactive C-N double 
bond. 
Relying on our previous experience in multicomponent reactions (MCRs) applied 
to the synthesis of heterocyclic compounds,
18
 we turned our attention to the 
Asinger sulfur-involving MCR.
19
 The method, which allows to synthesize the 
thiazoline scaffold by treating a ketone with sulfur and ammonia, exhibits high 
atom-economy (Scheme 1). 
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Scheme 1. Most widely accepted mechanism for the Asinger four 
components reaction (A-4CR). 
 
However, considerable more flexibility with respect to the original protocol is 
seen in the “resynthesis”, also discovered by Asinger, that is the reaction of 
preformed -sulfanyl-ketones or aldehydes with ammonia and an oxo 
component, able to largely widen the scope of substituents on the thiazoline ring 
(Scheme 2).
20
 Herein we report the first application of an Asinger-type reaction 
to isatin as the oxo component, allowing the synthesis of a large family of 
unprecedented 5'H-spiro[indoline-3,2'-thiazol]-2-one derivatives. 
 
IV.2 Results and Discussion 
Initially, N-benzyl-isatin IV∙1a and 1-mercaptopropan-2-one IV∙2a were selected 
to optimize the reaction conditions (Table 1). Since the reaction conducted by 
 
 
Scheme 2. “Resynthesis” variant of the Asinger reaction. 
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simultaneous addition of all components proved to be sluggish, probably due to 
the high instability of the isatin-derived NH-imine,
21
 we introduced a waiting 
time of 8 h before adding the mercapto component, in order to maximize the 
imine formation. Using aqueous ammonia solution in MeOH as solvent, after 
addition of IV∙2a the desired thiazoline IV∙3a could be detected only in traces 
(entry 1). We obtained better results employing 2N ammonia solution in 
methanol and changing the solvent to toluene. The addition of a dehydrating 
agent proved to be beneficial, with MgSO4 working better than molecular sieves 
(entry 2-3). Finally, lowering the substrate concentration elongated the reaction 
time reducing the conversion, while increasing the concentration gave a clean 
reaction, with a high isolated yield for IV∙3a (entries 4-5). Finally, also CH2Cl2 
proved to be a good solvent for the reaction, although thiazoline IV∙3a could be 
isolated in a bit lower yield (entry 6).  
 
Table 1. Optimization of the one-pot reaction conditions.a 
 
 
Entry Solvent 
Conc. 
[M] 
Dehydr.  agent Ammonia source Yield (%)
b
 
1 MeOH 0.5 none aq. NH3 trace 
2 Toluene 0.5 3Å ms NH3 2N in MeOH 60 
3 Toluene 0.5 MgSO4 NH3 2N in MeOH 66 
4 Toluene 0.3 MgSO4 NH3 2N in MeOH 61 
5 Toluene 1.0 MgSO4 NH3 2N in MeOH 88 
6 CH2Cl2 1.0 MgSO4 NH3 2N in MeOH 84 
a Reaction conditions: N-benzyl-isatin IV∙1a (0.25 mmol), NH3 (0.5 mmol); then 1-
mercaptopropan-2-one IV∙2a (0.3 mmol). b Isolated yields. ms = molecular sieves. 
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Therefore, the optimized conditions for this one-pot reaction has been found by 
adding 2N ammonia solution in methanol (0.5 mmol) to a toluene solution of 
IV∙1a (0.25 mmol), waiting for 8 h and then completing the reaction by addition 
of IV∙2a (0.3 mmol). The whole process is carried out at room temperature and 
the imine conversion is complete after just 30 minutes from the addition of the 
mercapto component. The scale-up experiment, performed employing 1 mmol of 
isatin IV∙1a, afforded the desired thiazoline IV∙3a in the same time and yield quite 
similar to that obtained on the small scale. 
With the optimized reaction conditions in hand, a variety of diversely substituted 
isatins IV∙1a-r were next explored to investigate the substrate scope of this 
Asinger-type reaction. The generality was also evaluated with respect to the 
mercapto component IV∙2a-c (Scheme 3). 
Working with 1-mercaptopropan-2-one IV∙2a, the protecting group on oxindole 
nitrogen atom was found to have a moderate effect on the reaction, with all 
compounds IV∙3a-g obtained in definitely satisfactory yields starting from 
corresponding isatins IV∙1a-g. Notably, unprotected NH-isatin IV∙1d also afforded 
the corresponding thiazoline derivative IV∙3d in very high yield, as a quite stable 
compound. Next, N-benzyl isatins (IV∙1h-m) with various substituents on the 
aromatic ring were explored. Good yields of the corresponding thiazolines were 
obtained in the presence of a variety of substituents, including an electron-
donating group (compound IV∙3h), halogen substituents (compounds IV∙3i-k,m) 
and a strong electron-withdrawing group (compound IV∙3l) at the 5- or 6-
position on the oxindole aromatic ring. Finally, we investigated the Asinger-type 
reaction with two different mercaptocarbonyl compounds, namely 2-
mercaptoacetaldehyde IV∙2b and ethyl 3-mercapto-2-oxopropanoate IV∙2c. We  
 
Asinger Reaction 
- 82 - 
 
were delighted to see that, also with these components, the desired thiazolines 
could be easily obtained, with yields up to 81% for the most reactive N-Me isatin 
V∙1b in reaction with 2-mercaptoacetaldehyde IV∙2b obtaining IV∙3o. 
Having established the scope of the method, we examined some further 
transformations. 
 
Scheme 3. Synthesis of various spirooxindole-fused 3-thiazoline derivatives.a 
 
 
 
 
continued 
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a Reaction conditions: isatin IV∙1 (1 mmol), NH3 (2 mmol); then compound IV∙2 (1.1 
mmol). Isolated yields are reported. Trt = trityl. PMB = p-Methoxy benzyl. PBB = p-
Bromo benzyl. 
 
The reaction of thiazoline IV∙3a with m-chloroperbenzoic acid under the 
standard conditions gave the sulfoxide IV∙4 in quantitative yield, as a single 
diastereoisomer (as demonstrated by 
1
H and 
13
C NMR spectra) whose relative 
stereochemistry was not further investigated. The latter compound could be then 
successfully further oxidized to sulfone IV∙5. When the reduction of IV∙3a was 
performed under standard conditions, the expected thiazolidine IV∙6 could be 
easily obtained, as an inseparable 7:3 diastereoisomeric mixture. Even more 
interesting, thiazoline IV∙3n proved to be an optimal substrate for a subsequent 
multicomponent reaction (MCR), namely the Ugi-Joullié 3-CR, involving an 
isocyanide and a carboxylic acid as components, beside the cyclic imine. Reacting 
IV∙3n with t-butyl isocyanide and acetic acid, compound IV∙7 was readily 
achieved in high yield, as a 4:1 mixture of IV∙7a and IV∙7b diastereoisomers, that 
could be easily separated by means of flash chromatography (Scheme 4). 
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Scheme 4. Further transformations of spirooxindole-fused 3-thiazolines. 
 
 
 
Diastereoisomers IV∙7a and IV∙7b were fully characterized by means of mono- 
and bi-dimensional NMR. In particular, the NOESY experiment allowed to 
disclose the 2'-4'-trans-configuration for the major diastereoisomer IV∙7a and the 
2'-4'-cis one for the minor IV∙7b. Diagnostic NOE contacts between H4 of the 
oxindole nucleus and thiazolidine's protons (safely assigned on the basis of the 
observed signals' multiplicity and dihedral angles considerations) could be indeed 
easily highlighted for both diastereoisomers. They are reported in Figure 2, 
together with most relevant chemical shift values. 
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Figure 2. Diagnostic NOE contacts for compounds IV∙7a and IV∙7b. 
 
 
 
IV.3 Conclusion 
In conclusion, we have successfully developed the application of an Asinger-type 
reaction to isatin as the oxo component, allowing the synthesis of a large family 
of spirooxindole-fused 3-thiazoline derivatives. The reaction's conditions have 
been optimized and applied to a wide variety of substituted isatins and different 
mercapto components underlining the robustness of the method. In addition, 
some post-transformations have been performed to increase the number of useful 
compounds. In particular, the discovery of the high reactivity of the C-N double 
bond in the thiazoline ring was the starting point for a related project aimed to 
explore diversity oriented synthesis (DOS) of spirooxindole-3-fused thiazolidine 
derivatives as possible leads compounds for drug discovery programs. 
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IV.4 Experimental Section 
All commercial materials (Aldrich, Fluka) were used without further purification. 
All solvents were of reagent grade or HPLC grade. All reactions were carried out 
under a nitrogen atmosphere unless otherwise noted. All reactions were 
monitored by thin layer chromatography (TLC) on precoated silica gel 60 F254; 
spots were visualized with UV light or by treatment with ninhydrin solution in 
ethanol. Products were purified by flash chromatography on silica gel 60 (230–
400 mesh). 
1
H NMR spectra and 
13
C NMR spectra were recorded on 300 and 
400 MHz spectrometers. Chemical shifts are reported in parts per million relative 
to the residual solvent. 
13
C NMR spectra have been recorded using the APT pulse 
sequence. Multiplicities in 
1
H NMR are reported as follows: s = singlet, d = 
doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution MS 
spectra were recorded with a Q-ToF micro TM mass spectrometer, equipped 
with an ESI source. All diversely substituted isatins (IV∙1a-r) were synthesized 
following literature procedures and the analytical data were consistent with those 
reported.
21 
 
 
General procedure A (GP-A) for the synthesis of spirooxindole-fused 3-thiazoline 
derivatives IV∙3a-x. To a solution of isatin derivative IV∙1a-r (1 mmol) in 
anhydrous toluene (1 mL, 1.0 M), MgSO4 (3 mmol) and NH3 solution 2M in 
methanol (2 mmol) were added. The reaction was stirred 8 hours at room 
temperature and then the mercapto-derivative IV∙2a-c was added (1.1 mmol). 
The resulting mixture was stirred for further 30 minutes at the same temperature. 
The reaction was diluted with CH2Cl2 (5 mL) and then the solvent was removed 
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under reduced pressure. The crude was purified by flash chromatography (FC) as 
indicated below. 
1-Benzyl-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3a). Prepared 
according to GP-A using isatin IV∙1a and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 271 mg, 88%; pale orange foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.36-7.24 (m, 6H), 7.19 (t, br, J = 7.7 Hz, 1H), 7.04 (t, br, J = 7.7 Hz, 
1H), 6.69 (d, br, J = 7.8 Hz, 1H), 4.94 (d, J = 15.7 Hz, 1H), 4.84 (d, J = 15.7 
Hz, 1H), 4.43 (d, J = 15.8 Hz, 1H), 4.27 (d, J = 15.8 Hz, 1H), 2.32 (s, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 175.3, 174.9, 142.4, 135.4, 130.2, 129.6, 128.9 (2C), 
127.7, 127.3 (2C), 125.5, 123.5, 109.5, 88.2, 48.7, 44.2, 19.9; HRMS (ESI) calcd 
for C18H16N2NaOS
+
 [MNa]
+
 331.0876, found 331.0884. 
1,4'-Dimethyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3b). Prepared according 
to GP-A using isatin IV∙1b and mercaptoacetone IV∙2a. FC: CH2Cl2:EtOAc, 9:1; 
yield: 209 mg, 90%; brown foam; 
1
H NMR (300 MHz, CDCl3) δ 7.38-7.21 (m, 
2H), 7.08 (t, br, J = 7.7 Hz, 1H), 6.81 (d, br, J = 7.7 Hz, 1H), 4.39 (d, J = 15.8 
Hz, 1H), 4.24 (d, J = 15.8 Hz, 1H), 3.19 (s, 3H), 2.28 (s, 3H); 
13
C NMR (75 
MHz, CDCl3) δ 175.1, 174.6, 143.2, 130.3, 130.0, 125.4, 123.3, 108.4, 88.1, 48.6, 
26.6, 19.8; HRMS (ESI) calcd for C12H12N2NaOS
+
 [MNa]
+
 255.0563, found 
255.0557. 
4'-Methyl-1-trityl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3c). Prepared 
according to GP-A using isatin IV∙1c and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 400 mg, 87%; brown foam; 
1
H NMR (400 MHz, 
CDCl3) δ 7.48 (d, br, J = 7.6 Hz, 6H), 7.36-7.18 (m, 10 H), 6.98 (t, br, J = 7.6 
Hz, 1H), 6.93 (td, J = 7.7 and 1.7 Hz, 1H), 6.27 (d, br, J = 7.8 Hz, 1H), 4.34 (d, 
J = 15.8 Hz, 1H), 4.21 (d, J = 15.8 Hz, 1H), 2.30 (s, 3H); 
13
C NMR (101 MHz, 
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CDCl3) δ 176.4, 176.0, 143.7, 142.5 (3C), 130.3, 130.2(6C), 129.3, 128.6, 128.4 
(6C), 127.6 (3C), 125.5, 123.5, 116.7, 88.8, 48.9, 20.6; HRMS (ESI) calcd for 
C30H24N2NaOS
+
 [MNa]
+
 483.1502, found 483.1511. 
4'-Methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3d). Prepared according to 
GP-A using isatin IV∙1d and mercaptoacetone IV∙2a. FC: CH2Cl2:EtOAc, 7:3; 
yield: 194 mg, 89%; pale orange foam; 
1
H NMR (300 MHz, CDCl3) δ 9.07 (s, 
br, 1H), 7.30-7.16 (m, 2H), 7.03 (d, br, J = 7.7 Hz, 1H), 6.85 (d, br, J = 7.7 Hz, 
1H), 4.39 (d, J = 15.9 Hz, 1H), 4.26 (d, J = 15.9 Hz, 1H), 2.30 (s, 3H); 
13
C NMR 
(75 MHz, CDCl3) δ 177.2, 175.5, 140.5, 130.3, 130.1, 125.7, 123.4, 110.5, 88.7, 
48.6, 19.9; HRMS (ESI) calcd for C11H10N2NaOS
+
 [MNa]
+
 241.0406, found 
241.0413. 
1-Allyl-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3e). Prepared 
according to GP-A using isatin IV∙1e and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 180 mg, 70%; brown foam; 
1
H NMR (300 MHz, 
CDCl3 ) δ 7.37-7.23 (m, 2H), 7.08 (t, br, J = 7.6 Hz, 1H), 6.82 (d, br, J = 7.7 
Hz, 1H), 5.84 (ddt, J = 15.6, 10.8 and 4.9 Hz, 1H), 5.35-5.14 (m, 2H), 4.40 (d, J 
= 16.6 Hz, 1H), 4.32 (m, br, 2H), 4.25 (d, J = 16.6 Hz, 1H), 2.30 (s, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 175.9, 175.1, 143.2, 131.6, 130.8, 130.2, 126.2, 124.0, 
118.6, 110.0, 88.7, 49.3, 43.5, 20.8; HRMS (ESI) calcd for C14H14N2NaOS
+
 
[MNa]
+
 281.0719, found 281.0711. 
1-(4-Methoxybenzyl)-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3f). 
Prepared according to GP-A using isatin IV∙1f and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 209 mg, 62%; brown foam; 
1
H NMR (300 MHz, 
CDCl3 ) δ 7.34 -7.16 (m, 4H), 7.04 (t, br, J = 7.6 Hz, 1H), 6.83 (d, br, J = 8.6 
Hz, 2H), 6.71 (d, br, J = 7.7 Hz, 1H), 4.88 (d, J = 15.5 Hz, 1H), 4.78 (d, J = 
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15.5 Hz, 1H), 4.43 (d, J = 15.8 Hz, 1H), 4.26 (d, J = 15.8 Hz, 1H), 3.76 (s, 3H), 
2.32 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 175.3, 174.8, 159.2, 142.4, 130.2, 
129.6, 128.7 (2C), 127.3, 125.5, 123.4, 114.2 (2C), 109.6, 88.2, 55.3, 48.6, 43.7, 
19.9; HRMS (ESI) calcd for C19H18N2NaO2S
+
 [MNa]
+
 361.0981, found 361.0987. 
1-(4-Bromobenzyl)-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3g). 
Prepared according to GP-A using isatin IV∙1g and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 267 mg, 69%; orange foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.43 (d, br, J = 8.3 Hz, 2H), 7.31 (d, br, J = 7.6 Hz, 1H), 7.25-7.15 
(m, 3H), 7.06 (t, br, J = 7.5 Hz, 1H), 6.64 (d, br, J = 7.7 Hz, 1H), 4.87 (d, J = 
15.6 Hz, 1H), 4.80 (d, J = 15.6 Hz, 1H), 4.43 (d, J = 15.8 Hz, 1H), 4.27 (d, J = 
15.8 Hz, 1H), 2.32 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 175.5, 170.1, 143.1, 
142.1, 132.0, 130.2 (2C), 129.6, 129.1 (2C), 129.0, 125.7, 123.7, 109.3, 88.1, 48.7, 
43.6, 19.9; HRMS (ESI) calcd for C18H15N2BrNaOS
+
 [MNa]
+
 408.9981, found 
408.9988. 
1-Benzyl-5-methoxy-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3h). 
Prepared according to GP-A using isatin IV∙1h and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 237 mg, 70%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.35-7.20 (m, 5H), 6.92 (d, br, J = 2.6 Hz, 1H), 6.72 (dd, J = 8.5, 2.6 
Hz, 1H), 6.57 (d, br, J = 8.5 Hz, 1H), 4.92 (d, J = 15.7 Hz, 1H), 4.82 (d, J = 
15.7 Hz, 1H), 4.44 (d, J = 15.8 Hz, 1H), 4.27 (d, J = 15.8 Hz, 1H), 3.74 (s, 3H), 
2.34 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 175.5, 174.8, 156.6, 135.7, 135.4, 
128.9 (2C), 127.7 (2C), 127.2, 115.4, 112.0, 111.4, 110.2, 88.5, 55.8, 48.7, 44.3, 
19.9; HRMS (ESI) calcd for C19H18N2NaO2S
+
 [MNa]
+
 361.0981, found 361.0974. 
1-Benzyl-5-bromo-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3i). 
Prepared according to GP-A using isatin IV∙1i and mercaptoacetone IV∙2a. FC: 
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CH2Cl2:EtOAc, 19:1; yield: 290 mg, 75%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.40 (d, br, J = 1.9 Hz, 1H), 7.35-7.22 (m, 6H), 6.54 (d, br, J = 8.3 
Hz, 1H), 4.91 (d, J = 15.7 Hz, 1H), 4.81 (d, J = 15.7 Hz, 1H), 4.42 (d, J = 15.8 
Hz, 1H), 4.27 (d, J = 15.8 Hz, 1H), 2.32 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 
176.2, 174.4, 141.4, 134.8, 133.0, 131.7, 129.0 (2C), 128.8, 128.0, 127.2 (2C), 
116.1, 111.1, 87.9, 48.9, 44.3, 19.9; HRMS (ESI) calcd for C18H15BrN2NaOS
+
 
[MNa]
+
 408.9981, found 408.9990. 
1-Benzyl-5-fluoro-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3j). 
Prepared according to GP-A using isatin IV∙1j and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 254 mg, 78%; pale orange foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.38-7.22 (m, 5H), 7.05 (dd, J = 7.8, 2.9 Hz, 4 1H), 6.89 (td, J = 8.8, 
2.9 Hz, 1H), 6.59 (dd, J = 8.8, 4.9 Hz, 1H), 4.93 (d, J = 15.8 Hz, 1H), 4.83 (d, J 
= 15.8 Hz, 1H), 4.44 (d, J = 15.8 Hz, 1H), 4.28 (d, J = 15.8 Hz, 1H), 2.33 (s, 
3H); 
13
C NMR (101 MHz, CDCl3) δ 175.9, 174.8, 159.6 (d, J = 241.8 Hz), 138.3, 
135.0, 131.2 (d, J = 7.4 Hz), 128.9 (2C), 127.9, 127.2 (2C), 116.6 (d, J = 23.6 
Hz), 113.6 (d, J = 25.1 Hz), 110.2 (d, J = 8.8 Hz), 88.1, 48.8, 44.4, 19.9; HRMS 
(ESI) calcd for C18H15FN2NaOS
+
 [MNa]
+
 349.0781, found 349.0786. 
1-Benzyl-5-chloro-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3k). 
Prepared according to GP-A using isatin IV∙1k and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 274 mg, 80%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.36-7.23 (m, 6H), 7.16 (dd, J = 8.3, 1.9 Hz, 1H), 6.59 (d, br, J = 8.3 
Hz, 1H), 4.93 (d, J = 15.8 Hz, 1H), 4.83 (d, J = 15.8 Hz, 1H), 4.44 (d, J = 15.8 
Hz, 1H), 4.28 (d, J = 15.8 Hz, 1H), 2.33 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 
176.0, 174.6, 140.9, 134.9, 131.2, 130.1, 130.0, 129.0 (2C), 127.9, 127.2 (2C), 
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126.1, 110.5, 90.4, 48.8, 44.3, 19.9; HRMS (ESI) calcd for C18H15ClN2NaOS
+
 
[MNa]
+
 365.0486, found 365.0492. 
1-Benzyl-4'-methyl-5-nitro-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3l). Prepared 
according to GP-A using isatin IV∙1l and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 226 mg, 64%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 8.23-8.13 (m, 2H), 7.40-7.23 (m, 5H), 6.77 (d, br, J = 7.8 Hz, 1H), 
4.99 (d, J = 15.6 Hz, 1H), 4.91 (d, J = 15.6 Hz, 1H), 4.48 (d, J = 15.9 Hz, 1H), 
4.36 (d, J = 15.9 Hz, 1H), 2.36 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 175.8, 
175.0, 147.9, 144.0, 134.2, 130.8, 129.2, 128.3 (2C), 127.2 (2C), 127.0, 121.7, 
109.3, 87.4, 49.1, 44.6, 19.9; HRMS (ESI) calcd for C18H15N3NaO3S
+
 [MNa]
+
 
376.0726, found 376.0721. 
1-Benzyl-6-bromo-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3m). 
Prepared according to GP-A using isatin IV∙1m and mercaptoacetone IV∙2a. FC: 
CH2Cl2:EtOAc, 19:1; yield: 252 mg, 65%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.40- 7.14 (m, 7H), 6.84 (s, br, 1H), 4.92 (d, J = 15.7 Hz, 1H), 4.80 (d, 
J = 15.8 Hz, 1H), 4.43 (d, J = 15.8 Hz, 1H), 4.26 (d, J = 15.8 Hz, 1H), 2.33 (s, 
3H); 
13
C NMR (101 MHz, CDCl3) δ 176.0, 174.8, 143.7, 134.7, 129.0 (2C), 128.5, 
128.0, 127.2 (2C), 126.8, 126.4, 123.9, 112.9, 88.9, 48.7, 44.4,19.9; HRMS (ESI) 
calcd for C18H15BrN2NaOS
+
 [MNa]
+
 408.9981, found 408.9987. 
1-Benzyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3n). Prepared according to 
GP-A using isatin IV∙1a and mercaptoacetaldehyde IV∙2b. FC: n-Hexane:EtOAc, 
19:1; yield: 209 mg, 71%; brown foam; 
1
H NMR (300 MHz, CD3OD) δ 7.97 (s, 
br, 1H), 7.44-7.18 (m, 7H), 7.09 (t, br, J = 7.8 Hz, 1H), 6.87 (d, br, J = 7.8 Hz, 
1H), 4.94 (m, 2H), 4.52 (d, br J = 16.8 Hz, 1H), 4.40 (d, br, J = 16.8 Hz, 1H); 
13
C NMR (75 MHz, CD3OD) δ 176.8, 169.0, 143.8, 137.1, 131.9, 131.2, 130.2 
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(2C), 129.2, 128.5 (2C), 127.0, 125.2, 111.4, 90.6, 48.2, 45.1; HRMS (ESI) calcd 
for C17H14N2NaO2S
+
 [MNa]
+
 317.0719, found 317.0711. 
1-Methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3o). Prepared according to 
GP-A using isatin V∙1b and mercaptoacetaldehyde IV∙2b. FC: CH2Cl2:EtOAc, 9:1; 
yield: 176 mg, 81%; orange foam; 
1
H NMR (300 MHz, CDCl3) δ 7.85 (s, br, 1H), 
7.35 (t, br, J = 7.8 Hz, 1H), 7.27 (d, br, J = 7.8 Hz, 1H), 7.10 (t, br, J = 7.8 Hz, 
1H), 6.85 (d, br, J = 7.8 Hz, 1H), 4.50-4.30 (m, 2H), 3.23 (s, 3H); 
13
C NMR (75 
MHz, CDCl3) δ 174.1, 165.2, 143.4, 130.5, 129.4, 125.5, 123.5, 108.6, 89.1, 47.1, 
26.8; HRMS (ESI) calcd for C11H10N2NaOS
+
 [MNa]
+
 241.0406, found 241.0414. 
1-Trityl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3p). Prepared according to GP-
A using isatin IV∙1c and mercaptoacetaldehyde IV∙2b. FC: CH2Cl2:EtOAc, 19:1; 
yield: 277 mg, 62%; yellow foam; 
1
H NMR (300 MHz, CDCl3) δ 7.81 (s, br, 1H), 
7.44 (d, br, J = 7.8 Hz, 6H), 7.33-7.15 (m, 10H), 7.00-6.86 (m, 2H), 6.25 (d, br, 
J = 7.8 Hz, 1H), 4.32 (s, 2H); 
13
C NMR (75 MHz, CDCl3) δ 174.8, 165.5, 143.2, 
141.7 (3C), 141.5, 129.4 (6C), 127.9, 127.7 (6C), 127.0 (3C), 125.0, 122.9, 116.1, 
89.3, 74.6, 46.8; HRMS (ESI) calcd for C29H22N2NaOS
+
 [MNa]
+
 469.1453, found 
469.1446. 
5'H-Spiro[indoline-3,2'-thiazol]-2-one (IV∙3q). Prepared according to GP-A using 
isatin IV∙1d and mercaptoacetaldehyde IV∙2b. FC: CH2Cl2:EtOAc, 7:3; yield: 154 
mg, 68%; grey foam; 
1
H NMR (300 MHz, CDCl3) δ 8.07 (m, br, 1H), 7.87 (s, br, 
1H), 7.36-7.19 (m, 2H), 7.07 (t, br, J = 7.8 Hz, 1H), 6.89 (d, br, J = 7.8 Hz, 
1H), 4.41 (s, 2H); 
13
C NMR (101 MHz, DMSO-d6) δ 175.4, 166.6, 142.0, 130.7, 
126.2, 125.9, 122.9, 110.6, 89.6, 47.3. HRMS (ESI) calcd for C10H8N2NaOS
+
 
[MNa]
+
 227.0250, found 227.0259. 
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5-Methoxy-1-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3r). Prepared 
according to GP-A using isatin IV∙1n and mercaptoacetaldehyde IV∙2b. FC: 
CH2Cl2:EtOAc, 9:1; yield: 169 mg, 68%; grey foam; 
1
H NMR (300 MHz, CDCl3) 
δ 7.85 (s, br, 1H), 6.92-6.85 (m, 2H), 6.75 (d, br, J = 7.8 Hz, 1H), 4.43 (d, J = 
16.6 Hz, 1H), 4.37 (dd, J = 16.6 and 1.9 Hz, 1H), 3.77 (s, 3H), 3.20 (s, 3H); 
13
C 
NMR (75 MHz, CDCl3) δ 174.0, 165.4, 156.7, 136.7, 130.5, 115.5, 112.1 109.2, 
89.4, 55.9, 47.1, 26.8 ; HRMS (ESI) calcd for C12H12N2NaO2S
+
 [MNa]
+
 271.0512, 
found 271.0519. 
5-Bromo-1-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3s). Prepared 
according to GP-A using isatin IV∙1o and mercaptoacetaldehyde IV∙2b. FC: 
CH2Cl2:EtOAc, 9:1; yield: 196 mg, 66%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.85 (s, br, 1H), 7.47 (dd, J = 7.8 and 2.0 Hz, 1H), 7.37 (d, br, J = 1.9 
Hz, 1H), 6.73 (d, br, J = 7.8 Hz, 1H), 4.50-4.320 (m, 2H), 3.20 (s, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 173.6, 165.6, 142.5, 133.3, 131.3, 128.8, 116.0, 110.1, 
88.8, 47.3, 26.9; HRMS (ESI) calcd for C11H9BrN2NaOS
+
 [MNa]
+
 318.9511, found 
318.9504. 
5-Fluoro-1-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3t). Prepared 
according to GP-A using isatin IV∙1p and mercaptoacetaldehyde IV∙2b. FC: 
CH2Cl2:EtOAc, 9:1; yield: 167 mg, 71%; grey foam; 
1
H NMR (400 MHz, CDCl3) 
δ 7.86 (s, 1H), 7.06 (td, J = 8.8, 2.4 Hz, 1H), 7.02 (dd, J = 7.5, 2.4 Hz, 1H), 
6.79 (dd, J = 8.5, 4.1 Hz, 1H), 4.43 (dd, J = 16.7 and 1.0 Hz, 1H), 4.39 (dd, J = 
16.7 and 1.4 Hz, 1H), 3.21 (s, 3H); 
13
C NMR (101 MHz, CDCl3) δ 173.9, 165.6, 
159.7 (d, J = 241.8 Hz), 139.3, 130.9 (d, J = 8.8 Hz), 116.8 (d, J = 23.6 Hz), 
113.6 (d, J = 25.0 Hz), 109.2 (d, J = 7.4 Hz), 89.1, 47.2, 26.9; HRMS (ESI) calcd 
for C11H9FN2NaOS
+
 [MNa]
+
 259.0312, found 259.0320. 
 
Asinger Reaction 
- 94 - 
 
5-Chloro-1-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3u). Prepared 
according to GP-A using isatin IV∙1q and mercaptoacetaldehyde IV∙2b. FC: 
CH2Cl2:EtOAc, 9:1; yield: 177 mg, 70%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.85 (s, br, 1H), 7.32 (dd, J = 8.3, 2.1 Hz, 1H), 7.25 (m, 1H), 6.78 (d, 
br, J = 8.3 Hz, 1H), 4.41 (m, 2H), 3.21 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 
173.7, 165.6, 141.9, 130.4, 130.3, 128.8, 126.1, 109.6, 88.8, 47.2, 26.8; HRMS 
(ESI) calcd for C11H9ClN2NaOS
+
 [MNa]
+
 275.0016, found 275.0022. 
6-Bromo-1-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one (IV∙3v). Prepared 
according to GP-A using isatin IV∙1r and mercaptoacetaldehyde IV∙2b. FC: 
CH2Cl2:EtOAc, 90:10; yield: 196 mg, 66%; brown foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.83 (s, br, 1H), 7.23 (dd, J = 7.8 and 1.9 Hz, 1H), 7.11 (d, br, J = 7.8 
Hz, 1H), 7.00 (d, br, J = 1.9 Hz, 1H), 4.41 (d, J = 15.6 Hz, 1H), 4.36 (d, J = 15.6 
Hz, 1H), 3.20 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 174.0, 165.5, 144.7, 128.3, 
126.8, 126.3, 124.2, 112.1, 88.6, 47.1, 26.9; HRMS (ESI) calcd for 
C11H9BrN2NaOS
+
 [MNa]
+
 318.9511, found 318.9516. 
Ethyl 1-benzyl-2-oxo-5'H-spiro[indoline-3,2'-thiazole]-4'-carboxylate (IV∙3w). 
Prepared according to GP-A using isatin IV∙1a and ethyl mercaptopiruvate IV∙2c. 
FC: CH2Cl2:EtOAc, 19:1; yield: 238 mg, 65%; brown foam; 
1
H NMR (400 MHz, 
CDCl3) δ 7.41-7.22 (m, 7H), 7.09 (t, br, J = 7.8 Hz, 1H), 6.74 (d, br, J = 7.8 Hz, 
1H), 4.99 (d, J = 15.7 Hz, 1H), 4.85 (d, J = 15.7 Hz, 1H), 4.71 (d, J = 16.9 Hz, 
1H), 4.64 (d, J = 16.9 Hz, 1H), 4.43 (m, 2H), 1.41 (t, J = 7.1 Hz, 3H); 
13
C NMR 
(101 MHz, CDCl3) δ 174.0, 168.2, 161.8, 143.3, 135.6, 131.4, 129.6 (2C), 129.2, 
128.5, 128.0 (2C), 126.8, 124.3, 110.3, 89.2, 63.7, 46.0, 45.1, 14.8; HRMS (ESI) 
calcd for C20H18N2NaO3S
+
 [MNa]
+
 389.0930, found 389.0937. 
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Ethyl 1-methyl-2-oxo-5'H-spiro[indoline-3,2'-thiazole]-4'-carboxylate (IV∙3x). 
Prepared according to GP-A using isatin IV∙1b and ethyl mercaptopiruvate IV∙2c. 
FC: CH2Cl2:EtOAc, 19:1; yield: 177 mg, 61%; orange foam; 
1
H NMR (300 MHz, 
CDCl3) δ 7.40-7.31 (m, 2H), 7.10 (t, br, J = 7.7 Hz, 1H), 6.83 (d, br, J = 7.7 Hz, 
1H), 4.65 (d, J = 16.6 Hz, 1H), 4.59 (d, J = 16.6 Hz, 1H), 4.38 (m, 2H), 3.21 (s, 
3H), 1.36 (t, J = 7.1 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 173.0, 167.1, 161.1, 
143.5, 130.9, 128.5, 126.1, 123.6, 108.6, 88.6, 62.9, 45.3, 26.8, 14.1; HRMS (ESI) 
calcd for C14H14N2NaO3S
+
 [MNa]
+
 313.0617, found 313.0625. 
 
Post-transformation reactions 
1-benzyl-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one 1'-oxide (IV∙4). To 
solution of  IV∙3a (308 mg, 1 mmol) in CH2Cl2 (0.5 mL) and aq. 5% NaHCO3 
(1.5 mL) cooled at 0°C, m-CPBA (1.1 mmol) was added in portions. The reaction 
mixture was warmed to room temperature and stirred for 4 h. The mixture was 
extracted with CH2Cl2 (2 x 5 mL) and the combined organic layer was washed 
with brine (5 mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure and the resulting crude was purified by flash column 
chromatography (n-Hexane:EtOAc, 1.5:1) on silica gel affording IV∙4 as single 
diastereoisomer (291 mg, 90% yield); brown foam; 
1
H NMR (300 MHz, CDCl3) 
δ 7.41 (d, br, J = 7.5 Hz, 1H), 7.39-7.21 (m, 6H), 7.13 (t, br, J = 7.6 Hz, 1H), 
6.81 (d, br, J = 7.7 Hz, 1H), 4.98 (d, J = 15.6 Hz, 1H), 4.84 (d, J = 15.6 Hz, 
1H), 4.44 (d, J = 17.6 Hz, 1H), 3.98 (d, J = 17.6 Hz, 1H), 2.48 (s, 3H); 
13
C NMR 
(75 MHz, CDCl3) δ 176.3, 168.9, 142.8, 134.7, 131.2, 129.0 (2C), 128.0, 127.6, 
127.2 (2C), 123.9, 120.9, 109.8, 102.1, 66.9, 44.4, 21.0; HRMS (ESI) calcd for 
C18H16N2NaO2S
+
 [MNa]
+
 347.0825, found 347.0813. 
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1-benzyl-4'-methyl-5'H-spiro[indoline-3,2'-thiazol]-2-one 1',1'-dioxide (IV∙5). To a 
solution of IV∙4 (33 mg, 0.1 mmol) in CH2Cl2 (0.5 mL) and aq. 5% NaHCO3 (1.5 
mL) cooled at 0°C, m-CPBA (0.11 mmol) was added in one portion. The reaction 
mixture was warmed to room temperature and stirred for 4 h. The mixture was 
extracted with CH2Cl2 (2 x 5 mL) and the combined organic layer was washed 
with brine (5 mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure and the resulting crude was purified by flash column 
(CH2Cl2:EtOAc, 19:1) to give compound IV∙5 (20 mg, 60% yield); yellow foam; 
1
H NMR (300 MHz, CDCl3) δ 7.44 (d, br, J = 7.4 Hz, 1H), 7.39-7.23 (m, 6H), 
7.13 (t, br, J = 7.6 Hz, 1H), 6.76 (d, br, J = 7.6 Hz, 1H), 5.10 (d, J = 15.6 Hz, 
1H), 4.78 (d, J = 15.6 Hz, 1H), 4.42 (d, J = 16.6 Hz, 1H), 3.92 (d, J = 16.6 Hz, 
1H), 2.42 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 174.6, 168.0, 144.2, 134.4, 131.8, 
129.0 (2C), 128.0, 127.8, 127.1 (2C), 123.8, 118.7, 110.2, 90.7, 56.2, 44.6, 24.4; 
HRMS (ESI) calcd for C18H16N2NaO3S
+
 [MNa]
+
 363.0774, found 363.0782. 
1-benzyl-4'-methylspiro[indoline-3,2'-thiazolidin]-2-one (IV∙6). To a solution of 
V∙3a (62 mg, 0.2 mmol) in CH2Cl2:EtOH:AcOH, 1:1:0.1 (2 mL), NaBH3CN (76 
mg, 1.2 mmol) was added at room temperature. The reaction mixture was stirred 
for 24 h at the same temperature and then quenched with saturated aq. solution 
of NaHCO3 (5 mL). The mixture was extracted with CH2Cl2 (2 x 5 mL) and the 
combined organic layer was washed with brine (5 mL) and dried over Na2SO4. 
The solvent was removed under reduced pressure and the resulting crude was 
purified by flash column chromatography (n-Hexane:EtOAc, 1.5:1) on silica gel 
affording IV∙6 as a 7:3 inseparable mixture of distereoisomers (53 mg, 85% 
yield); white oil; 
1
H NMR (400 MHz, CDCl3, 7:3 mixture of two 
diastereoisomers) δ 7.43 (dd, J = 7.5 and 1.0 Hz, 0.7H), 7.40 (dd, J = 7.5 and 
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1.0 Hz, 0.3H), 7.38-7.25 (m, 5H), 7.22 (td, J = 7.6 and 1.2 Hz, 0.3H), 7.17 (td, 
J = 7.6 and 1.2 Hz, 0.7H), 7.07 (t, br, J = 7.6 Hz, 1H), 6.72 (d, br, J = 7.7 Hz, 
0.7H), 6.69 (d, br, J = 7.7 Hz, 0.3H), 5.00 (d, J = 15.6 Hz, 0.7H), 4.96 (d, J = 
15.6 Hz, 0.3H), 4.92 (d, J = 15.6 Hz, 0.7H), 4.83 (d, J = 15.6 Hz, 0.3H), 4.38 
(ddq, J = 9.5, 6.1 and 6.4 Hz, 0.3H), 3.86 (ddq, J = 10.3, 6.1 and 4.9 Hz, 07H), 
3.58 (dd, J = 9.5 and 6.1 Hz, 0.3H), 3.49 (dd, J = 10.3 and 4.9 Hz, 0.7H), 2.96 
(t, J = 9.5 Hz, 0.3H), 2.92 (t, J = 10.3 Hz, 0.7H), 2.25-1.80 (m, br, 1H), 1.54 (d, 
J = 6.1 Hz, 2.1H), 1.49 (d, J = 6.4 Hz, 0.9H); 
13
C NMR (101 MHz, CDCl3, 7:3 
mixture of two diastereoisomers) δ 177.0 and 176.9(1C), 142.5 and 141.2 (1C), 
135.6 and 135.2 (1C), 133.9 and 128.3 (1C), 130.0 and 129,1 (1C), 128.9 (2C), 
127.8 and 127.7 (1C), 127.3 and 127.2 (2C), 124.6 and 123.7 (1C), 123.6 and 
123.1 (1C), 109.7 and 109.4 (1C), 76.4 and 75.7 (1C), 63.5 and 60.4 (1C), 44.8 
and 43.9 (1C), 44.4 and 43.8 (1C), 19.3 and 18.6 (1C); HRMS (ESI) calcd for 
C18H18N2NaOS
+
 [MNa]
+
 333.1032, found 333.1039. 
3'-acetyl-1-benzyl-N-(tert-butyl)-2-oxospiro[indoline- 3,2'-thiazolidine]-4'-
carboxamide (IV∙7). To a solution of IV∙3n (88 mg, 0.2 mmol) in 2,2,2-
trifluoroethanol (400 µL), acetic acid (23 µL, 0.4 mmol) and tert-
buthylisocyanide (45 µL, 0.4 mmol) were added at room temperature. The 
reaction was stirred at the same temperature and the conversion was monitored 
by TLC. The solvent was removed under reduced pressure and the crude was 
purified by flash chromatography (FC: n-Hexane:EtOAc, 3:7) obtaining the two 
diasteroisomer in 91% overall yield. 
IV∙7a (major diasteroisomer, 2'-4'-trans): 64 mg; pale beige foam; 1H NMR (400 
MHz, CDCl3, mixture of rotamers 4:1) δ 7.44 (d, br, J = 7.5 Hz, 0.2H), 7.42-
7.24 (m, 6H), 7.20 (t, br, J = 7.7 Hz, 0.8H), 7.13 (t, br, J = 7.6 Hz, 0.2H), 7.06 
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(t, br, J = 7.6 Hz, 0.2H), 6.94 (m, br, 0.2H), 6.84 (d, br, J = 7.6 Hz, 0.2H), 
6.66 (d, br, J = 7.7 Hz, 0.8H), 6.58 (m, br, 0.8H), 5.41 (d, br, J = 5.9 Hz, 
0.2H), 5.08 (d, J = 15.7 Hz, 0.2H), 5.00-4.90 (m, 2.8H), 4.82 (d, J = 15.7 Hz, 
0.2H), 4.13 (dd, br, J = 11.4, 6.2 Hz, 0.8H), 3.79 (dd, br, J = 11.2, 5.9 Hz, 
0.2H), 3.62 (d, J = 11.2 Hz, 0.2H), 3.52 (d, J = 11.4 Hz, 0.8H), 2.19 (s, 3H), 
1.52 (s, 9H); 
13
C NMR (75 MHz, CDCl3, mixture of rotamers 4:1) δ 175.3, 169.5, 
168.7, 142.6, 135.4 and 135.1 (1C), 130.8 and 130.1 (1C), 129.0 and 128.9 (2C), 
128.8, 128.1 and 127.5 (1C), 127.0 (2C), 124.5 and 123.0 (1C), 124.2 and 122.8 
(1C), 110.2 and 110.1 (1C), 72.3, 67.6 and 67.1 (1C), 52.2 and 51.4 (1C), 44.3 and 
44.1 (1C), 33.9, 28.8 (3C), 23.7; HRMS (ESI) calcd for C24H27N3NaO3S
+
 [MNa]
+
 
460.1665, found 460.1677. 
IV∙7b (minor diasteroisomer, 2'-4'-cis): 16 mg; pale beige foam; 1H NMR (400 
MHz, CDCl3) δ 8.55 (m, br, 1H), 7.44- 7.23 (m, 6H), 7.17 (t, br, J = 7.7 Hz, 
1H), 7.04 (t, br, J = 7.7 Hz, 1H), 6.65 (d, br, J = 7.7 Hz, 1H), 5.08 (d, J = 16.1 
Hz, 1H), 4.98 (d, J = 16.1 Hz, 1H), 4.96 (d, br, J = 7.0 Hz, 1 H), 4.00 (dd, J = 
12.2, 7.0 Hz, 1H), 3.63 (d, J = 12.2 Hz, 1H), 2.16 (s, 3H), 1.49 (s, 9H); 
13
C NMR 
(75 MHz, CDCl3) δ 174.6, 169.4, 168.0, 141.0, 134.9, 131.1, 129.4, 128.9 (2C), 
127.6, 126.9 (2C), 123.6, 120.7, 110.4, 73.4, 67.4, 52.3, 44.7, 36.1, 28.4 (3C), 
23.3; HRMS (ESI) calcd for C24H27N3NaO3S
+
 [MNa]
+
 460.1665, found 460.1674. 
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V. Spirooxindole-fused 3-Thiazolidine-Carboxamide and 
Tetrazol Derivatives: 
Sequential Asinger/Ugi-like Reactions 
 
We developed two Ugi-type three-component reactions of spirooxindole-fused 
3-thiazolines, isocyanides and either carboxylic acids or trimethylsilylazide to give 
highly functionalized spirooxindole-fused thiazolidines. Two small but diverse 
libraries were generated using practical and robust procedures affording the 
products in typically good yields. The obtained thiazolidines proved to be 
suitable substrates for further transformations. Notably, both the Ugi-Joullié and 
the azido-Ugi reactions were highly diastereoselective, affording predominantly 
the trans-configured products, as confirmed by X-ray crystallographic analysis. 
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V.1 Introduction 
In light of our interest in 3,3-disubstituted oxindoles and spiro-fused analogues,
1
 
we have recently reported the synthesis of a small library of spirooxindole-fused 
3-thiazoline derivatives, by means of a one-pot Asinger-type three-component 
reaction (Scheme 1).
2 
Such compounds represent an underexploited scaffold in the context of sulfur-
containing spirooxindoles. As demonstrated, they are in themselves endowed 
with R
1
 and R
2
 diversity, but can be also regarded as versatile intermediates 
towards further scaffold diversity, because of the presence of the reactive C–N 
double bond (see Chapter IV). 
In continuation of our oxindole-based diversity oriented synthesis (DOS) 
program, we demonstrate here the suitability of spirooxindole-fused 3-thiazolines 
as useful substrates for two further multicomponent transformations, i.e. the Ugi–
Joullié and the azido-Ugi reaction.  
 
Scheme 1. Previously reported Asinger-type synthesis of spirooxindole-fused thiazolines. 
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Figure 1. Examples of biologically relevant compounds containing spirooxindoles, 
thiazolidine and tetrazole moieties.3 
 
Since the important and diverse bioactivity of spirooxindole-based products, we 
aimed to functionalize the central spiro scaffold with a variety of lipophilic and 
polar groups, as well as with the pharmacologically relevant tetrazole ring (Figure 
1). 
 
V.2 Results and Discussion 
Initially, isatin-derived thiazoline V∙1a, tert-butyl isocyanide V∙2a and cyclohexyl 
carboxylic acid V∙3a were selected to optimize the conditions for the Ugi-Joullié 
reaction (Table 1). 
As expected for Ugi-type processes,
6
 the reaction was found to be sluggish in 
aprotic solvents (dichloromethane and toluene, entries 1-2). The same reaction in 
MeOH (entry 3) afforded the desired thiazolidine product in 55% yield as a 
readily separable 1:1 mixture of trans and cis diastereomers. Switching to more 
acidic 2,2,2-trifluoroethanol (TFE) increased the reaction rate and yield (entry 4). 
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Table 1. Optimization of the Ugi-Joullié 3-CR.a 
 
 
a Reactions conditions: thiazoline V∙1a (0.30 mmol), isocyanide V∙2a (0.30 mmol) and 
carboxylic acid V∙3a (0.30 mmol) at rt, unless otherwise indicated. b Evaluated by 1H NMR 
analysis of the crude mixture considering both diasteroisomers. c Determined by 1H NMR 
analysis of the crude mixture. d Isolated yield for the trans diasteroisomer. e Reaction 
performed at 0 °C. TFE = 2,2,2-trifluoroethanol. nd = not determined. 
 
It also led to a more diastereoselective process affording trans- V∙4a as the major 
product (dr 75:25).
7
 The dr was further improved by increasing the 
concentration (0.5 M, entry 5), while lowering either the concentration (entry 6) 
or the temperature (entry 7) reduced the conversion without improving the dr. 
With the optimal conditions in hand, we investigated the scope and limitations of 
the protocol, varying the three components one at a time (Scheme 2). Reaction 
of oxindole-based thiazolines V∙1a-h with tert-butyl isocyanide (V∙2a) and 
cyclohexanecarboxylic acid (V∙3a) afforded the expected products V∙4a-4h with 
good dr (up to 93:7 for compound V∙4e) and in generally reasonable to good 
yield, although moderate yields were observed for V∙4b and V∙4g. Next, 
Entry Solvent Conc. [M] Time [h] Conversion (%)
b
 dr [trans:cis]
c 
1 CH2Cl2 0.25 24 trace nd 
2 Toluene 0.25 24 trace nd 
3 MeOH 0.25 24 55 50:50 
4 TFE 0.25 6 95 75:25 
5 TFE 0.5 4 95 (83)
d 
87:13 
6 TFE 0.125 6 85 76:24 
7
e
 TFE 0.25 6 85 74:26 
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different isocyanides were combined with thiazoline V∙1a and carboxylic acid 
V∙3a. Compounds V∙4i-4n were obtained in acceptable yields, with aliphatic 
isocyanides affording the best results (69% and 82% yield for compounds V∙4i 
and V∙4j, respectively). Due to their lower stability in acidic media, 
isocyanoacetates gave products V∙4k and V∙4l in lower yields. However, the 
highest dr was achieved in the reaction with tert-butyl isocyanoacetate (V∙4l, dr 
99:1). Good results were obtained with both phenyl and benzyl isocyanide 
(V∙4m and V∙4n), whereas no product V∙4o was observed in the reaction with 2-
morpholinoethyl isocyanide. As reported,
8
 this reagent may undergo a facile 
internal cyclization reaction after protonation by the carboxylic acid, preventing 
the UJ-3CR.  
Finally, twelve different carboxylic acids were tested in the reaction with 
thiazoline V∙1a and tert-butyl isocyanide (V∙2a). The resulting products V∙4p-z 
were obtained in generally high yields (up to 80%) and with satisfactory dr (up 
to 86:14), except compound V∙4s that was detected only in trace amounts. In this 
case, most likely the employed carboxylic acid [N-methylpiperidine-4-carboxylic 
acid] was present in its zwitterionic form and therefore not reactive. In support 
of this hypothesis, the reaction with the 1-(tert-butoxycarbonyl)-piperidine-4-
carboxylic acid (structurally similar but lacking basicity) furnished the expected 
UJ-3CR product V∙4t in good yield and dr. The wide variety of successfully tested 
carboxylic acids is noteworthy, ranging from phenylacetic acid to carboxylic acids 
containing both electron-rich and electron-deficient heterocycles (V∙4u-z). 
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Scheme 3. Scope of components in the Ugi-Joullié 3-CR.a 
 
continued 
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a Reactions conditions: thiazoline V∙1a-h (0.30 mmol), isocyanide V∙2a-h (0.30 mmol) and 
carboxylic acid V∙3a-l (0.30 mmol) in TFE (600 μL) at rt.  Isolated yield for the trans 
diasteroisomer are reported. The indicated dr was determined by 1H NMR on the crude 
mixture. nd = not determined. 
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We then moved on to the azido-Ugi process, optimizing the reaction conditions 
using thiazoline V∙1a, tert-butyl isocyanide (V∙2a) and trimethylsilyl azide as the 
inputs (Table 2). Also in this case, the reaction was found to be sluggish in 
dichloromethane and toluene (entries 1-2), whereas excellent conversions to the 
target tetrazole derivative V∙5a were observed in polar protic solvents (entries 3-
5).  
 
Table 3. Optimization of the azido-Ugi 3-CR.a 
 
a Reactions conditions: thiazoline V∙1a (0.15 mmol), isocyanide V∙2a (0.15 mmol) and 
TMS-N3 (0.15 mmol) in solvent at rt, unless otherwise indicated. 
b Evaluated on the crude 
mixture considering both diasteroisomers. c Determined by 1H NMR on the crude mixture. d 
Reaction performed at 0 °C. e Reaction performed at -18 °C. f Isolated yield for the trans 
diasteroisomer. TFE = 2,2,2-trifluoroethanol. HFIP = 1,1,1,3,3,3-hexafluoro-2-propanol. nd 
= not determined. 
 
Entry Solvent Conc. [M] Time [h] 
Conversion 
(%)
b
 
dr [trans:cis]
c
 
1 CH2Cl2 0.5 24 <5 nd 
2 Toluene 0.5 24 <5 nd 
3 MeOH 0.5 2 95 56:44 
4 TFE 0.5 1 99 81:19 
5 HFIP 0.5 1 99 85:15 
6 TFE 1.0 1 99 78:22 
7 TFE
d
 0.5 1 99 83:17 
8 TFE
e
 0.5 1 99 83:17 
9 HFIP 1.0 1 99 84:16 
10 HFIP 0.05 1 99 82:18 
11 HFIP
d
 0.5 1 99 (87)
f
 92:8 
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As for the above UJ-3CR, fluorinated solvents (TFE and 1,1,1,3,3,3-hexafluoro-2-
propanol, HFIP) led to a more a diastereoselective transformation, affording the 
trans diastereoisomer V∙5a as the major compound. 
Aiming to further improve the dr, different concentrations and temperatures 
were screened. We found that increasing the concentration in TFE led to a slight 
decrease in dr (entry 6), whereas lowering the temperature only gave a small 
improvement in dr (entry 7). Similarly, varying the concentration in HFIP did not 
lead to an appreciable improvement (entries 9,10), while in this case excellent 
diastereoselectivity was achieved at 0 °C (entry 11). Aiming to further improve 
the dr, different concentrations and temperatures were screened. We found that 
increasing the concentration in TFE led to a slight decrease in dr (entry 6), 
whereas lowering the temperature only gave a small improvement in dr (entry 
7). Similarly, varying the concentration in HFIP did not lead to an appreciable 
improvement (entries 9,10), while in this case an excellent dr was achieved at 0 
°C (entry 11). 
Next, we investigated the reaction scope, combining thiazolines V∙1a-e and 
isocyanides V∙2a-h with trimethylsilyl azide, leading to good results in nearly all 
cases (Scheme 3).  
When aliphatic isocyanides were used, the corresponding products (V∙5a-j; 5l) 
were obtained in satisfactory yield and dr, with the exception of V∙5g (67:33 dr). 
Unlike the case of the UJ-3CR, tert-butyl isocyanoacetate also worked well in the 
azido-Ugi reaction, affording the desired product V∙5j in 72% yield and with 
84:16 dr. Finally, phenyl isocyanide behaved similarly as in the UJ-3CR, giving 
the corresponding product V∙5k in moderate yield and dr. 
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Scheme 3. Scope of components in the azido-Ugi 3-CR.a 
a Reactions conditions: thiazoline V∙1a-e (0.30 mmol), isocyanide V∙2a-c,e,g,i-k (0.30 
mmol) and TMS-N3 (0.30 mmol) in HFIP (600 μL) at 0 °C. Isolated yield for the trans 
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diasteroisomer are reported. Determined by 
1
H NMR on the crude mixture. Compound 
V∙5i was obtained as a mixture of inseparable diastereoisomers. 
 
To determine the relative configuration for the two product types (V∙4 and V∙5), 
single crystals of V∙4a and V∙5a were subjected to X-ray crystallographic analysis, 
leading to the unambiguous assignment of the trans stereochemistry for both 
compounds (Figure 2). Since all products V∙4 and V∙5 were obtained under the 
same conditions employed for compounds V∙4a and V∙5a, respectively, and 
given common trends in 
1
H NMR chemical shifts as well as similarities in TLC 
retention times, he same relative trans-stereochemistry was assigned to all 
products V∙4 and V∙5. 
To provide a plausible explanation for the highly diastereo-selective outcome of 
both reactions, we consider the mechanism proposed in Figure 3 for the UJ-3CR. 
We presume that the preferred conformation of imine V∙1a in solution is mainly  
 
 
a) 
 
 
b) 
 
Figure 2. a) ORTEP view of compound V∙4a at room temperature. The methyl group on 
the left is rotationally disordered. Thermal ellipsoids of non-H atoms were drawn at the 
50% probability level. b) ORTEP view of compound V∙5a at T = 105 K. Thermal ellipsoids 
of non-H atoms were drawn at the 50% probability level. 
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determined by the spiro junction between the oxindole and the thiazoline ring 
system, with the latter adopting an envelope-like conformation oriented nearly 
perpendicularly with respect to the oxindole. This spatial arrangement highlights 
the substantial shielding of the Si-face of the imine for both steric and electronic 
reasons, mainly due to the proximity of the oxindole carbonyl. 
As a consequence, in strongly hydrogen-bonding solvents such as TFE and HFIP, 
the protonated imine exposes the Re-face to the incoming isocyanide, affording 
predominantly the trans isomer (Figure 3a). 
Taking into account the eﬀect of the solvent on the diastereoselectivity of the UJ-
3CR involving a ﬁve-membered cyclic imine, as reported by Katsuyama et al.,7a 
we can also rationalize the poor reactivity observed in toluene. Indeed, in such 
nonpolar solvents, the protonation of the imine by the carboxylic acid likely 
results in the formation of a contact ion pair. This close interaction lowers the 
overall electrophilic reactivity of the imine and, more decisively, hinders the 
 
Figure 3. Plausible explanation of the stereochemical outcome for the UJ-3CR. 
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approach of isocyanide, shielding the sterically more available Re-face (Figure 
3b).  
The use of MeOH as the solvent represents an intermediate scenario, providing 
sufficient activation for the reaction to occur, but very limited discrimination 
between the diastereotopic faces. Similar considerations on the molecular 
conformation of the imine component can be made to rationalize the high dr 
observed in the azido-Ugi 3-CR. 
Having established the reaction scope, further transformations were examined to 
extend the library of potentially useful compounds. Selected post-transformations 
of Ugi-Joullié products V∙4 are depicted in Scheme 5. Primary amide V∙6 is 
readily obtained by treatment of compound V∙4i with trifluoroacetic acid.  
Starting from compound V∙4l, cleavage of the tert-butyl ester afforded the free 
acid V∙7 in quantitative yield. Finally, the piperidine derivative V∙8 was obtained 
treating compound V∙4t with 20% TFA in dichloromethane. 
 
V.3 Conclusions 
In conclusion, we have efficiently synthesized two structurally diverse libraries of 
highly functionalized spiooxindole thiazolidines, via Ugi-Joullié and azido-Ugi 
multicomponent reactions. The MCR-derived central spiro scaffold was 
effectively functionalized with a variety of lipophilic and polar appendages, as 
well as with tetrazole as a carboxylic acid isostere. The products were obtained in 
generally high yields, with simple workup procedures and 
straightforwardisolation. The observed high diastereoselectivity for both the 
transformations is particularly noteworthy. Further biological evaluation of 
compounds V∙4 and V∙5 is currently ongoing. 
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Scheme 5. Further post-transformation reactions on selected UJ-3 CR products. 
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V.4 Experimental Section 
All commercial materials (Aldrich, Fluka, Fluorochem) were used without further 
purification. All solvents were of reagent grade or HPLC grade. Reactions 
requiring anhydrous conditions were performed under nitrogen atmosphere. All 
reactions were monitored by thin layer chromatography (TLC) on precoated 
silica gel 60 F254; spots were visualized with UV light (254 nm) or by treatment 
with KMnO4 solution in water or ninhydrin solution in ethanol. Products were 
purified by flash chromatography on silica gel 60 (230–400 mesh). 1H NMR 
spectra and 
13
C NMR spectra were recorded on 300, 400 and 500 MHz 
spectrometers. Chemical shifts are reported in parts per million relative to the 
residual solvent. 
13
C NMR spectra have been recorded using the APT pulse 
sequence. Multiplicities in 
1
H NMR are reported as follows: s = singlet, d = 
doublet, t = triplet, m = multiplet, br s = broad singlet. High-resolution MS 
spectra (HR-MS) were recorded with a Waters Micromass Q-ToF micro TM mass 
spectrometer, equipped with an ESI source. 
Unless otherwise noted, materials obtained from commercial suppliers were used 
without further purification. Thiazolines V∙1a-h were synthesized as described 
previously in Chapter IV. 
 
General procedure A (GP-A) for the synthesis of compounds V∙4a-z via Ugi-
Joullié 3-CR reaction. To a solution of thiazoline V∙1 (0.3 mmol, 1 eq) in TFE 
(0.62 mL), isocyanide V∙2 (0.3 mmol, 1 eq) and the carboxylic acid V∙3 (0.3 
mmol, 1 eq) were added at room temperature. The reaction was stirred and the 
conversion was monitored by TLC. The solvent was removed under reduced 
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pressure and the crude was purified by flash chromatography (FC) as indicated 
below. 
(3S*,4'R*)-N-(tert-butyl)-3'-(cyclohexanecarbonyl)-1-methyl-2-oxospiro[indoline-
3,2'-thiazolidine]-4'-carboxamide (V∙4a). Prepared according to GP-A using 
thiazoline V∙1a, cyclohexanecarboxylic acid V∙3a and tert-butyl isocyanide V∙2a. 
FC: CH2Cl2:EtOAc, 95:5; yield: 83%; grey foamy solid; 
1
H NMR (300 MHz, 
CDCl3, 4:1 mixture of two rotamers) δ 7.43-7.18 (m, 2H), 7.11 (t, br, J = 7.8Hz, 
0.2H), 7.14 (t, br, J = 7.8Hz, 0.8H), 6.95-6.86 (m, br, 0.4H), 6.83 (d, br, J = 
7.8Hz, 0.8H),  6.52 (m, br, 0.8H), 5.42 (d, br,  J = 4.9 Hz, 0.2H), 4.89 (d, J = 
7.8 Hz, 0.8H), 4.04 (dd, J = 11.6 and 6.9 Hz, 0.8H), 3.69-3.57 (m, 0.4H), 3.45 
(d, J = 11.6 Hz, 0.8H), 3.26 (s, 0.6H), 3.22 (s, 2.4H), 2.25 (t, br, J = 10.7Hz, 
0.8H), 1.84-1.08 (m, 10 methylene protons + 0.2H), 1.47 (s, 7.2H), 1.40 (s, 
1.8H); 
13
C NMR (101 MHz, CDCl3) δ 177.3, 175.6 and 175.0 (1C), 169.2 and 
168.8 (1C), 143.7 and 142.2 (1C), 130.8 and 130.1 (1C), 127.3 and 126.1 (1C), 
124.3 and 123.8 (1C) 122.8 and 122.3 (1C), 109.1 and 108.9 (1C), 71.8, 66.8 and 
66.2 (1C), 52.1 and 52.3 (1C), 44.1 and 42.7 (1C), 33.4, 29.9 and 29.6 (2C), 28.7 
(3C), 26.6, 25.4 and 25.3 (3C); HR-MS (ESI) calcd for C23H31N3NaO3S
+ 
[MNa]
+
 
452.1978, found 452.1987. 
(3S*,4'R*)-N-(tert-Butyl)-3'-(cyclohexanecarbonyl)-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carboxamide (V∙4b). Prepared according to GP-A using thiazoline 
V∙1b, cyclohexanecarboxylic acid V∙3a and tert-butyl isocyanide V∙2a. FC: 
Hexane:EtOAc, 6:4; yield: 34%; grey foamy solid; 
1
H NMR (400 MHz, DMSO-
d6, 9:1 mixture of rotamers) δ 10.87 (s, 0.1H), 10.34 (s, 0.9H), 7.93 (d, br,  J = 
7.7 Hz, 0.1H), 7.82 (s, br, 0.9H), 7.76 (d, br, J = 7.6 Hz, 0.9H), 7.54 (s, br, 
0.1H), 7.33 (t, br,  J = 7.7 Hz, 0.1H), 7.16 (t, br,  J = 7.7 Hz, 0.9H), 7.11 (t, J = 
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7.6 Hz, 0.1H), 6.94 (t, br,  J = 7.6 Hz, 0.9H), 6.75 (d, br,  J = 7.7 Hz, 1H), 5.19 
(d, J = 6.5 Hz, 0.1H), 5.11 (d, J = 6.8 Hz, 0.9H), 3.73 (dd, J = 12.0 and 6.8 Hz, 
0.9H), 3.61 (dd, J = 12.0, 6.5 Hz, 0.1H), 3.37-3.22 (m, 1H), 2.24-2.12 (m, 1H), 
1.77-1.52 (4H), 1.35 (s, 8.1H), 1.31 (s, 0.9H), 1.26-0.97 (m, 6H);
 13
C NMR (101 
MHz, DMSO-d6) δ 177.8 and 176.9 (1C), 174.2 and 173.1 (1C), 169.3 and 168.6 
(1C), 141.8 and 140.7 (1C), 130.8 and 129.2 (1C), 128.9 and 128.8 (1C), 126.0 and 
125.0 (1C), 123.1 and 122.1 (1C), 110.9 and 109.7 (1C), 71.9 and 69.9 (1C), 65.8 
and 64.1 (1C), 50.8 and 50.6 (1C), 43.1 and 41.9 (1C), 35.3 and 33.3 (1C), 29.4 
and 29.2 (1C), 28.9 and 28.7 (3C), 28.9 and 28.5 (1C), 25.7-25.3 (3C); HR-MS 
(ESI) calcd for C22H29N3NaO3S
+ 
[MNa]
+
 438.1822, found 438.1829. 
(3S*,4'R*)-1-Benzyl-N-(tert-butyl)-3'-(cyclohexanecarbonyl)-2-oxospiro[indoline-
3,2'-thiazolidine]-4'-carboxamide (V∙4c).  Prepared according to GP-A using 
thiazoline V∙1c, cyclohexanecarboxylic acid V∙3a and tert-butyl isocyanide V∙2a. 
FC: CH2Cl2:EtOAc, 95:5;  yield: 53%; pale brown foamy solid; 
1
H NMR (300 
MHz, CDCl3, 4:1 mixture of two rotamers) δ 7.44-7.21 (m, 6.2H), 7.17 (t, br,  J 
= 7.8 Hz, 0.8H), 7.09 (t, br,  J = 7.8 Hz, 0.2H), 7.01 (t, br,  J = 7.7 Hz, 0.8H), 
6.94 (m, br, 0.2H), 6.71 (d, br, J = 7.6 Hz, 0.2H), 6.65 (d, br, J = 7.7 Hz, 
0.8H), 6.58 (m, br, 0.8H), 5.47 (d, J = 5.9 Hz, 0.2H), 5.20 (d, J = 14.7 Hz, 
0.2H), 5.02 (d, J = 15.6 Hz, 0.8H), 4.95 (d, J = 6.8 Hz, 0.8H), 4.85 (d, J = 
15.6 Hz, 0.8H), 4.64 (d, J = 14.7 Hz, 0.2H), 4.10 (dd, J = 11.7 and 6.8 Hz, 
0.8H), 3.72 (dd, J = 11.7 and 5.9 Hz, 0.2H), 3.63 (d, J = 11.7 Hz, 0.2H), 3.49 
(d, J = 11.7 Hz, 0.8H), 2.30 (m, 1H), 1.89-0.92 (m, 10H, methylene protons) 
1.49 (s, 7.2H), 1.41 (s, 1.8H); 
13
C NMR  (75 MHz, CDCl3) δ 177.4-175.2 (2C), 
169.2,and 168.8 (1C), 142.6 and 141.3 (1C), 135.6 and135.1 (1C), 130.7 and 130.0 
(1C), 129.1 and 128.9 (2C), 128.1-127.1 (3C),  126.7 and 126.1 (1C), 124.3-122.3 
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(2C), 110.0, 72.1 and 70.3 (1C),  67.0 and 66.2 (1C), 52.1 and 51.3 (1C), 44.3 and 
44.1 (1C), 44.0 and 42.5 (1C), 33.4-29.2 (3C), 28.8 (3C), 27.7-22.6 (3C); HR-MS 
(ESI) calcd for C29H35N3NaO3S
+
 [MNa]
+
 528.2291, found 528.2302. 
(3S*,4'R*)-N-(tert-Butyl)-3'-(cyclohexanecarbonyl)-5-fluoro-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4d).  Prepared according 
to GP-A using thiazoline V∙1d, cyclohexanecarboxylic acid V∙3a and tert-butyl 
isocyanide V∙2a. FC: CH2Cl2:EtOAc, 95:5; yield: 54%; orange foamy solid; 1H 
NMR (300 MHz, CDCl3, 17:3 mixture of two rotamers) δ 7.17-6.95 (m, 2H), 
6.85 (dd, J = 7.8 and 3.9 Hz, 0.15H), 6.77 (dd, J = 8.6 and 3.9 Hz, 0.85H), 
6.38 (m, br, 1H), 5.44 (t, J = 3.3 Hz, 0.15H), 4.89 (d, J = 6.8 Hz, 0.85H), 4.04 
(dd, J = 11.7 and 6.8 Hz, 0.85H), 3.62 (d, J = 3.3 Hz, 0.3H), 3.48 (d, J = 11.7 
Hz, 0.85H), 3.26 (s, 0.45H), 3.22 (s, 2.55H), 2.25 (tt, J = 10.7 and 3.5 Hz, 1H), 
1.83-1.05 (m, 10H, methylene protons), 1.48 (s, 7.65H), 1.40 (s, 1.35H); 
13
C NMR 
(101 MHz, CDCl3) δ 175.6, 174.9, 168.9, 160.4 and 158.0 (1C), 139.6, 127.8, 
116.4 and 116.2 (1C), 111.0 and 110.7 (1C), 109.4 and 109.3 (1C), 71.5, 66.0, 52.2, 
44.0, 33.7, 29.5 (2C), 28.7 (3C), 26.7, 25.3(3C); HR-MS (ESI) calcd for 
C23H30FN3NaO3S
+
 [MNa]
+
 470.1884, found 470.1872. 
(3S*,4'R*)-N-(tert-Butyl)-5-chloro-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4e). Prepared according 
to GP-A using thiazoline V∙1e, cyclohexanecarboxylic acid V∙3a and tert-butyl 
isocyanide V∙2a. FC: Hexane:EtOAc, 1:1; yield: 48%; grey foamy solid; 1H NMR 
(300 MHz, CDCl3, 9:1 mixture of two rotamers) δ 7.40-7.33 (m, 0.2H), 7.29 
(dd, J = 7.8 and 2.0 Hz, 0.9H), 7.24 (d, J = 2.0 Hz, 0.9H), 6.86-6.79 (m, 
0.2H), 6.76 (d, J = 7.8 Hz, 0.9H), 6.40 (m, br, 0.9H), 5.45 (d, J = 4.9 Hz, 
0.1H), 4.90 (d, J = 6.8 Hz, 0.9H), 4.00 (dd, J = 11.7 and 6.8 Hz, 0.9H), 3.65 
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(d, J = 10.7 Hz, 0.1H), 3.60 (dd, J = 10.7 and 4.9 Hz, 0.1H), 3.52 (d, J = 11.7 
Hz, 0.9H), 3.26 (s, 0.3H), 3.22 (s, 2.7H), 2.25 (t, br J = 11.0 Hz, 1H), 1.83-1.04 
(m, 10H, methylene protons), 1.49 (s, 8.1H), 1.42 (s, 0.9H); 
13
C NMR  (75 MHz, 
CDCl3) δ 177.0-174.7 (2C), 168.8 and 168.6 (1C), 142.2 and 140.6 (1C), 130.7 
and 130.0 (1C), 129.6-128.0 (2C), 124.8 and 123.2 (1C), 110.2 and 109.8 (1C), 
71.6 and 69.6 (1C), 66.8 and 66.0 (1C), 52.2 and 51.4 (1C), 44.0 and 42.9 (1C), 
33.7, 30.3-25.3 (9C); HR-MS (ESI) calcd for C23H30ClN3NaO3S
+
 [MNa]
+
 
486.1589, found 486.1578. 
(3S*,4'R*)-5-Bromo-N-(tert-butyl)-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4f). Prepared according to 
GP-A using imine V∙1f, cyclohexanecarboxylic acid V∙3a and tert-butyl isocyanide 
V∙2a. FC: CH2Cl2:EtOAc, 95:5; yield: 61%; pale brown foamy solid; 1H NMR 
(300 MHz, CDCl3, 17:3 mixture of two rotamers) δ 7.54-7.48 (m, 0.3H), 7.43 
(dd, J = 7.8 and 2.0 Hz, 0.85H), 7.36 (d, J = 2.0 Hz, 0.85H), 6.74 (d, J = 7.8 
Hz, 0.15H), 6.72 (d, J = 7.8 Hz, 0.85H), 6.51 (m, br, 0.15H), 6.40 (m, br, 
0.85H), 5.45 (d, J = 4.9 Hz, 0.15H), 4.90 (d, J = 6.8 Hz, 0.85H), 3.98 (dd, J = 
11.7 and 6.8 Hz, 0.85H), 3.66 (d, J = 11.7 Hz, 0.15H), 3.59 (dd, J = 11.7 and 4.9 
Hz, 0.15H), 3.53 (d, J = 11.7 Hz, 0.85H), 3.26 (s, 0.45H), 3.21 (s, 2.55H), 2.25 
(t, br J = 11.2 Hz, 1H), 1.85-1.10 (m, 10H, methylene protons), 1.49 (s, 7.65H), 
1.48 (s, 1.35H); );  
13
C NMR  (75 MHz, CDCl3) δ 173.9 and 171.3 (1C), 171.2 and 
170.2 (1C), 164.9 and 164.4 (1C), 138.4, 129.2 and 128.5 (1C), 124.2 and 124.0 
(1C), 123.4 and 121.6 (1C), 123.0, 106.3 and 105.9 (1C), 69.7 and 69.4 (1C), 62.4 
and 61.8 (1C), 48.9 and 47.8 (1C), 39.7 and 38.3 (1C), 29.2 and 29.1 (1C), 25.9-
25.1 (2C), 24.4 (3C), 22.4, 21.4; HR-MS (ESI) calcd for C23H30BrN3NaO3S
+
 
[MNa]
+
  530.1083, found 530.1077. 
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(3S*,4'R*)-N-(tert-Butyl)-3'-(cyclohexanecarbonyl)-5-methoxy-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4g). Prepared according 
to GP-A using thiazoline V∙1g, cyclohexanecarboxylic acid V∙3a and tert-butyl 
isocyanide V∙2a. FC: CH2Cl2:EtOAc, 95:5; yield: 30%; pale orange foamy solid; 
1
H NMR (500 MHz, CDCl3, 3:1 mixture of two rotamers) δ 6.96-6.88 (m, 0.5H), 
6.85-6.79 (m, 1.5H), 6.75 (d, br,  J = 7.8 Hz, 1H), 6.51 (m, br, 0.75H), 6.41 (m, 
br, 0.25H), 5.44 (m, br, 0.25H), 4.89 (d, J = 7.2 Hz, 0.75H), 4.05 (dd, J = 11.7 
and 7.2 Hz, 0.75H), 3.76 (s, 3H), 3.63 (m, br, 0.5H), 3.46 (d, J = 11.7 Hz, 
0.75H), 3.21 (s, 0.75H), 3.21 (s, 2.25H), 2.25 (t, br, J = 11.3 Hz, 1H), 1.35-1.09 
(m, 10H, methylene protons), 1.48 (s, 6.75H), 1.40 (s, 2.25H); 
13
C NMR (126 
MHz, CDCl3) δ 177.4-174.3 (2C), 169.1 and 168.8 (1C), 156.7 and 156.0 (1C), 
136.9 and 135.2 (1C), 128.1 and 127.1 (1C), 115.9 and 113.3 (1C), 110.6 and 110.5 
(1C), 109.9 and 109.1 (1C), 72.0 and 71.3 (1C), 66.6 and 66.1 (1C), 55.9 and 55.7 
(1C), 52.3 and 52.0 (1C), 44.0 and 43.9 (1C), 33.5 and 33.3 (1C), 29.8- 29.5 
(2C) , 28.8 (3C), 26.9 and 26.7 (1C), 27.7-25.3 (3C); HR-MS (ESI) calcd for 
C24H33N3NaO4S
+
 [MNa]
+
 482.2084, found 482.2095. 
(3S*,4'R*)-6-Bromo-N-(tert-butyl)-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4h). Prepared according 
to GP-A using thiazoline V∙1h, cyclohexanecarboxylic acid V∙3a and tert-butyl 
isocyanide V∙2a. FC: CH2Cl2:EtOAc, 95:5; yield: 55%; pale grey foamy solid; 1H 
NMR (400 MHz, CDCl3, 17:3 mixture of two rotamers) δ 7.21 (dd, J = 7.5 and 
1.9 Hz, 1H), 7.14 (d, J = 7.7 Hz, 1H), 7.01 (d, J = 1.9 Hz, 1H), 6.83 (m, br, 
0.15H), 6.41 (m, br, 0.85H), 5.43 (d, J =  4.9 Hz, 0.15H), 4.92 (d, J =  6.7 Hz, 
0.85H), 4.04 (dd, J = 12.0 and 6.7 Hz, 0.85H), 3.64 (dd, J = 11.7 and 4.9 Hz, 
0.15H), 3.47 (d, J = 11.7 Hz, 0.85H), 3.27 (s, 0.45H), 3.23 (s, 2.55H), 2.30-2.22 
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(m, 1H), 1.84-1.56 (m, 4H), 1.48-1.10 (m, 15H); 
13
C NMR  (101 MHz, CDCl3) δ 
175.6-174.9 (2C), 168.9, 145.0, 126.6 and 125.7 (1C), 125.2, 123.9, 123.7, 112.6 
and 112.4 (1C), 71.2, 66.7 and 66.0 (1C), 52,1 and 51.6 (1C), 44.0 and 42.8 (1C), 
33.6, 30.1-29.5 (2C), 28.8 (3C), 26.8, 25.8-25.3 (3C); HR-MS (ESI) calcd for 
C23H30BrN3NaO3S
+
 [MNa]
+
 530.1083, found 530.1090. 
(3S*,4'R*)-3'-(Cyclohexanecarbonyl)-1-methyl-2-oxo-N-(2,4,4-trimethylpentan-2-
yl)spiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4i). Prepared according to 
GP-A using thiazoline V∙1a, cyclohexanecarboxylic acid V∙3a and 1,1,3,3-
tetramethylbutyl isocyanide V∙2b. FC: c-Hexane:EtOAc, from 4:1 to 1.5:1; yield: 
69%; light yellow foamy solid; 
1
H NMR (500 MHz, CDCl3, 3:1 mixture of two 
rotamers) δ 7.43-7.38 (m, 0.5H), 7.34 (t, J = 7.6 Hz, 0.75H), 7.30 (d, J = 7.6 
Hz, 0.75H), 7.14 (t, J = 7.6 Hz, 0.25H), 7.07 (t, J = 7.6 Hz, 0.75H), 6.98 (m, 
br, 0.25H), 6.92 (d, J = 7.6 Hz, 0.25H), 6.87 (d, J = 7.6 Hz, 0.75H), 6.49 (m, 
br, 0.75H), 5.41 (d, J = 5.7 Hz, 0.25H), 4.90 (d, J = 6.9 Hz, 0.75H), 4.06 (dd, 
J = 11.8  and 6.9 Hz, 0.75H), 3.67 (dd, J = 11.4  and 5.7 Hz, 0.25H), 3.62 (d, J 
= 11.4Hz, 0.25H), 3.47 (d, J = 11.8 Hz, 0.75H), 3.28 (s, 0.75H), 3.24 (s, 
2.25H), 2.26 (tt, J = 11.5 and 2.9 Hz, 1H), 2.05 (d, J = 14.8 Hz, 0.25H), 1.96 (d, 
J = 14.8 Hz, 0.75H), 1.92 (d, J = 14.8 Hz, 0.75H), 1.87-1.12 (m, 16.25H), 1.05 
(s, 6.75H), 1.04 (s, 2.25H); 
13
C NMR (126 MHz, CDCl3) δ 177.3 and 175.7 (1C), 
175.6 and 175.0 (1C), 168.8 and 168.3 (1C), 143.6 and 142.1 (1C), 130.8 and 
130.1 (1C), 127.0 and 126.0 (1C), from 124.3 to 122.4 (2C), 109.1 and 108.8 (1C), 
72.0 and 70.0 (1C), 67.0 and 66.1 (1C), 56.2 and 55.2 (1C), 51.4 and 51.3 (1C), 
43.8 and 42.6 (1C), from 33.4 to 25.1 (13C); HR-MS (ESI) calcd for C27H40N3O3S
+
 
[MH]
+
 486.2785, found 486.2773. 
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(3S*,4'R*)-3'-(Cyclohexanecarbonyl)-N-cyclohexyl-1-methyl-2-oxospiro[indoline-
3,2'-thiazolidine]-4'-carboxamide (V∙4j). Prepared according to GP-A using 
thiazoline V∙1a, cyclohexanecarboxylic acid V∙3a and cyclohexyl isocyanide V∙2c. 
FC: c-Hexane:EtOAc 1.5:1; yield: 80%; light pink foamy solid. 
1
H NMR (500 
MHz, CDCl3, 3:1 mixture of two rotamers) δ 7.40-7.35 (m, 0.5H), 7.32 (t, J = 
7.6 Hz, 0.75H), 7.21 (d, J = 7.6 Hz, 0.75H), 7.11 (t, J = 7.6 Hz, 0.25H), 7.05 (t, 
J = 7.6 Hz, 0.75H), 6.94-6.88 (m, 0.5H), 6.86 (d, J = 7.6 Hz, 0.75H), 6.50 (d, 
br,  J = 8.3 Hz, 0.75H), 5.45 (d, J = 5.7 Hz, 0.25H), 4.97 (d, J = 6.9 Hz, 
0.75H), 4.04 (dd, J = 11.8 and 6.9 Hz, 0.75H), 4.00-3.86 (m, 1H), 3.69 (dd,  J 
= 11.8 and 5.9 Hz, 0.25H), 3.62 (d, J = 11.8, 0.25H) 3.49 (d, J = 11.8 Hz, 
0.75H), 3.27 (s, 0.75H), 3.23 (s, 2.25H), 2.23 (tt, J = 11.5 and 3.2 Hz, 1H), 2.11 
(m, 0.75H), 2.00-1.86 (m, 1.25H), 1.85-1.52 (m, 6.75H), 1.51-1.07 (m, 11.25H); 
13
C NMR (126 MHz, CDCl3) δ 177.3 and 175.0 (1C), 175.6, 168.8, 143.6 and 
142.0 (1C), 130.8 and 130.1 (1C), 127.1 and 126.0 (1C), from 124.4 to 122.4 (2C), 
109.1 and 108.8 (1C), 71.8 and 69.9 (1C), 66.4 and 65.6 (1C), 49.0 and 48.0 
(1C), 43.9 and 42.6 (1C), from 33.3 to 24.3 (12C); HR-MS (ESI) calcd for 
C25H34N3O3S
+
 [MH]
+
 456.2315, found 456.2303. 
Methyl ((3S*,4'R*)-3'-(cyclohexanecarbonyl)-1-methyl-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carbonyl) glycinate (V∙4k).  Prepared according to GP-A using 
thiazoline V∙1a, cyclohexanecarboxylic acid V∙3a and methyl isocyanoacetate 
V∙2d. FC: Hexane:EtOAc, 6:4; yield: 47%; light brown foamy solid; 1H NMR 
(300 MHz, CDCl3, 7:3 mixture of two rotamers) δ 7.65 (d, J = 7.3 Hz, 0.3H), 
7.45 (d, J = 7.3 Hz, 0.7H), 7.43- 7.28 (m, 1.3 H), 7.20-7.11 (m, br, 1H), 7.06 (t, 
J = 7.6 Hz, 0.7H), 6.90 (d, J = 7.6 Hz, 0.3H), 6.84 (d, J = 7.6 Hz, 0.7), 5.51 
(d, J = 5.7 Hz, 0.3H), 5.06 (d, J = 6.8 Hz, 0.7H), 4.35 (dd, J = 18.5 and 6.8 
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Hz, 0.3H), 4.25 (d, J = 5.9 Hz, 1.4H), 4.10 (dd, J = 11.7 and 6.8 Hz, 0.7H), 
3.95 (dd, J = 18.5 and 3.9 Hz, 0.3H), 3.83 (s, 2.1H), 3.78 (m, 0.3H), 3.79 (s, 
0.9H), 3.61 (d, J = 11.7 Hz, 0.3H), 3.46 (d, J = 11.2 Hz, 0.7H), 3.28 (s, 0.9H), 
3.24 (s, 2.1H), 2.29 (tt, J = 10.7 and 2.9 Hz, 1H), 1.87-0.99 (m, 10H);
 13
C NMR 
(75 MHz, CDCl3) δ 175.8 and 173.4 (1C), 174.0,  168.7, 168.5 and 168.0 (1C), 
141.8 and 140.3 (1C), 129.1 and 128.3 (1C), 125.0 and 124.1 (1C), 123.3 and 122.4 
(1C), 121.4 and 121.3 (1C), 107.2 and 106.9 (1C), 70.4 and 68.4 (1C), 64.7 and 
63.7 (1C), 51.0 and 50.7 (1C), 42.1 and 41.0 (1C), 40.0 and 39.8 (1C), 31.6-23.4 
(7C); HR-MS (ESI) calcd for C22H27N3NaO5S
+ 
[MNa]
+
 468.1564, found 468.1553. 
tert-Butyl 2-((3S*,4'R*)-3'-(cyclohexanecarbonyl)-1-methyl-2-oxospiro[indoline-
3,2'-thiazolidin]-4'-ylcarboxamido)acetate (V∙4l). Prepared according to GP-A 
using thiazoline V∙1a, cyclohexanecarboxylic acid V∙3a and tert-butyl 
isocyanoacetate V∙2e.  FC: c-Hexane:EtOAc, from 1:1 to 1:1.5; yield: 41%; beige 
foamy solid; 
1
H NMR (500 MHz, CDCl3, 7:3 mixture of two rotamers) δ 7.69 (d, 
J = 7.6 Hz, 0.3H), 7.49 (d, J = 7.6 Hz, 0.7H), 7.41 (t, J = 7.6 Hz, 0.3H), 7.32 
(t, J = 7.6 Hz, 0.7H), 7.24 (m, br, 0.3H), 7.18 (m, br, 0.7H), 7.14 (t, J = 7.6 Hz, 
0.3H), 7.07 (t, J = 7.6 Hz, 0.7H), 6.91 (d, J = 7.6 Hz, 0.3H), 6.84 (d, J = 7.6 
Hz, 0.7H), 5.52 (d, J = 6.3 Hz, 0.3H), 5.07 (d, J = 6.9 Hz, 0.7H), 4.19 (dd, J = 
18.3 and 6.0 Hz, 0.3H), 4.14 (d, J = 4.7 Hz, 1.4H), 4.09 (dd, J = 11.7 and 6.9 
Hz, 0.7H), 3.89 (dd, J = 18.3 and 4.1 Hz, 0.3H), 3.81 (dd, J = 11.7, 6.3 Hz, 
0.3H), 3.60 (d, J = 11.7 Hz, 0.3H), 3.48 (d, J = 11.7 Hz, 0.7H), 3.29 (s, 0.9H), 
3.25 (s, 2.1H), 2.31 (tt, br, J = 11.3 and 2.9 Hz, 1H), 1.98-0.99 (m, 10H, 
methylene protons), 1.51 (s, 6.3H), 1.50 (s, 2.7H); 
13
C NMR (126 MHz, CDCl3) δ 
177.2 and 175.7 (1C), 175.6 and 175.2 (1C), 170.1 and 169.9 (1C), 168.6 and 
168.2 (1C), 143.4 and 142.0 (1C), 130.7 and 130.0 (1C), 126.7 and 125.8 (1C), 
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from 125.1 to 123.0 (2C), 108.9 and 108.6 (1C), 83.0 and 82.2 (1C),  72.0 and 
70.1 (1C), 66.4 and 65.5 (1C), 43.8 and 42.7 (1C), 42.5, and 42.4 (1C), from 
33.3 to 25.1 (10C);  HR-MS (ESI) calcd for C25H34N3O5S
+
 [MH]
+
 488.2214, found 
488.2205.  
(3S*,4'R*)-3'-(Cyclohexanecarbonyl)-1-methyl-2-oxo-N-phenylspiro[indoline-3,2'-
thiazolidine]-4'-carboxamide (V∙4m). Prepared according to GP-A using thiazoline 
V∙1a, cyclohexanecarboxylic acid V∙3a and isocyanobenzene V∙2f. FC: 
Hexane:EtOAc, 1.5:1; yield: 43%; grey foamy solid; 
1
H NMR (300 MHz, CDCl3, 
11:9 mixture of two rotamers) δ 9.25 (m, br, 0.45 H), 8.47 (m, br, 0.55H), 7.64 
(d, br, J = 7.7 Hz, 1H), 7.58 (d, br, J = 7.8 Hz, 1H), 7.48-7.19  (m, 4.55H), 7.13 
(t, br, J = 7.7 Hz, 0.45H), 7.05 (t, br, J = 7.7 Hz, 1H), 6.88 (m, 1H), 5.64 (d, J 
= 4.9 Hz, 0.45H), 5.16 (d, J = 6.8 Hz, 0.55H), 4.12 (dd, J = 11.7, 6.8 Hz, 
0.55H), 3.78 (dd, J = 11.7 and 4.9 Hz, 0.45H), 3.71 (d, J = 11.7 Hz, 0.45H), 
3.59 (d, J = 11.7 Hz, 0.55H), 3.29 (s, 1.35H), 3.26 (s, 1.65H), 2.37 (tt, br, J = 
11.6 and 2.9 Hz, 1H), 1.93-0.90 (m, 10H, methylene protons);
 13
C NMR (75 
MHz, CDCl3) δ 178.2 and 175.6 and 175.1 (2C), 168.1 and 167.8 (1C), 143.7 and 
142.1 (1C), 138.1 and 136.9 (1C), 131.0 and 130.3 (1C), 129.5 (2C), 129.1 (2C), 
126.8 and 126.1 (1C), 125.4-122.8 (3C), 119.9 and 119.8 (1C), 109.1 and 19.0 (1C), 
72.1, and 70.1 (1C), 67.1 and 66.1 (1C), 44.0 and 42.8 (1C), 33.8-25.4 (7C); HR-
MS (ESI) calcd for C25H27N3NaO3S
+
 [MNa]
+
 472.1665, found 472.1653. 
(3S*,4'R*)-N-Benzyl-3'-(cyclohexanecarbonyl)-1-methyl-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carboxamide (V∙4n).  Prepared according to GP-A using 
thiazoline V∙1a, cyclohexanecarboxylic acid V∙3a and benzyl isocyanide V∙2g. FC: 
Hexane:EtOAc, 1:1; yield: 57%; light pink foamy solid; 
1
H NMR (400 MHz, 
CDCl3, 7:3 mixture of two rotamers) δ 7.45-7.22 (m, 6H), 6.98-6.77 (m, 4H), 
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5.53 (d, J = 5.8 Hz, 0.3H), 5.08 (d, J = 6.8 Hz, 0.7H), 4.78 (dd, J = 14.7 and 
6.8 Hz, 0.3H), 4.72 (dd, J = 14.3 and 6.2 Hz, 0.7H), 4.59 (dd, J = 14.3 and 5.5 
Hz, 0.7H),   4.32 (dd, J = 14.7 and 4.8 Hz, 0.3H), 4.06 (dd, J = 12.0 and 6.8 
Hz, 0.7H), 3.75 (dd, J = 11.6 and 5.8 Hz, 0.3H), 3.65 (d, J = 11.6 Hz, 0.3H), 
3.56 (d, J = 12.0 Hz, 0.7H), 3.27 (s, 0.9H), 3.22 (s, 2.1H), 2.26 (tt, br, J = 11.3 
and 3.4 Hz, 1H), 1.95-0.98 (m, 10H, methylene protons); 
13
C NMR (101 MHz, 
CDCl3) δ 178.2 and 177.5 (1C), 175.6 and 175.0 (1C), 169.7, 143.6 and 142.1 (1C), 
138.5 and 137.3 (1C), 130.8-127.5 (6C), 126.9 and 125.9 (1C), 124.5-122.7 (2C), 
109.0 and 108.7 (1C), 72.0 and 70.0 (1C), 66.4 and 65.7 (1C), 44.4 and 43.7 
(1C), 43.9 and 42.7 (1C), 33.5-25.2 (10C); HR-MS (ESI) calcd for 
C26H29N3NaO3S
+
 [MNa]
+
 486.1822, found 486.1833. 
(3S*,4'R*-3'-Acetyl-N-(tert-butyl)-1-methyl-2-oxospiro[indoline-3,2'-thiazolidine]-
4'-carboxamide (V∙4p). Prepared according to GP-A using thiazoline V∙1a, acetic 
acid V∙3b and tert-butyl isocyanide V∙2a. FC: Hexane:EtOAc, 1:9; yield: 52%; 
yellow foamy solid; 
1
H NMR (300 MHz, CDCl3, 9:1 mixture of two rotamers) δ 
7.43-7.23 (m, 2.1H), 7.14 (t, br, J = 7.7 Hz, 0.1H), 7.07 (t, br, J = 7.7 Hz, 
0.9H), 6.89 (m, br, 0.1H), 6.85 (d, br,  J = 7.8 Hz, 0.9H), 6.49 (m, br, 0.9H), 
5.36 (d, J = 5.8 Hz, 0.1H), 4.83 (d, J = 6.8 Hz, 0.9H), 4.08 (dd, J = 11.7 and 
6.8 Hz, 0.9H), 3.69 (dd, J = 11.7 and 5.8 Hz, 0.1H), 3.59 (d, J = 11.7 Hz, 0.1H), 
3.46 (d, J = 11.7 Hz, 0.9H), 3.26 (s, 0.3H), 3.24 (s, 2.7H), 2.12 (s, 2.7H), 2.03 
(s, 0.3H), 1.52 (s, 0.9H), 1.49 (s, 8.1H); 
13
C NMR (101 MHz, CDCl3) δ 175.1, 
169.5, 168.7, 143.7 and 142.3 (1C), 130.9 and 130.2 (1C), 126.3 and 126.0 (1C), 
124.5-122.8 (2C), 109.2 and 108.9 (1C), 74.2 and 72.1 (1C), 67.5 and 67.0 (1C), 
52.2 and 51.4 (1C), 33.9, 28.8 (3C), 26.8 and 26.6 (1C), 23.6 and 21.4 (1C); HR-
MS (ESI) calcd for C18H23N3NaO3S
+ 
[MNa]
+
 384.1352, found 384.1360. 
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(3S*,4'R*)-N-(tert-Butyl)-3'-(cyclopentanecarbonyl)-1-methyl-2-oxospiro[indoline-
3,2'-thiazolidine]-4'-carboxamide (V∙4q). Prepared according to GP-A using 
thiazoline V∙1a, cyclopentanecarboxylic acid V∙3c and tert-butyl isocyanide V∙2a. 
FC: c-Hexane:EtOAc, 1:1; yield: 80%; yellow foamy solid; 
1
H NMR (500 MHz, 
CDCl3, 9:1 mixture of two rotamers) δ 7.38 (d, br, J = 7.8 Hz, 0.1H), 7.32 (t, br, 
J = 7.8 Hz, 0.9H), 7.28-7.22 (m, 1H), 7.12 (t, J = 7.7 Hz, 0.1H), 7.05 (t, br,  J 
= 7.7 Hz, 0.9H), 6.96 (m, br, 0.1H), 6.86 (d, br, J = 7.8 Hz, 0.1H), 6.84 (d, br, 
J = 7.8 Hz, 0.9H),, 6.54 (m, br, 0.9H), 5.44 (d, J = 5.4 Hz, 0.1H), 4.94 (d, J = 
6.9 Hz, 0.9H), 4.03 (dd, J = 12.0 and 6.9 Hz, 0.9H), 3.65 (dd, J = 11.3 and 5.4 
Hz, 0.1H), 3.60 (d, J = 11.3 Hz, 0.1H), 3.46 (d, J = 12.0 Hz, 0.9H), 3.25 (s, 
0.3H), 3.23 (s, 2.7H), 2.71 (m, 1H), 1.91 (m, 1H), 1.78-1.45 (m, 7H), 1.48 (s, 
8.1H), 1.41 (s, 0.9H); 
13
C NMR (126 MHz, CDCl3) δ 178,4 and 176.4 (1C) 175.5 
and 175.0(1C), 169.1 and 168.7 (1C), 143.6 and 141.9 (1C), 130.4 and 130.1 (1C), 
127.1 and 126.0 (1C), 123.8-122.3 (2C), 109.1 and 108.9 (1C), 72.0 and 70.0 (1C), 
67.3 and 66.2 (1C), 52.1 and 51.2 (1C), 43.5 and 42.2 (1C), 33.4-26.0 (9C); HR-
MS (ESI) calcd for C22H30N3O3S
+
[MH]
+
 416.2002, found 416.1993.  
(3S*,4'R*)-N-(tert-Butyl)-1-methyl-2-oxo-3'-(tetrahydro-2H-pyran-4-
carbonyl)spiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4r). Prepared 
according to GP-A using thiazoline V∙1a, tetrahydropyran-4-carboxylic V∙3d and 
acid tert-butyl isocyanide V∙2a. FC: c-Hexane:EtOAc, 1:1; yield: 79%; white 
foamy solid; 
1
H NMR (500 MHz, CDCl3, 3:1 mixture of two rotamers) δ 7.44-
7.37 (m, 0.5H), 7.33 (t, J = 7.6 Hz, 0.75H), 7.23 (d, J = 7.6 Hz, 0.75H), 7.12 
(t, J = 7.6 Hz, 0.25H), 7.06 (t, J = 7.6 Hz, 0.75H), 6.93 (d, J = 7.6 Hz, 
0.25H), 6.90-6.81 (m, 1H), 6.52 (m, b, 0.75H), 5.41 (d, J = 5.4 Hz, 0.25H), 
4.90 (d, J = 6.9 Hz, 0.75H), 4.06 (dd, J = 11.7, 6.9 Hz, 0.75H), 4.00-3.83 (m, 
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1.75H), 3.69-3.56 (m, 0.75H), 3.47-3.28 (m, 2.25H), 3.28 (s, 0.9H), 3.24 (s, 
2.1H), 2.90 (t, br, J = 11.3 Hz, 0.25H), 2.54 (m, 1H), 2.44 (t, J = 11.4 Hz, 
0.25H), 1.84-1.48 (m, 4H), 1.47 (s, 6.75H), 1.40 (s, 2.25H); 
13
C NMR (126 MHz, 
CDCl3) δ 175.6-173.7 (2C), 169.0 and 168.4 (1C), 143.5 and 142.0 (1C), 131.1 and 
130.3 (1C), 127.1 and 125.7 (1C), 124.4-122.3 (2C), 109.2 and 109.0 (1C), 72.0 
and 69.9 (1C), 67.2-66.7 (2C), 66.9 and 66.0 (1C), 52.1 and 51.3 (1C), 41.1 and 
39.9 (1C), 33.5 (1C), 30.2-26.7 (6C); HR-MS (ESI) calcd for C22H30N3O4S
+ 
[MH]
+
 
432.1952, found 432.1947. 
tert-Butyl 4-((3S*,4'R*)-4'-(tert-butylcarbamoyl)-1-methyl-2-oxospiro[indoline-
3,2'-thiazolidin]-3'-ylcarbonyl)piperidine-1-carboxylate (V∙4t). Prepared according 
GP-A using thiazoline V∙1a, 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid 
V∙3f and tert-butyl isocyanoacetate V∙2a; FC: c-Hexane:EtOAc, gradient from 1:1, 
gradually changed to 1:1.5; yield: 59%; white foamy solid; 
1
H NMR (500 MHz, 
CDCl3, 7:3 mixture of two rotamers) δ 7.45-7.39 (m, 0.6H), 7.36 (t, br, J = 7.7 
Hz, 0.7H), 7.25 (d, br,  J = 7.7 Hz, 0.7H), 7.16 (t, J = 7.7 Hz, 0.3H), 7.08 (t, 
br,  J = 7.7 Hz, 0.7H), 6.93 (d, br,  J = 7.7 Hz, 0.3H), 6.88 (d, br, J = 7.7 Hz, 
0.7H), 6.85 (m, br, 0.3H), 6.55 (m, br, 0.7H), 5.44 (d, J = 5.7 Hz, 0.3H), 4.92 
(d, J = 6.9 Hz, 0.7H), 4.24 – 3.97 (m, br, 1.4H), 4.10 (dd, J = 12.0 and 6.9 Hz, 
0.7H) 3.83 (m, br, 0.6H), 3.71 (dd, J = 11.8, 5.7 Hz, 0.3H), 3.62 (d, J = 11.8, 
0.3H), 3.43 (d, J = 11.8 Hz, 0.7H), 3.29 (s, 0.9H), 3.25 (s, 2.1H), 2.69 (m, br, 
1.4H), 2.47 (m, 1H), 2.21 (m, br, 0.6H), 1.83-1.68 (m, 1.7H), 1.64-1.52 (m, 
2.3H), 1.50 (s, 6.3H), 1.43 (s, 2.7H), 1.42 (s, 6.3H), 1.40(s, 2.7H); 
13
C NMR (126 
MHz, CDCl3) δ 175.6 and 175.5 (1C), 174.8 and 174.0 (1C), 169.0 and 168.4 (1C), 
154.4 and 154.3 (1C), 143.5 and 141.9 (1C), 131.1 and 130.3 (1C), 127.0 and 125.6 
(1C), 124.3-122.3 (2C), 109.2 and 108.9 (1C), 79.7 and 79.6 (1C), 71.9 and 69.9 
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(1C), 66.8 and 66.0 (1C), 52.1 and 51.3 (1C), 43.2-42.3 (br, 2C), 41.9 and 40.8 
(1C), 33.6, 30.0-26.6 (9C); HR-MS (ESI) calcd for C27H39N4O5S
+
 [MH
+
] 
531.2636, found 531.2615.  
(3S*,4'R*)-N-(tert-Butyl)-3'-(furan-2-carbonyl)-1-methyl-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carboxamide (V∙4u). Prepared according to GP-A using thiazoline 
V∙1a, 2-furoic acid V∙3g and tert-butyl isocyanide V∙2a. FC: c-Hexane:EtOAc, 1:1; 
yield: 78%; light pink foamy solid; 
1
H NMR (500 MHz, CDCl3) δ 7.47 (s, br, 
1H), 7.40-7.31 (m, 2H), 7.16 (d, br,  J = 3.4 Hz, 1H), 7.07 (t, br,  J = 7.8 Hz, 
1H), 6.89 (d, J = 7.8 Hz, 1H), 6.49 (dd, J = 3.5 and 1.6 Hz, 1H), 6.45 (m, br, 
1H), 5.40 (d, J = 6.3 Hz, 1H), 4.10 (dd, J = 11.9 and 6.3 Hz, 1H), 3.59 (d, J = 
11.9 Hz, 1H), 3.29 (s, 3H), 1.46 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ 174.9, 
169.5, 158.1, 146.4, 145.2, 143.9, 130.4, 125.3, 122.9, 122.8, 119.8, 112.3, 108.8, 
73.1, 67.1, 52.0, 29.7, 28.7 (3C), 26.7; HR-MS (ESI) calcd for C21H24N3O4S
+
 
[MH
+
] 414.1482, found 414.1478. 
(3S*,4'R*)-N-(tert-Butyl)-1-methyl-2-oxo-3'-(thiophene-2-carbonyl)spiro[indoline-
3,2'-thiazolidine]-4'-carboxamide  (V∙4v). Prepared according to GP-A using 
thiazoline V∙1a, thiophene-2-carboxylic acid V∙3h and tert-butyl isocyanide V∙2a. 
FC: c-Hexane:EtOAc, 1:1; yield: 76%; light yellow foamy solid; 
1
H NMR (500 
MHz, CDCl3) δ 7.54 (d, J = 4.8 Hz, 1H), 7.47 (m, br, 1H), 7.38 (d, br, J = 7.6 
Hz, 1H), 7.35 (d, br, J = 7.6 Hz, 1H), 7.07 (t, br, J = 7.7 Hz, 1H), 7.05 (m, br, 
1H),  6.88 (d, br, J = 7.8 Hz, 1H), 6.71 (m, br, 1H), 5.27 (d, J = 6.7 Hz, 1H), 
4.11 (dd, J = 11.8, 6.7 Hz, 1H), 3.54 (d, J = 11.8 Hz, 1H), 3.29 (s, 3H), 1.52 (s, 
9H); 
13
C NMR (126 MHz, CDCl3) δ 174.8, 169.0, 162.5, 143.8, 137.2, 132.3, 
130.7, 130.4, 127.6, 125.4, 122.8, 122.7, 108.9, 73.3, 68.1, 52.3, 29.7, 28.6 (3C), 
26.7; HR-MS (ESI) calcd for C21H24N3O3S2
+
 [MH
+
] 430.1254, found 430.1258. 
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(3S*,4'R*)-N-(tert-Butyl)-1-methyl-3'-nicotinoyl-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carboxamide (V∙4w). Prepared according to GP-A using thiazoline 
V∙1a, nicotinic acid V∙3i and tert-butyl isocyanide V∙2a. FC: CH2Cl2:EtOAc, 19:1; 
yield: 56%; orange foamy solid; 
1
H NMR (300 MHz, DMSO-d6, 3:1 mixture of 
two rotamers) δ  8.70 (d, br, J = 4.9 Hz, 0.75H), 8.53 (s, br, 0.75H),  8.07 (d, 
br, J = 7.8 Hz, 1H), 7.94 (s, br, 0.25H), 7.88 (d, br, J = 4.8 Hz, 0.25H), 7.79-
7.70 (m, br, 2H), 7.47 (m, 0.75H), 7.42-7.32 (m, 1.25H), 7.14 (t, br,  J = 7.6 
Hz, 1H), 7.04 (t, br,  J = 7.8 Hz, 1H), 5.17 (d, J = 6.3 Hz, 0.25H), 4.78 (d, J = 
5.8 Hz, 0.75H), 3.76 (m, 1H), 3.45-3.32 (m, 1H), 3.21 (s, 2.25H), 3.13 (s, 
0.75H), 1.36 (s, 2.25H), 1.31 (s, 6.75H); 
13
C NMR (75 MHz, CDCl3) δ 176.1-
175.3 (2C), 169.4, 152.1 (br), 148.2 (br), 142.9, 135.2, 131.4 and 130.6 (1C), 131.0 
(br), 128.8, 128.7, 125.5 and 123.9 (1C), 125.1 (br), 110.5, 72.2, 67.4 and 66.7 
(1C), 52.9 and 52.8 (1C), 34.7 and 34.4 (1C), 29.4 (3C), 27.4; HR-MS (ESI) calcd 
for C22H24N4NaO3S
+
 [MNa]
+
 447.1461, found 447.1457.  
(3S*,4'R*)-N-(tert-Butyl)-1-methyl-2-oxo-3'-(2-phenylacetyl)spiro[indoline-3,2'-
thiazolidine]-4'-carboxamide (V∙4x). Prepared according to GP-A using thiazoline 
V∙1a, phenylacetic acid V∙3j and tert-butyl isocyanide V∙2a. FC: Hexane:EtOAc, 
7:3; yield: 55%; yellow foamy solid; 
1
H NMR (300 MHz, CDCl3) δ 7.43-7.11 (m, 
7H), 7.05 (t, J = 7.8 Hz, 1H), 6.83 (d, J = 7.7 Hz, 1H), 6.43 (m, br, 1H), 4.92 
(d, J = 6.8 Hz, 1H), 3.99 (dd, J = 11.7 and 6.8 Hz, 1H), 3.69 (s, 2H), 3.43 (d, J 
= 11.7 Hz, 1H), 3.24 (s, 3H), 1.44 (s, 9H); 
13
C NMR (101 MHz, CDCl3) δ 175.2, 
170.1, 168.8, 143.9, 133.3, 130.4, 129.9, 129.1 (2C), 129.0 (2C), 127.5, 123.1 
(2C), 109.1, 72.5, 66.6, 52.3, 42.5, 34.1, 28.9 (3C), 26.9; HR-MS (ESI) calcd for 
C24H27N3NaO3S
+ 
[MNa]
+
 460.1665, found 460.1657. 
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(3S*,4'R*)-3'-(2-(1H-Indol-3-yl)acetyl)-N-(tert-butyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4y). Prepared according 
to GP-A using thiazoline V∙1a, 3-indoleacetic acid V∙3k  and tert-butyl isocyanide 
V∙2a. FC: c-Hexane:EtOAc, 1:1; yield: 72%; white foamy solid;  1H NMR (500 
MHz, DMSO-d6) δ 10.92 (s, br, 1H), 7.90-7.85 (m, 2H), 7.36 (d, J = 7.9 Hz, 
1H), 7.31 (d, J = 8.1 Hz, 1H), 7.27 (t, J = 7.9 Hz, 1H), 7.15 (s, br, 1H), 7.10-7.05 
(m, 2H), 6.96-6.91 (m, 2H), 5.18 (d, J = 6.7 Hz, 1H), 3.73 (dd, J = 12.1 Hz and 
6.7, 1H), 3.62 (d, J = 16.0 Hz, 1H), 3.47 (d, J = 16.0 Hz, 1H), 3.42 (d, J = 12.1 
Hz, 1H) 3.10 (s, 3H), 1.33 (s, 9H); 
13
C NMR (126 MHz, DMSO-d6) δ 175.5, 168.9, 
168.8, 143.4, 136.5, 129.7, 127.9, 127.6, 125.1, 123.8, 122.9, 121.6, 118.9, 118.7, 
111.8, 108.8, 107.6, 71.6, 64.9, 55.4, 51.1, 35.9, 28.8 (3C), 26.7; HR-MS (ESI) 
calcd for C26H29N4O3S
+
 [MH]
+
 477.1955, found 477.1942.  
(3S*,4'R*)-N-(tert-Butyl)-3'-((E)-3-(furan-2-yl)acryloyl)-1-methyl-2- 
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide (V∙4z). Prepared according to 
GP-A using thiazoline V∙1a, 3-(2-furyl)acrylic acid V∙3l and tert-butyl isocyanide 
V∙2a. FC: CH2Cl2:EtOAc, 19:1; yield: 42%; grey foamy solid; 1H NMR (400 MHz, 
CDCl3) δ 7.52-7.23 (m, 4H), 7.10 (t, br, J = 7.5 Hz, 1H), 6.91 (d, br, J = 7.6 Hz, 
1H), 6.64-6.40 (m, 4H), 5.08 (d, J = 7.0 Hz, 1H), 4.13 (dd, J = 11.6 and 7.0 Hz, 
1H), 3.59 (d, J = 11.6 Hz, 1H), 3.31 (s, 3H), 1.52 (s, 9H); 
13
C NMR  (75 MHz, 
CDCl3 ) δ 175.1, 168.9, 165.3, 150.8, 143.9, 132.4, 130.3 (2C), 125.8, 122.8, 
122.7, 116.0, 114.0, 112.5, 108.8, 72.3, 66.4, 52.3, 33.6, 28.8 (3C), 26.7; HR-MS 
(ESI) calcd for C23H25N3NaO4S
+
 [MNa]
+
 462.1458, found 462.1446. 
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General procedure B (GP-B) for the synthesis of compounds V∙5a-l via azido-Ugi 
3-CR reaction. To a solution of thiazoline V∙1 (0.3 mmol, 1 eq) in HFIP (0.68 mL) 
cooled to 0 °C, isocyanide V∙2 (0.3 mmol, 1 eq) and trimethylsilyl azide (0.3 
mmol, 1 eq) were added. The reaction was stirred at room temperature and the 
conversion was monitored by TLC. The solvent was evaporated under reduce 
pressure and the crude was purified by flash chromatography (FC) or triturated as 
reported below. 
(3S*,4'R*)-4'-(1-(tert-butyl)-1H-tetrazol-5-yl)-1-methylspiro[indoline-3,2'-
thiazolidin]-2-one (V∙5a). Prepared according to GP-B using thiazoline V∙1a, tert-
butyl isocyanide V∙2a and trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 100:0, to 
96:4; yield: 87%; amorphous  solid; 
1
H NMR (300 MHz, CDCl3) δ 7.49 (dd, J = 
7.6, 1.3 Hz, 1H), 7.38 (td, J = 7.6, 1.3 Hz, 1H), 7.15 (td, J = 7.6, 1.3 Hz, 1H), 
6.88 (d, J = 7.6, 1H), 5.80 (dd, J = 9.5, 6.3 Hz, 1H), 4.00 - 3.90 (m, 1H), 3.75 
(dd, J = 9.5, 6.3 Hz, 1H), 3.22 (s, 3H), 2.85 (br s, 1H), 1.81 (s, 9H); 
13
C NMR (76 
MHz, CDCl3) δ 176.4, 152.6, 143.3, 130.7, 126.4, 124.1, 123.6, 108.7, 75.5, 62.1, 
57.3, 41.0, 30.0 (3C), 29.8; HR-MS (ESI) calcd for  C16H21N6OS
+
 [MH]+ 
345.1492, found 345.1512. 
(3S*,4'R*)-4'-(1-(tert-butyl)-1H-tetrazol-5-yl)spiro[indoline-3,2'-thiazolidin]-2-one 
(V∙5b). Prepared according to GP-B using thiazoline V∙1b, tert-butyl isocyanide 
V∙2a and trimethylsilyl azide. Triturated in MeOH; yield: 69%; pale yellow 
amorphous solid; 
1
H NMR (300 MHz, DMSO-d6) δ 10.55 (br s, 1H), 7.51 (d, J = 
7.4 Hz, 1H), 7.26 (t, J = 7.4 Hz, 1H), 7.00 (t, J = 7.4 Hz, 1H), 6.84 (d, J = 7.4 
Hz, 1H), 5.52 (ddd, J = 11.9, 9.3, 6.0 Hz, 1H), 4.66 (d, J = 11.9 Hz, 1H), 4.00 (t, 
J = 9.3 Hz, 1H), 3.73 (dd, J = 9.3, 6.0 Hz, 1H), 1.72 (s, 9H); 
13
C NMR (76 MHz, 
DMSO-d6) δ 178.0, 152.6, 141.8, 130.6, 127.8, 126.1, 122.5, 110.2, 76.2, 62.7, 
Sequential Asinger/Ugi-type Reactions 
- 133 - 
 
58.1, 29.5 (3C); HR-MS (ESI) calcd for C15H19N6OS
+
 [MH]
+
 331.1336, found 
331.1321. 
(3S*,4'R*)-1-benzyl-4'-(1-(tert-butyl)-1H-tetrazol-5-yl)spiro[indoline-3,2'-
thiazolidin]-2-one (V∙5c). Prepared according to GP-B using thiazoline V∙1c, tert-
butyl isocyanide V∙2a and trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 100:0 to 
96:4; yield: 80%; pale yellow amorphous solid; 
1
H NMR (500 MHz, DMSO-d6) 
δ 7.59 (d, J = 7.6 Hz, 1H), 7.50 – 7.25 (m, 6H), 7.05 (t, J = 7.6 Hz, 1H), 6.96 
(d, J = 7.6 Hz, 1H), 5.65 – 5.48 (m, 1H), 5.04 – 4.75 (m, 3H), 4.25 – 4.3.90 (m, 
1H), 3.80 (dd, J = 9.5, 5.8 Hz, 1H), 1.73 (s, 9H);
 13
C NMR (126 MHz, DMSO-d6) 
δ 176.4, 152.5, 142.2, 136.6, 130.6, 129.1 (2C), 128.0, 127.6 (2C), 127.1, 126.1, 
123.3, 109.9, 75.9, 62.8, 58.1, 42.8, 39.7, 29.5 (3C); HR-MS (ESI) calcd for 
C22H25N6OS
+ 
[MH]
+
 421.1805, found 421.1799. 
(3S*,4'R*)-4'-(1-(tert-butyl)-1H-tetrazol-5-yl)-5-fluoro-1-methylspiro[indoline-3,2'-
thiazolidin]-2-one (V∙5d). Prepared according to GP-B using thiazoline V∙1d, tert-
butyl isocyanide V∙2a and trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 100:0 to 
96:4; yield: 78%; pale yellow amorphous solid; 
1
H NMR (500 MHz, CDCl3) δ 
7.35 – 7.28 (m, 1H), 6.80 (dt, J = 8.5, 3.9 Hz, 1H), 6.79 (dd, J = 8.5, 3.9 Hz, 
1H), 5.90 – 5.75 (m, 1H), 4.00 – 3.89 (m, 1H), 3.75 (dd, J = 9.8, 6.3 Hz, 1H), 
3.22 (s, 3H), 3.07 (br s, 1H), 1.81 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ 176.2, 
160.5 and 158.6 (1C), 152.4, 139.3 and 139.2 (1C), 128.0 and 127.9 (1C), 117.2 
and 117.0 (1C), 112.5 and 112.3 (1C), 109.5 and 109.4 (1C), 75.4, 62.1, 57.4, 41.0, 
30.0 (3C), 26.6; HR-MS (ESI) calcd for C16H20FN6OS
+ 
[MH]
+
 363.1398, found 
363.1417. 
(3S*,4'R*)-5-bromo-4'-(1-(tert-butyl)-1H-tetrazol-5-yl)-1-methylspiro[indoline-3,2'-
thiazolidin]-2-one (V∙5e). Prepared according to GP-B using thiazoline V∙1f, tert-
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butyl isocyanide V∙2a and trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 100:0 to 
96:4; yield: 81%; white amorphous solid; 
1
H NMR (300 MHz, CDCl3) δ 7.63 (d, 
J = 1.7 Hz, 1H), 7.52 (dd, J = 8.3, 1.7 Hz, 1H), 6.75 (d, J = 8.3 Hz, 1H), 5.92 – 
5.66 (m, 1H), 4.00 – 3.89 (m, 1H), 3.77 (dd, J = 9.8, 6.4 Hz, 1H), 3.22 (s, 3H), 
3.00 ( br s, 1H), 1.82 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ 175.9, 152.4, 142.4, 
133.6, 128.4, 127.5, 116.0, 110.2, 75.0, 62.1, 57.4, 41.1, 30.0 (3C), 26.6; HR-MS 
(ESI) calcd for C16H20BrN6OS
+ 
[MH]
+
 423.0597, found 422.0524. 
(3S*,4'R*)-1-methyl-4'-(1-(2,4,4-trimethylpentan-2-yl)-1H-tetrazol-5-
yl)spiro[indoline-3,2'-thiazolidin]-2-one (V∙5f). Prepared according to GP-B using 
imine V∙1a, 1,1,3,3-tetramethylbutyl isocyanide V∙2b and trimethylsilyl azide. FC: 
CH2Cl2:EtOAc, from 100:0 to 96:4; yield: 84%; pale yellow amorphous solid; 
1
H 
NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.3 Hz, 1H), 7.39 (t, J = 7.3 Hz, 1H), 
7.16 (t, J = 7.3 Hz, 1H), 6.86 (d, J = 7.3 Hz, 1H), 5.96 – 5.75 (m, 1H), 4.00 – 
3.83 (m, 1H), 3.81 – 3.69 (m, 1H), 3.22 (s, 3H), 2.16 (d, J = 15.5 Hz, 1H), 2.01 
(d, J = 15.5 Hz, 1H), 1.89 (d, J = 14.1 Hz, 4H), 0.77 (s, 9H); 
13
C NMR (126 
MHz, CDCl3) δ 176.3, 153.2, 143.4, 130.7, 126.4, 124.1, 123.5, 108.7, 75.5, 65.4, 
57.4, 53.2, 41.3, 31.7, 30.8, 30.6 (3C), 30.1, 26.4; HR-MS (ESI) calcd for 
C20H29N6OS
+ 
[MH]
+
 401.2118, found 401.2130. 
(3S*,4'R*)-1-methyl-4'-(1-pentyl-1H-tetrazol-5-yl)spiro[indoline-3,2'-thiazolidin]-2-
one (V∙5g). Prepared according to GP-B using imine V∙1a, 1-pentyl isocyanide 
V∙2i and trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 100:0 to 96:4; yield: 59%; 
pale yellow foam; 
1
H NMR (300 MHz, DMSO-d6) δ 7.64 – 7.29 (m, 2H), 7.18 – 
6.78 (m, 2H), 5.40 (ddd, J = 11.5, 8.7, 6.3 Hz, 1H), 4.73 (d, J = 11.5 Hz, 1H), 
4.61 – 4.23 (m, 2H), 4.11 – 3.67 (m, 2H), 3.15 (s, 3H), 1.82 (p, J = 7.2 Hz, 2H), 
1.32 – 1.17 (m, 4H), 0.79 (t, J = 6.8 Hz, 3H); 13C NMR (126 MHz, DMSO-d6) δ 
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176.5, 153.5, 143.3, 130.7, 127.3, 125.4, 123.2, 109.4, 75.8, 57.2, 47.7, 38.6, 
28.5, 28.3, 26.6, 21.8, 14.1; HR-MS (ESI) calcd for C17H23N6OS
+ 
[MH]
+
 359.1649, 
found 359.1629. 
(3S*,4'R*)-4'-(1-cyclohexyl-1H-tetrazol-5-yl)-1-methylspiro[indoline-3,2'-
thiazolidin]-2-one (V∙5h). Prepared according to GP-B using imine V∙1a, 
cyclohexyl isocyanide V∙2c and trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 
100:0 to 96:4; yield: 76%; white foam; 
1
H NMR (500 MHz, DMSO-d6) δ 7.43 – 
7.27 (m, 2H), 7.14 – 6.94 (m, 2H), 5.65 – 5.37 (m, 1H), 4.73 (d, J = 11.1 Hz, 
1H), 4.57 (t, J = 11.1 Hz, 1H), 3.96 – 3.85 (m, 1H), 3.82 – 3.70 (m, 1H), 3.15 (s, 
3H), 2.07 (d, J = 11.7 Hz, 1H), 1.96 (d, J = 11.7 Hz, 1H), 1.90 – 1.70 (m, 4H), 
1.69 – 1.56 (m, 1H), 1.40 – 1.15 (m, 3H); 13C NMR (126 MHz, DMSO-d6) δ 176.6, 
152.9, 143.3, 130.6, 127.5, 125.3, 123.2, 109.4, 75.7, 57.8, 57.2, 38.5, 32.7, 
32.6, 26.6, 25.3, 25.2, 24.9; HRMS (ESI) calcd for C18H23N6OS
+ 
[MH]
+
 371.1649, 
found 371.1632. 
tert-butyl 4-(5-((3S*,4'R*)-1-methyl-2-oxospiro[indoline-3,2'-thiazolidin]-4'-yl)-
1H-tetrazol-1-yl)piperidine-1-carboxylate (V∙5i). Prepared according to GP-B using 
imine V∙1a, tert-butyl 4-(methylidyne-λ4-azanyl)piperidine-1-carboxylate V∙2j and 
trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 100:0 to 96:4; yield: 69%; pale 
yellow amorphous solid; 
1
H NMR (500 MHz, DMSO-d6, disteroisomeric mixture 
7:3) δ 7.62 (d, J = 7.4 Hz, 0.3H), 7.42 – 7.30 (m, 1.3H), 7.14 (t, J = 7.4 Hz, 
0.3H), 7.10 – 6.99 (m, 1.3H), 5.55 – 5.35 (m, 1H), 5.24 – 5.09 (m, 0.3H), 4.87 – 
4.78  (m, 0.7H), 4.74 (d, J = 11.0 Hz, 0.7H), 4.57 (d, J = 11.0 Hz, 0.3H), 4.19 – 
3.69 (m, 4H), 3.14 (s, 2.1H), 3.09 (s, 0.9H), 3.00 – 2.70 (br m, 2H), 2.19 – 1.76 
(m, 4H), 1.41 (s, 2.7H) 1.40 (s, 6.3H); 
13
C NMR (126 MHz, DMSO-d6) δ 176.5 
and 175.8 (1C), 154.3 and 154.2 (1C), 154.1 and 153.4 (1C), 143.3 and 143.0 (1C), 
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130.6 and 130.5 (1C), 129.3 and 127.4 (1C), 125.3 and 125.0 (1C), 123.3 and 
123.2 (1C), 109.5 and 109.4 (1C), 79.6 and 79.5 (1C), 75.7 and 75.0 (1C), 59.2 
and 57.3 (1C), 55.8 and 55.2 (1C), 38.9 and 38.5 (1C), 32.1 and 31.7 (2C), 28.6 
and 28.5 (3C), 26.8 (2C), 26.7 and 26.6 (1C); HR-MS (ESI) calcd for 
C22H30N7O3S
+ 
[MH]
+
 472.2125, found 472.2121. 
tert-butyl 2-(5-((3S*,4'R*)-1-methyl-2-oxospiro[indoline-3,2'-thiazolidin]-4'-yl)-
1H-tetrazol-1-yl)acetate (V∙5j). Prepared according to GP-B using imine V∙1a, tert-
butyl isocyanoacetate V∙2e and trimethylsilyl azide. FC: CH2Cl2:EtOAc from 
100:0 to 96:4; yield: 72%; pale yellow amorphous solid; 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.46 (d, J = 7.5 Hz, 1H), 7.36 (t, J = 7.5 Hz, 1H), 7.07 (t, J = 7.5 
Hz, 1H), 7.03 (d, J = 7.5 Hz, 1H), 5.48 – 5.24 (m, 3H), 4.65 (d, J = 11.6 Hz, 
1H), 3.94 – 3.66 (m, 2H), 3.13 (s, 3H), 1.27 (s, 9H); 13C NMR (126 MHz, CDCl3) 
δ 176.3, 165.5, 154.4, 143.3, 130.7, 127.2, 125.4, 123.2, 109.3, 83.2, 75.4, 57.1, 
49.7, 38.3, 27.8 (3C), 26.5; HR-MS (ESI) calcd for C18H23N6O3S
+ 
[MH]
+
 
403.1547, found 403.1538. 
(3S*,4'R*)-4'-(1-(4-methoxyphenyl)-1H-tetrazol-5-yl)-1-methylspiro[indoline-3,2'-
thiazolidin]-2-one (V∙5k). Prepared according to GP-B using imine V∙1a, 4-
methoxyphenyl isocyanide V∙2k and trimethylsilyl azide. FC: CH2Cl2:EtOAc from 
100:0 to 96:4; yield: 37%; pale yellow amorphous solid; 
1
H NMR (500 MHz, 
DMSO-d6) δ 7.66 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 7.4 Hz, 1H), 7.35 (t, J = 7.4 
Hz, 1H), 7.11 (d, J = 8.3 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 7.00 (d, J = 7.4 Hz, 
1H), 5.50 – 5.32 (m, 1H), 4.64 (d, J = 11.2 Hz, 1H), 3.95 – 3.85 (m, 1H), 3.83 (s, 
3H), 3.75 – 3.64 (m, 1H), 3.08 (s, 3H); 13C NMR (126 MHz, DMSO-d6) δ 176.1, 
160.7, 153.7, 143.3, 130.7, 126.9 (2C), 126.8, 125.5, 123.1, 115.1 (2C), 109.3, 
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75.8, 56.9, 56.1, 39.0, 26.5; HR-MS (ESI) calcd for C19H19N6O2S
+
 [MH]
+
 
395.1285, found 395.1272. 
(3S*,4'R*)-4'-(1-benzyl-1H-tetrazol-5-yl)-1-methylspiro[indoline-3,2'-thiazolidin]-2-
one (V∙5l). Prepared according to GP-B using imine V∙1a, benzyl isocyanide V∙2g 
and trimethylsilyl azide. FC: CH2Cl2:EtOAc, from 100:0 to 96:4; yield: 70%; pale 
yellow amorphous solid; 
1
H NMR (500 MHz, DMSO-d6) δ 7.43 (d, J = 7.2 Hz, 
1H), 7.35 (d, J = 16.8 Hz, 5H), 7.12 – 6.88 (m, 2H), 5.68 (s, 2H), 5.42 (q, J = 
8.3, 7.7 Hz, 1H), 4.86 (d, J = 11.4 Hz, 1H), 3.82 (dt, J = 27.6, 8.8 Hz, 2H), 3.15 
(s, 2H); 
13
C NMR (126 MHz, DMSO-d6) δ 176.5, 153.7, 143.3, 134.8, 130.7, 
129.3 (2C), 128.9, 128.8 (2C), 127.3, 125.4, 123.2, 109.4, 75.7, 57.2, 51.0, 38.6, 
26.6; HR-MS (ESI) calcd for C19H19N6OS
+ 
[MH]
+
 379.1336, found 379.1321. 
 
Post-transformations 
(3S*,4'R*)-3'-(cyclohexanecarbonyl)-1-methyl-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carboxamide (V∙6). Compound V∙4i (0.11 mmol, 1 eq) was 
dissolved in TFA (0.22 mL) and stirred overnight at room temperature. The 
mixture was diluted in EtOAc (5 mL) and washed with water (1x5 mL) and brine 
(1x5 mL). The solvent was dried over anhydrous Na2SO4 and the solvent 
evaporated under reduced pressure affording product V∙6 (37 mg, quantitative 
yield). 
1
H NMR (500 MHz, DMSO-d6) δ 7.67 (m, br, 1H), 7.65 (d, J = 7.4 Hz, 
1H), 7.44 (m, br, 1H), 7.26 (t, J = 7.7 Hz, 1H), 6.99 (t, J = 7.6 Hz, 1H), 6.94 (d, 
J = 7.6 Hz, 1H), 5.20 (d, J = 6.6 Hz, 1H), 3.70 (dd, J = 12.3 and 6.5 Hz, 1H), 
3.48 (d, J = 12.3 Hz, 1H), 3.09 (s, 3H), 1.02 (m, br, 1H), 1.71-1.51 (m, 4H), 1.40-
0.93 (m, 6H);  
13
C NMR (126 MHz, DMSO-d6) δ 174.9, 173.0, 171.1, 143.0, 
129.1, 127.7, 124.4, 122.3, 108.3, 64.9, 63.8, 42.5, 34.5, 28.7, 28.6, 26.3, 25.3, 
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25.1, 25.0; HR-MS (ESI) calcd for C19H24N3O3S
+
 [MH]
+
 374.1538, found 
374.1526.  
((3S*,4'R*)-3'-(cyclohexanecarbonyl)-1-methyl-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carbonyl)glycine (V∙7). To a solution of V∙4l (0.1 mmol, 1 eq) in 
CH2Cl2 (0.4 mL), TFA (0.1 mL) was added and the mixture stirred for 6 hours at 
room temperature. The reaction was diluted in EtOAc and washed with saturated 
aq. NaHCO3 (2x5 mL) and then with HCl 1M (2x5 mL). The organic phase was 
dried over anhydrous Na2SO4 and the solvents were evaporated. Product V∙7 (42 
mg, 95%) was obtained as a grey foamy solid. 
1
H NMR (300 MHz, DMSO-d6, 
9:1 mixture of two rotamers) δ 13.46-12.16 (m, br, 1H), 8.58 (m, br, 0.9H), 8.35 
(m, br, 0.1H),  8.03 (d, br, J = 7.6 Hz, 0.1H), 7.76 (d, br, J = 7.6 Hz, 0.9H), 
7.46 (t, br, J = 7.7 Hz, 0.1H),7.29 (d, br, J = 7.6 Hz, 0.9H), 7.17 (m, br, 0.2H), 
7.10-6.91 (m, 1.8H), 5.77 (m, br, 0.1H), 5.30 (d, J = 6.6 Hz, 0.9H), 4.19-3.24 
(m, 4H), 3.18 (s, 0.3H), 3.12 (s, 2.7H), 2.26 (m, br, 1H), 1.80-1.42 (m, 4H), 1.38-
0.62 (m, 6H); 
13
C NMR (126 MHz, DMSO-d6) δ 175.5 and 174.9 (1C), 173.7 and 
173.2 (1C), 171.3 and 171.1 (1C), 170.1 and 169.5 (1C), 143.0 and 141.8 (1C), 130.7 
and 129.2 (1C), 127.6 and 127.5 (1C), 125.4 and 124.5 (1C), 123.5 and 122.4 (1C) 
109.6 and 108.3 (1C), 71.0 and 69.2 (1C), 64.9 and 63.7 (1C), 42.4 and 41.8 (1C), 
41.2 and 41.0 (1C), 34.5 and 32.8 (1C), 28.7 (2C), 26.6 and 26.3 (1C), 25.3, 
25.1, 24.7; HR-MS (ESI) calcd for C21H26N3O5S
+
 [MH]
+
 432.1588, found 
432.1581.  
(3'S*,4'R*)-N-(tert-butyl)-1-methyl-2-oxo-3'-(piperidine-4-carbonyl)spiro[indoline-
3,2'-thiazolidine]-4'-carboxamide (V∙8). To a solution of V∙4t (0.084 mmol, 1 eq) 
in CH2Cl2 (0.4 mL), TFA (0.1 mL) was added and the mixture was stirred for 2 
hours at room temperature. The reaction was diluted with CH2Cl2 and washed 
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with saturated aq. NaHCO3 (2x5 mL).  The organic phase was dried over 
anhydrous Na2SO4 and the solvent was evaporated under reduce pressure 
affording compound V∙8 (37 mg, 91%) as a yellow foamy solid. 1H NMR (500 
MHz, CDCl3, mixture of two rotamers 73:27) δ 7.44 – 7.39 (m, J = 7.4 Hz, 
0.44H), 7.35 (t, J = 7.7 Hz, 0.73H), 7.27 (d, J = 9.8 Hz, 1.01H), 7.15 (t, J = 7.6 
Hz, 0.25H), 7.08 (t, J = 7.5 Hz, 0.66H), 6.94 (d, J = 8.1 Hz, 0.24H), 6.90 – 
6.84 (m, J = 6.7 Hz, 0.75H), 6.55 (br s, 0.43H), 6.52 (br s, 0.09H), 5.44 (d, J = 
5.7 Hz, 0.25H), 4.91 (dd, J = 18.0, 7.0 Hz, 0.66H), 4.08 (dd, J = 11.9, 7.2 Hz, 
0.70H), 3.71 – 3.65 (m, 0.26H), 3.65 – 3.60 (m, J = 11.5 Hz, 0.26H), 3.47 (dd, 
J = 17.9, 9.5 Hz, 0.67H), 3.30 (s, 0.47H), 3.26 (s, J = 8.0 Hz, 1.39H), 3.24 (s, 
0.27H), 3.15 – 3.02 (m, 1.14H), 2.82 – 2.40 (m, 2.12H), 2.08 (br s, J = 30.9, 
20.7 Hz, 1.41H), 1.83 – 0.64 (m, 29.11H). 13C NMR (126 MHz, CDCl3) δ 175.9, 
175.6, 175.0 and 174.3 (2C), 169.1 and 168.6 (1C), 143.6 and 142.1 (1C), 131.1 
and 130.2 (1C), 127.1 and 125.9 (1C), 124.4, 124.0, 122.9 and 122.4 (2C), 109.3 
and 109.0 (1C), 71.9 and 70.0 (1C), 66.9 and 66.0 (1C), 52.1 and 51.3 (1C), 45.8, 
45.6, 45.3 and 45.3 (2C), 42.3 and 41.1 (1C), from 33.67 to 26.70 (7C). HR-MS 
(ESI) calcd for [C22H31N4O3S
+
] 431.2111, found 431.2112.  
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VI. Spirooxindole-fused 4-Methylene azetidines: 
Formal [2+2] Annulation Reaction 
 
A diastereoselective, DABCO-catalyzed reaction of isatin-derived ketimines and 
allenoates is described. Exploiting the stereodirecting effect of the bulky tert-
butanesulfinyl chiral auxiliary, the method provides an efficient access to single 
diastereoisomers of unprecedented spirocyclic oxindoles, bearing a 4-
methyleneazetidine ring at the spiro junction. The versatility of the method is 
fully demonstrated by further transformations including the conversion to 
relevant spirocyclic oxindolo-β-lactams. 
Moreover, a β-ICD-based catalysed enantioselective approach is undergoing in 
order to obtain enantioenriched spirooxindole-fused 4-methylene azetidines. 
 
 
 
 
 
 
 
 
 
 
 
Published in Chem. Commun. 2016, 52, 11575-11578. 
Published in Molecules, 2017, 22, 2016. 
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VI.1 Introduction 
The strained four-membered ring system of azetidines
1
 is present as a partial 
structure of a number of natural products
2
 and pharmaceutical agents
3
 (Figure 1). 
Owing to their strong molecular rigidity and, at the same time, to their 
reasonable stability, azetidines are of special interest, being able to potentially 
provide improved physicochemical properties in their interaction with biological 
systems. 
They have had enormous application in medicinal chemistry in the form of 
azetidin-2-ones (β-lactams), that are the key components of many biologically 
active compounds showing antibacterial, antifungal, and anti-inflammatory 
properties.
4
 Various multifunctional spiro β-lactam derivatives have also been 
reported recently,
5
 among which spirooxindolyl β-lactams are particularly 
relevant.
6
 Despite this interest for azetidin-2-ones, in general azetidines have 
received much less attention with respect to their lower and higher small-ring 
homologues, and their application in the context of drug discovery is not so 
common. In particular, only few novel spirocyclic azetidine scaffolds have been 
recently proposed,
7
 able to access unexplored chemical space and to act as 
 
 
Figure 1. Examples of biologically relevant compounds containing azetidines and 
azetidin-2-ones moieties. 
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Scheme 1. Proposed mechanism for the formal [2+2] annulation reaction catalysed by a 
nucleophilic amine. 
 
potential new lead compounds.
8
Our long-standing interest in the asymmetric 
synthesis of 3,3-disubstituted oxindoles derivatives and related spiro compounds,
9
 
unitely to the growing interest in hybrid drugs as therapeutic agents, inspired us 
to combine the two biologically active oxindole and azetidine moieties, by 
means of a spiro arrangement of the two ring systems.
10
 We conceived the 
synthesis of chiral spirooxindole-based 4-methyleneazetidines, as an 
unprecedented, intriguing combination of pharmacologically relevant motifs. 
Such methyleneazetidines can be also seen as key intermediates for the synthesis 
of particularly relevant spirooxindolyl β-lactams derivatives. 
Relying on our previous experience with isatin-derived ketimines, we looked at 
the formal [2+2] annulation reactions of such compounds with allenoates, as a 
practical and direct strategy to obtain highly functionalized target compounds, 
with a good level of atom-economy (Scheme 1). 
Since Shi's pioneer work
11
 disclosing an abnormal aza-Baylis-Hillman reaction of 
N-tosylated imines with allenoates to give azetidine derivatives in the presence of 
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the strong Lewis base DABCO (1,4-diazabicyclo[2.2.2]octane), additional 
examples of such [2+2] annulation were reported, both on electron-deficient 
aldimines and ketimines. A detailed investigation on the effect of different Lewis 
bases in the reaction of allenoates with cyclic trifluoromethyl ketimines was 
accomplished by Ma and co-workers.
12
 
Remarkable is also the application of this strategy from Ye and co-
workers,
13
 affording functionalized biologically relevant sultam-fused 
azetidines. The asymmetric approach to this [2+2] annulation is more 
challenging, with only two reports reporting enantioselective, 
organocatalytic versions employing Cinchona alkaloid-derived catalysts 
(Scheme 2).
14
 Finally, a diasteroselective synthesis of 2-azetidines was 
exploited by Santos and co-workers,
15
 based on allenoates bearing a chiral 
auxiliary on the ester moiety. 
At the best of our knowledge, no diastereoselective [2+2] annulation-based 
strategies employing chiral imines have been described for the preparation 
of methyleneazetidines. 
Herein we first demonstrate the suitability of chiral, isatin-derived tert-
butanesulfinyl ketimines for reaction with allenoates, applying this reaction 
to the synthesis of unprecedented, enantiopure spirooxindole-based 4-
methyleneazetidines. 
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Scheme 2. Reported examples of enantioselective synthesis of methyleneazetidines 
using cinchona-based catalysts. 
 
VI.2 Results and Discussion 
We began our investigation by catalyst screening and reaction optimization 
using the known 1-benzyl-isatin-derived N-tert-butanesulfinyl ketimine VI∙1a 
and ethyl buta-2,3-dienoate VI∙2a (Table 1). A number of amines as 
diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU), N,N-dimethyl-4-aminopyridine (DMAP) and pyridine were 
screened at room temperature in THF for 24 hours (entries 1-4). Only 
DABCO promoted efficiently the reaction to give the desired azetidine 
VI∙3a. DBU proved to be quite ineffective, while with pyridine or DMAP 
the reaction afforded complex mixtures, from which only traces of the 
probable aza-Morita-Baylis-Hillman adduct could be tentatively identified 
by NMR. Next, solvent screening revealed that the reaction with DABCO 
also worked in toluene, dioxane and dichloromethane, but in slightly 
lower yields with respect to THF (entries 5-7). 
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Using a greater excess of ethyl buta-2,3-dienoate VI∙2a had positive effects 
on the chemical yield, with 2.0 equivalents performing best (entries 8-9). 
Finally, lowering the substrate concentration elongated the reaction time 
reducing the conversion, while increasing the concentration gave a less 
clean reaction, however with a good isolated yield for VI∙3a (entries 10-11). 
With respect to the stereochemical outcome, we were delighted to realize 
that, in all reactions, only the E-double bond isomer was formed, bearing, 
at the best of 
1
H NMR sensitivity, only a single C-3 relative configuration 
with respect to the chiral auxiliary.  
 
Table 1. Survey of the reaction conditions for the formal [2+2] annulation reaction of isatin 
ketimine VI∙1a with ethyl buta-2,3-dienoate VI∙2a.a 
 
 
 
Entry Catalyst Solvent 
Eq 
VII∙2a 
Conc 
[M] 
Time 
[h] 
Yield 
(%)
b
 
1 DABCO THF 1.5 0.1 24 76 
2 DBU THF 1.5 0.1 24 nd 
3 DMAP THF 1.5 0.1 24 - 
4 Pyridine THF 1.5 0.1 24 - 
5 DABCO toluene 1.5 0.1 24 67 
6 DABCO dioxane 1.5 0.1 24 57 
7 DABCO CH2Cl2 1.5 0.1 24 72 
8 DABCO THF 2.0 0.1 8 83 
9 DABCO THF 2.5 0.1 8 69 
10 DABCO THF 2.0 0.05 24 48 
11 DABCO THF 2.0 0.2 8 79 
a Reaction conditions: ketimine VII∙1a (0.15 mmol). b Isolated yields. nd = no detected. 
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With the optimized reaction conditions in hand, a variety of N-tert-
butanesulfinyl ketimines VI∙1 were next explored, to investigate the 
substrate scope of this novel, DABCO-catalyzed formal [2+2] annulation 
reaction. The generality was also evaluated with respect to allenoates VI∙2 
(Scheme 3). The protecting group on oxindole nitrogen atom was found to 
have a moderate effect on the reactivity, with best yields obtained with 
R
1
= Bn, Me, Trt and PBB (p-Bromobenzyl). 
 
Scheme 3. Diastereoselective formal [2+2] annulation reaction of various isatin ketimines 
VI∙1 with allenoates VI∙2, catalyzed by DABCO.a 
 
continued 
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a Reactions conditions: ketimine VI∙1 (0.15 mmol), VI∙2 (0.30 mmol), DABCO (0.030 
mmol) in THF (1.5 mL). Isolated yields are reported. dr was determined by 1H NMR 
analysis of crude mixture. a Reaction performed with 4 equiv of VI∙2a. Trt = Trityl; PNB = 
p-Nitrobenzyl; PMB = p-Methoxybenzyl; PBB = p-Bromobenzyl; nd = not detected. 
 
Surprisingly, ketimine VI∙1c, bearing the N-trityl protecting group, afforded 
the corresponding azetidine VI∙3c with the highest yield, but definitely 
lower stereocontrol, probably due to a steric mismatching effect of the 
bulky trityl group with the chiral auxiliary tert-butanesulfinyl moiety. 
Unprotected ketimine VI∙1d also gave the reaction, affording the 
unexpected compound VI∙3d, deriving from both the [2+2] annulation and 
the competitive NH participation with allenoate. The same compound 
VI∙3d could be also recovered from the reaction of N-Ac ketimine VI∙1h, 
probably as a result of the lability of the N-acetyl protecting group. 
Next, N-benzylisatin ketimines with various substituents on the aromatic 
ring were explored. Moderate to good yields of the corresponding 
azetidines were obtained in the presence of a variety of substituents 
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including electron-donating groups, and halogen substituents at the 5- or 6-
position on the oxindole aromatic ring. Finally, we investigated the formal 
[2+2] annulation with two different allenoates, namely benzyl buta-2,3-
dienoate VI∙2b and ethyl 2-methylbuta-2,3-dienoate VI∙2c. Employing 
VI∙2b, the corresponding azetidine VI∙3n could be easily obtained, albeit in 
moderate yield. On the other hand, α-substituted allenoate VI∙2c proved to 
be completely unreactive under the reaction conditions and the 
corresponding azetidine could not be detected, even after a longer reaction 
time. This result can be ascribed both to the stereoelectronic influence of 
the methyl group on the allenoate VI∙2c, and to the high steric challenge 
inherent to the formation of the tetrasubstituted double bond, joint to the 
spiroazetidine ring.  
As usual for such kinds of studies, we also proceeded to a scale-up 
experiment, employing 1 mmol of ketimine VI∙1a (reaction conditions as 
reported in Scheme 3). After 24 hours, the desired azetidine VI∙3a could be 
obtained in yield quite similar to that obtained on the small scale, still as a 
single diastereoisomer (yield 80%, dr >99:1). 
To determine the absolute stereochemistry of the oxindole C-3 spiro 
center, a single crystal of 4-methyleneazetidine VI∙3a was subjected to X-
ray crystallographic analysis. This experiment unambiguously confirmed the 
E-double bond configuration and assigned the absolute configuration of the 
spiro center as (S), derived from (R)-tert-butanesulfinyl ketimine VI∙1a 
(Figure 2). 
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Figure 2. ORTEP view of compound VI∙3a, with the atom-numbering scheme and the 
crystallographic reference system.  Thermal ellipsoids of non-H atoms were drawn at the 25 
% probability level. The two equiprobable conformations of the disordered 
ethoxy chain of the ester moiety are shown. 
 
In order to explain this stereochemical outcome, we refer to the established 
mechanism of Lewis base-catalysed similar formal [2+2] annulations.
11 
Accordingly, the nitrogen base DABCO acts as a nucleophilic activator, 
producing a zwitterionic allylic carbanion from the allenoate reagent. Such 
intermediate undergoes a γ-addition to the ketimine, followed by 
intramolecular nucleophilic attack to give the azetidine ring with 
regeneration of DABCO. On this basis, a plausible transition state for the 
formation of (3,S)-VI∙3a is illustrated in Figure 3. In the working model, the 
stereochemical outcome can be explained assuming a syn-periplanar 
relationship between the imine and the S=O double bond,
16
 which favors 
the shown conformation for starting ketimine VI∙1a. The excellent 
diastereoselectivity observed in the azetidine formation may be due to the 
high stereodirecting effect of the bulky tert-butanesulfinyl group.  
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Figure 3. Plausible explanation of the stereochemical outcome. 
 
Consequently, the delivery of the DABCO-activated nucleophile would 
occur from the less hindered re-face, resulting in the formation of the (3S)-
azetidine. 
To demonstrate the synthetic utility of highly functionalized azetidines, we 
subjected compound VI∙3a to cleavage of N-tert-butanesulfinyl chiral 
auxiliary, to sulfur oxidation and to ozonolysis (Scheme 4). 
Treatment of sulfinyl amide VI∙3a with anhydrous HCl in dioxane at room 
temperature afforded the secondary amine VI∙4 in acceptable yield. 
Whereas, by action of m-chloroperbenzoic acid at room temperature, the 
sulfinyl amide VI∙3a was readily oxidized to the corresponding sulfonamide 
VI∙5. Finally, -lactam VI∙6 was obtained in quantitative yield by treatment 
with ozone. This last result can be considered particularly relevant, given 
the interest in the spirocyclic oxindolo--lactam skeleton, which, combining 
two privileged heterocycles such as indole and -lactam, is a motif strictly 
related to natural products and synthetic compounds with significant 
biological activities.
17
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Scheme 4. Further transformations of azetidine VI∙3a. 
 
 
 
VI.3 Conclusion 
In conclusion, an efficient asymmetric approach for the preparation of 
unprecedented, chiral spirooxindole-fused 4-methyleneazetidines has been 
developed, based on a diastereoselective, DABCO-catalysed formal [2+2] 
annulation reaction. The method provides easy access to a range of highly 
functionalized compounds, which are obtained as single diastereoisomers, 
under mild conditions. By taking advantage of the functional groups 
transformations, a rapid asymmetric construction of the relevant spirocyclic 
oxindolo--lactam has been also achieved. 
Further work is underway, aimed to establish spirooxindole-fused 4-
methyleneazetidines as possible lead compounds for drug discovery 
programs. 
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VI.4 Update work 
Moreover, considering the importance of asymmetric catalytic approaches 
over chiral auxiliary strategies, we investigated the possibility of carried out 
the synthesis of enantiomerically enriched spirooxindole-fused 4-
methyleneazetidines using cinchona-based catalysts. 
We started our investigation evaluating the reaction of ethyl buta-2,3-
dienoate VI·2a with different N-benzyl isatin-derived ketimines, namely N-
tert butanesulfonyl imine 1a, N-p-toluensulfonyl imine 2 and N-Boc imine 3 
(Table 2). 
All substrates VI·7a, VI·8 and VI·9 afforded the corresponding azetidines 
VI·11a, VI·12 and VI·13 in presence of DABCO (entries 1-3). In the case of 
N-Boc ketimine VI·9, also the aza-Morita-Baylis-Hillman (AMBH) product 
VI·14 was isolated in low yield. Then the same ketimines VI·7a, VI·8 and 
VI·9 have been tested in the organocatalytic reaction, employing the 
quinidine-derived alkaloid β-isocupridine (β-ICD) catalyst VI·10a. Both N-
tert butanesulfonyl imine VI·7a and tosyl imine VI·8 afforded the expected 
azetidines VI·11a and VI·12 in good yield and enantiomeric ratio (er) 
(entries 4 and 5), whereas in this condition the N-Boc ketimine VI·9 
provided only the AMBH product VI·14 (entry 6).  
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Table 2. Preliminary screening for the isatin-derived ketimine selection.a 
 
 
 
Entry Imine (R
1
) Catalyst Yield (%)
b
  er
 c
 
1
 
 VI·7a (SO2tBu) DABCO VI·11a (90) - 
2
 
 VI·8 (Ts) DABCO VI·12 (77) - 
3 VI·9 (Boc) DABCO VI·13 (48), VI·14 (28) - 
4 VI·7a (SO2tBu) VI·10a VI·11a (91) 70:30 
5 VI·8 (Ts) VI·10a VI·12 (80) 61:39 
6 VI·9 (Boc) VI·10a VI·14 (52) - 
a Reaction conditions: ketimine VI∙7a,8,9 (0.15 mmol), VI∙2a (0.30 mmol) and 
catalyst (0.030 mmol) in THF (1.5 mL) at room temperature. b Isolated yields. c 
Determined by chiral HPLC analysis. 
 
N-tert butanesulfonyl imine VI·7a was selected for further optimization of 
the reaction conditions, as reported in Table 3. Starting our screening 
testing different catalysts, we observed that typical quinidine-derived 
catalysts VI·10b-f were unable to promote the reaction even for prolonged 
reaction times (entries 1-5). In all cases only degradation of the starting 
ketimine was observed. Instead, using β-isocupridine-based catalysts 
(VI·105g-l), the desired azetidine VI·11a was obtained in all cases, with the 
exception of reaction with catalyst VI·10h (entries 6-12).  
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Table 3. Catalyst and solvent screen for the reaction of VI∙7a with VI∙2a.a 
 
Entry Solvent Catalyst Time [h] Yield (%)
b
 er 
c
 
1 THF VI·10b 48 nd - 
2 THF VI·10c 48 nd - 
3 THF VI·10d 48 nd - 
4 THF VI·10e 48 nd - 
5 THF VI·10f 48 nd - 
6 THF VI·10a 1 91 70:30 
7 THF VI·10g 3 90 80:20 
8 THF VI·10h 48 nd - 
9 THF VI·10i 3 64 74:26 
10 THF VI·10j 3 87 70:30 
11 THF VI·10k 3 86 77:23 
12 THF VI·10l 3 83 70:30 
13 CH2Cl2 VI·10g 24 12 - 
14 Toluene VI·10g 24 16 - 
15
d
 THF VI·10g 24 78 80:20 
16
e
 THF VI·10g 48 nd - 
17
f
 THF VI·10g 24 68 80:20 
a Reaction conditions: ketimine VI∙7a (0.15 mmol), VI∙2a (0.30 mmol) and catalyst 
VI∙10 (0.03 mmol) in solvent (1.5 mL) unless otherwise noted. b Isolated yields. c 
Determined by chiral HPLC analysis. d Reaction performed at 0 °C. e Reaction 
performed at -20 °C. f Catalyst loading 10% mol. nd = no detected. 
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The high conformational bias of β-ICD and its derivatives, as well as the 
presence of at least a hydrogen bond donor group at the C6 position of 
the quinoline ring, seem to be necessary requirements to coordinate the 
substrate and therefore to catalyse the reaction. Best results in terms of 
both er and chemical yield have been obtained employing catalyst VI·10g, 
which was then used for a further screening of solvents and temperature. 
Performing the reaction in apolar solvents such as dichloromethane and 
toluene, the desired product was observed just in very low yields (entries 
13 and 14). Lowering the temperature to 0 °C no appreciable improvement 
of er was observed and prolonged reaction time was needed to obtain the 
desired azetidine in good yield (entry 15). At - 20 °C the reaction is 
completely inhibited (entry 16). Finally, reducing the catalyst amount (entry 
17) no improved er was observed, but just elongation of reaction time with 
reduction of the chemical yield. 
With the best conditions in hands, we planned to screen N-tert 
butanesulfonyl ketimines bearing different N-substituents at the oxindole 
ring (VI·7b-f, Scheme 5). Such starting compounds have been prepared by 
m-cloroperbenzoic acid-mediated oxidation of the corresponding N-tert-
butanesulfinyl ketimines and immediately used without purification.  
General good yields and er were observed in the reaction with allenoate 
VI·2a, under the catalysis of VI·10g. The presence of the bulky trityl 
substituent at the oxindole nitrogen leads to the corresponding 
spiroazetidine derivative VI·11c with the best yield, but with the lowest 
enantioselectivity. 
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Scheme 5. Substrate scope for the reaction of various ketimines VI∙7a-j with 
allenoates VI∙2a,b, catalyzed by β-ICD-based catalyst VI∙10g .a 
a Reactions conditions: ketimine VI∙7a-j (0.15 mmol), VI∙2a,b (0.30 mmol), VI∙10g (0.030 
mmol) in THF (1.5 mL). Isolated yields are reported. er was determined by chiral HPLC 
analysis. Trt = Trityl; nd = not detected. 
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The best result in terms of er was obtained performing the reaction with N-
methyl substituted ketimine VI·7b, leading to product VI·11b.  
Depending on whether electron-withdrawing or electron-donating group 
was introduced at 4-,5- or 6-position of the benzene ring of starting 
ketimines (VI·7g-j), the reactions proceeded in a different way. Good yield 
and enatioselectivity were observed for the synthesis of 5-OMe substituted 
spiroazetidine VI·11g. In the presence of the electron withdrawing Cl-
substituent at C5 position, a very low yield was achieved (VI·11h). Finally, 
compounds VI·11i and VI·11j were not detected in the crude, but just 
degradation of the ketimine starting material was observed. 
At the end, we investigated the formal [2+2] annulation with a different 
allenoate. Considering the possibility of a favourable - interaction with 
the aromatic portion of the catalyst, we selected benzyl buta-2,3-dienoate 
VI·2b. Indeed, the corresponding azetidine VI·11k could be easily obtained 
in good yield, even if in quite similar er. 
The absolute configuration of the major enantiomer of compound VI·11a 
was determined through chemical correlation, exploiting a proper 
conversion of reference compound VI·3a (Scheme 6). More precisely, 
performing a selective sulfur oxidation, enantiopure compound VI·11a’ 
could be easily obtained from compound VI·3a. Relying on comparison of 
both optical rotation signs and chiral HPLC chromatograms, the (S)-
configuration at the quaternary stereocenter of product VI·11a could be 
assigned with certainty. 
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Scheme 6. Chemical correlation for the assignment of absolute configuration of 
compound VI·11a. 
 
 
 
To rationalize the stereochemical outcome, we referred to the proposed 
mechanism for similar cinchona-base catalysed [2+2] annulation reactions.
18
 
Accordingly, the basic quinuclidine moiety acts as a nucleophile activator, 
producing a zwitterionic allylic carbanion from the allenoate reagent. The 
activated -position of this intermediate undergoes addition to the 
ketimine, followed by an intramolecular attack back from the ketimine’s 
nitrogen atom, leading to azetidine ring formation and catalyst 
regeneration. From our experimental data, it results that the peculiar 
skeleton of -ICD-type catalysts (e.g. VI·10g), more rigid with respect to 
that of corresponding quinidine-catalysts (e.g. VI·10b), seems the only one 
able to bring the reactants to the correct distance for a productive reaction.  
Moreover, the presence of the N-Boc glycinamide unit at C6' position in 
catalyst VI·10g ensures a proper activation of the ketimine, through up to 
two hydrogen bonds. Relying on this disposition, to minimize the steric 
hindrance with the catalyst’s residue, ketimine offers its Re-face to the 
incoming γ-carbanion, leading to the corresponding spiroazetidine 
derivative in the prevailing (S)-configuration at the C3 of the oxindole ring. 
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Figure 4. Possible transition state for reaction of ketimine VI·7b with allenoate VI·2a, 
under catalysis of VI·10g. Ketimine VI·7b is reported without the condensed phenyl 
ring for clarity. 
 
 
 
On this basis, a plausible transition state for the reported reaction is 
illustrated in Figure 3, where ketimine VI·7b is shown coordinated to the 
catalyst VI·10g  by double H-bonding, so explaining the found superiority 
of the amide N-H over the O-H group in this kind of process. 
To demonstrate the synthetic utility of obtained compounds, some post-
transformation reactions have been performed (Scheme 7). Starting from 
compound VI·11a, acid VI·15 could be quantitatively obtained by reaction 
with LiOH. 
Aiming to selectively remove the tert-butylsulfonyl group, we refer to a 
milestone literature procedure,
19
 reporting the cleavage of such protecting 
groups to the parent amines by mild acidic solvolysis. Surprisingly, exposure 
of VI·11a to 0.075 N TfOH/CH2Cl2 at 0 °C for two hours afforded 
quantitatively the rearranged product VI·16, without trace of the expected 
spiroazetidine N-deprotected derivative. The spiropyrroline ring system of 
compound VI·16 was disclosed by careful  
Scheme 7. Post-Trasformation Reactions Performed from Compound VI·11a. 
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analysis of mono- and bidimensional NMR spectra. In particular, the 
HMBC (Heteronuclear Multiple Bond Correlation) experiment allowed a 
complete and confident assignment of all 
1
H and 
13
C NMR signals. 
Changing the acid to trifluoroacetic acid (TFA) and adding anisole as 
scavenger, the reaction followed a different course, affording the 
unprecedented 3-tert-butylsulfonylamino, 3-substituted derivative VI·17, as 
the result of the acid catalyzed azetidine ring opening. Evidently, the 
presence of the methylene acetic ester moiety as substituent in compound 
VI·11a diverts from the expected cleavage of the tert-butylsulfonyl group, 
addressing the reaction toward less predictable pathways. Anyway, 
preserving the integrity at the oxindole C3 stereogenic centre, compounds 
VI·16 and VI·17 can be considered relevant examples of almost unexplored 
spiro and 3,3-disubstituted oxindole derivatives. 
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VI.5 Experimental Section 
All commercial materials (Aldrich, Fluka) were used without further 
purification. All solvents were of reagent grade or HPLC grade. All 
reactions were carried out under a nitrogen atmosphere unless otherwise 
noted. All reactions were monitored by thin layer chromatography (TLC) 
on precoated silica gel 60 F254; spots were visualized with UV light or by 
treatment with ninhydrin solution in ethanol. Products were purified by 
flash chromatography (FC) on silica gel 60 (230–400 mesh). 1H NMR 
spectra and 
13
C NMR spectra were recorded on 300 and 400 MHz 
spectrometers. Chemical shifts are reported in parts per million relative to 
the residual solvent. 
13
C NMR spectra have been recorded using the APT 
pulse sequence. Multiplicities in 
1
H NMR are reported as follows: s = 
singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet. High-
resolution MS spectra were recorded with a Waters Micromass Q-ToF 
micro TM mass spectrometer, equipped with an ESI source. Chiral HPLC 
analysis was performed on a Jasco PU-2080 (UV Detector and binary 
HPLC pump) at 254 nm. Chiralcel AD columns were purchased from Daicel 
Chemical Industries®. Optical rotator power [α]T D was measured with a 
Jasco P-1030 polarimeter, endowed with a cell of 1 dm pathlength and 1 
mL capacity. The light used has a wavelength of 589 nm (sodium D line). 
 
General procedure A (GP-A) for the synthesis of isatin-derived (R)-sulfinyl 
ketimines VI∙1a-m. To a solution of N-substituted isatin (1.17 mmol, 1.0 eq) 
in anhydrous CH2Cl2 (2.9 mL, 0.4M), Ti(OiPr)4 (2.34 mmol, 2.0 eq) and 
(R)-2-methyl-2-propanesulfinamide (1.4 mmol, 1.2 eq) were added. The 
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solution was refluxed until complete disappearance of the starting materials 
(monitored by TLC). The reaction was quenched by adding saturated aq. 
NaHCO3 (15 mL) and diluted with CH2Cl2 (15 mL). The biphasic solution 
was filtered through a pad of Celite and the organic phase washed with 
water (2 x 15 mL), dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. The crude was purified by FC as indicated below. 
(R,E)-2-Methyl-N-(1-(4-nitrobenzoyl)-2-oxoindolin-3-ylidene)propane-2-
sulfinamide (VI∙1e). Prepared according to GP-A using N-p-nitrobenzyl 
isatin. FC: CH2Cl2:EtOAc, 49:1; yield: 180 mg, 40%; brown solid; m.p.: 
104-106 °C; [α]D25 = - 124.9 (c 0.6, CHCl3); 1H NMR (300 MHz, CDCl3) δ 
1.43 (s, 9H), 4.99 (d, J =  16.6 Hz,  1H), 5.05 (d, J =  16.6 Hz,  1H), 6.64 
(d, J = 7.7 Hz, 1H), 7.07 (t, J = 7.7 Hz, 1H), 7.37 (t, br, J = 7.7 Hz, 1H),  
7.49 (d, br, J = 7.8 Hz, 2H), 8.21 (d, J = 7.8 Hz, 2H), 8.32-8.64 (m, br, 
1H); 
13
C NMR (75 MHz, CDCl3) δ 23.3 (3C), 43.4, 51.6, 109.6, 123.6 (2C), 
124.2, 124.3 (2C), 128.2 (2C), 135.5, 142.2 (2C), 146.5, 147.8, 162.2; 
HRMS-ESI: [M+Na]
+
, calcd for C19H19N3NaO4S
+
 408.0988, found 
408.0980. 
(R,E)-N-(1-Allyl-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfinamide 
(VI∙1i). Prepared according to GP-A using N-allyl isatin. FC: CH2Cl2:EtOAc, 
49:1; yield: 248 mg, 73%; red foam; [α]D25 = - 147.5 (c 0.6, CHCl3); 1H 
NMR (300 MHz, CDCl3) δ 1.30 (s, 9H), 4.25 (d, J = 4.8 Hz, 2H), 5.11-
5.24 (m, 2H),  5.73 (m, 1H), 6.72 (d, br,  J = 7.7 Hz, 1H), 6.94 (t, br, J = 
7.7 Hz, 1H), 7.31 (t, br,  J = 7.7 Hz, 1H), 8.07-8.58 (m, br, 1H); 
13
C NMR 
(75 MHz, CDCl3) δ 23.1 (3C), 42.6, 66.8, 109.9, 118.4, 123.1, 123.5 (2C), 
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130.6, 135.4, 148.0 (2C), 160.7; HRMS-ESI: [M+Na]
+
, calcd for 
C15H18N2NaO2S
+
 313.0981, found 313.0993. 
General procedure B (GP-B) for diasteroselective formal [2+2] annulation 
reaction for the synthesis of compounds VI∙3a-n. To a solution of ketimine 
VI∙1a-m (0.15 mmol, 1.0 eq) and DABCO (0.03 mmol, 0.2 eq) in THF (1.5 
mL), 2a-c was added (0.30 mmol, 2.0 eq) and the reaction was stirred at 
room temperature for 24 hours. The solvent was evaporated under 
reduced pressure to provide an oily residue that was purified by FC as 
reported below. 
Ethyl-(E)-2-((S)-1'-benzyl-1-((R)-tert-butylsulfinyl)-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙3a). Prepared according to GP-B using VI∙1a 
and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 56 mg, 83%; pale yellow solid; 
m.p.: 126.4-127.6 °C; [α]D25 = - 90.0 (c 0.5, CHCl3); 1H NMR (300 MHz, 
CDCl3) δ 1.09 (s, 9H), 1.26 (t, J = 7.3 Hz, 3H), 3.56 (dd, J = 15.9 and 1.9 
Hz, 1H), 3.83 (dd, J = 15.9 and 1.9 Hz, 1H), 4.14 (m, 2H), 4.85 (d, J = 
15.6 Hz, 1H), 5.02 (d, J = 15.6 Hz, 1H), 5.55 (t, J = 1.9 Hz, 1H), 6.73 (d, 
br, J = 7.6 Hz, 1H), 7.07 (t, br, J = 7.6 Hz, 1H), 7.18-7.36 (m, 6H), 7.51 
(d, br, J = 7.6 Hz, 1H); 
13
C NMR (101 MHz, CD3OD) δ 14.0, 22.1 (3C), 
41.3, 44.1, 59.3, 60.2, 70.7, 95.0, 110.6, 123.9, 125.9, 127.9 (2C), 128.2, 
129.1 (2C), 130.4, 131.5, 136.2, 141.6, 157.3, 168.8, 173.0; HRMS-ESI: 
[M+Na]
+
, calcd for C25H28N2NaO4S
+
 475.1662 found 475.1655. 
Ethyl (E)-2-((S)-1-((R)-tert-butylsulfinyl)-1'-methyl-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙3b). Prepared according to GP-B using VI∙1b 
and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 47 mg, 85%; pale yellow foam; 
[α]D25 = - 96.9 (c 1.1, CHCl3); 1H NMR (300 MHz, CDCl3) δ 1.08 (s, 9H), 
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1.22 (t, J = 7.1 Hz, 3H), 3.23 (s, 3H), 3.50 (dd, J = 15.9 and 1.9 Hz, 1H), 
3.74 (dd, J = 15.9 and 1.9 Hz, 1H), 4.10 (m, 2H), 5.51 (t, J = 1.9 Hz, 1H), 
6.83 (d, br, J = 7.5 Hz, 1H), 7.10 (t, br, J = 7.5 Hz, 1H), 7.35 (d, br, J = 
7.5 Hz, 1H), 7.49 (d, br, J = 7.5 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 
14.4, 22.7 (3C), 26.6, 41.6, 58.7, 59.5, 71.0, 94.2, 108.7, 123.2, 125.1, 
125.7, 130.9, 143.3, 159.47, 167.3, 173.2; HRMS-ESI: [M+Na]
+
, calcd for 
C19H24N2NaO4S
+
 399.1349, found 399.1354. 
Ethyl (E)-2-((S)-1-((R)-tert-butylsulfinyl)-2'-oxo-1'-tritylspiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙3c). Prepared according to GP-B using VI∙1c 
and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 88 mg, 97%; pale yellow foam; 
[α]D25 = - 55.2 (c 1.2, CHCl3); 1H NMR (300 MHz, CDCl3) δ 0.94 (s, 9H), 
1.24 (t, J = 7.1 Hz, 3H), 3.55 (dd, J = 15.7 and 1.8 Hz, 1H), 3.81 (dd, J = 
15.7 and 1.8 Hz, 1H), 4.11 (m, 2H), 5.48 (t, J = 1.8 Hz, 1H), 6.29 (d, br, J 
= 7.5 Hz, 1H), 6.82-7.08 (m, 2H), 7.06-7.37 (m, 10H), 7.31-7.52 (m, 6H); 
13
C NMR (101 MHz, CDCl3) δ 14.5, 22.6 (3C), 42.0, 58.4, 59.5, 71.6, 75.4, 
94.3, 116.4, 122.7, 124.8, 126.4, 127.1 (3C), 127.8 (6C), 129.2 (6C), 129.4, 
141.6 (3C), 143.3, 159.3, 167.5, 174.8; HRMS-ESI: [M+Na]
+
, calcd for 
C37H36N2NaO4S
+
 627.2288, found 627.2293. 
(E)-Ethyl 3-((S,E)-1-((R)-tert-butylsulfinyl)-4-(2-ethoxy-2-oxoethylidene)-2'-
oxospiro[azetidine-2,3'-indolin]-1'-yl)but-2-enoate (VI∙3d). Prepared 
according to GP-B using VI∙1d and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 18 
mg, 38%; brown foam; [α]D25 = - 31.5 (c 0.2, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 1.28 (s, 9H), 1.29 (t, J = 7.1 Hz, 3H), 1.35 (t, J = 7.3 Hz, 3H), 
2.58 (d, J = 0.9 Hz, 3H), 3.59 (dd, J = 16.1 and 2.0 Hz, 1H), 3.83 (dd, J 
= 16.1 and 2.0 Hz, 1H), 4.17 (m, 2H), 4.27 (q, J = 7.3 Hz, 2H), 5.55 (t, J 
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= 2.0 Hz, 1H), 6.05 (q, br,  J = 0.9 Hz, 1H), 6.99 (d, br, J = 7.6 Hz, 1H), 
7.19 (td, br, J = 7.7 and 0.9 Hz, 1H), 7.38 (td, br, J = 7.6 and 0.9 Hz, 
1H), 7.60 (d, br, J = 7.7 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 14.1, 17.3, 
22.3 (3C), 41.8, 42.7, 56.6, 59.4, 60.3, 70.6, 93.7, 110.3, 118.4, 123.7, 
125.0, 125.4, 130.6, 141.2, 147.7, 159.2, 165.3, 171.8, 171.9; HRMS-ESI: 
[M+Na]
+
, calcd for C24H30N2NaO6S
+
 497.1717, found 497.1724. 
ethyl (E)-2-((S)-1-((R)-tert-butylsulfinyl)-1'-(4-nitrobenzoyl)-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙3e). Prepared 
according to GP-B using VI∙1e and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 27 
mg, 36%; pale yellow foam; [α]D25 = - 70.4 (c 0.3, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 1.10 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H), 3.58 (dd, J = 15.8 
and 1.9 Hz, 1H), 3.82 (dd, J = 15.8 and 1.9 Hz, 1H), 4.13 (m, 2H), 4.92 (d, 
J = 16.6 Hz, 1H), 5.15 (d, J = 16.6 Hz, 1H), 5.53 (t, J = 1.9 Hz, 1H), 6.64 
(d, br, J = 7.1 Hz, 1H), 7.12 (t, br, J = 7.2 Hz, 1H), 7.25 (t, br, J = 7.2 Hz, 
1H), 7.47 (d, br, J = 8.8 Hz, 2H), 7.55 (d, br, J = 7.1 Hz, 1H), 8.18 (d, br, 
J = 8.8 Hz, 2H); 
13
C NMR (101 MHz, CDCl3) δ 14.4, 22.7 (3C), 41.6, 43.6, 
59.1, 59.7, 70.8, 94.6, 109.3, 121.7, 123.8, 124.2 (2C), 125.4, 128.2 (2C), 
130.9, 141.8, 142.5, 147.8, 159.1, 167.3, 175.0; HRMS-ESI: [M+Na]
+
, calcd 
for C25H27N3NaO6S
+
 520.1513, found 520.1521. 
Ethyl (E)-2-((S)-1-((R)-tert-butylsulfinyl)-1'-(4-methoxybenzyl)-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙3f). Prepared 
according to GP-B using VI∙1f and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 37 
mg, 51%; pale yellow foam; [α]D25 = - 87.7 (c 0.5, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 1.07 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H), 3.53 (dd, J = 15.9 
and 1.8 Hz, 1H), 3.76 (s, 3H), 3.80 (dd, J = 15.9 and 1.8 Hz, 1H), 4.14 (m, 
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2H), 4.77 (d, J = 15.6 Hz, 1H), 4.94 (d, J = 15.6 Hz, 1H), 5.54 (t, J = 1.8 
Hz, 1H), 6.75 (d, br, J = 7.3 Hz, 1H), 6.82 (d, br, J = 8.7 Hz, 2H), 7.06 (t, 
br, J = 7.3 Hz, 1H), 7.18-7.33 (m, 3H), 7.49 (d, br, J = 7.3 Hz, 1H); 
13
C 
NMR (75 MHz, CDCl3) δ 14.4, 22.6 (3C), 41.6, 43.7, 55.3, 58.7, 59.6, 
71.0, 94.3, 109.8, 114.2 (2C), 123.1, 125.1, 125.8, 127.2, 128.9 (2C), 130.7, 
142.4, 159.2, 159.3, 167.4, 173.3; HRMS-ESI: [M+Na]
+
, calcd for 
C26H30N2NaO5S
+
 505.1768 found 505.1759. 
Ethyl (E)-2-((S)-1'-(4-bromobenzyl)-1-((R)-tert-butylsulfinyl)-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙3g). Prepared 
according to GP-B using VI∙1g and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 59 
mg, 95%; pale yellow foam; [α]D25 = - 70.7 (c 1.2, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 1.08 (s, 9H), 1.25 (t, J = 7.0 Hz, 3H), 3.54 (dd, J = 16.6 
and 1.9 Hz, 1H), 3.81 (dd, J = 16.6 and 1.9 Hz, 1H), 4.13 (m, 2H), 4.76 (d, 
J = 15.6 Hz, 1H), 4.98 (d, J = 15.6 Hz, 1H), 5.53 (t, J = 1.9 Hz, 1H), 6.69 
(d, br, J = 7.1 Hz, 1H), 7.08 (t, br, J = 7.2 Hz, 1H), 7.18 (d, br, J = 8.8 
Hz, 2H), 7.25 (t, br, J = 7.2 Hz, 1H), 7.42 (d, br, J = 8.8 Hz, 2H) , 7.51 
(d, br, J = 7.1 Hz, 1H); 
13
C NMR (75 MHz, CDCl3) δ 14.4, 22.7 (3C), 41.6, 
43.6, 58.9, 59.6, 70.9, 94.6, 109.6, 121.9, 123.5, 125.3, 125.8, 129.3 (2C), 
130.9, 132.0 (2C), 134.2, 142.1, 159.1, 167.4, 173.4; HRMS-ESI: [M+Na]
+
, 
calcd for C25H27BrN2NaO4S
+
 553.0767 found 553.0769. 
Ethyl (E)-2-((S)-1'-allyl-1-((R)-tert-butylsulfinyl)-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙3i). Prepared according to GP-B using VI∙1i 
and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 40 mg, 66 %; pale yellow foam; 
[α]D25 = - 62.3 (c 1.1, CHCl3); 1H NMR (300 MHz, CDCl3) δ 1.09 (s, 9H), 
1.23 (t, J = 7.1 Hz, 3H), 3. 49 (dd, J = 15.6 and 1.9 Hz, 1H), 3.76 (dd, J = 
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15.6 and 1.9 Hz, 1H), 4.11 (m, 2H), 4.29 (dd, J = 16.6 and 4.9 Hz, 1H), 
4.42 (dd, J = 16.6 and 4.9 Hz, 1H), 5.16-5.29 (m, br, 2H), 5.50 (m, br, 
1H), 5.80 (m, 1H), 6.82 (d, br, J = 7.6 Hz, 1H), 7.09 (t, br, J = 7.7 Hz, 
1H), 7.31 (t, br, J = 7.7 Hz, 1H), 7.50 (d, br, J = 7.5 Hz, 1H); 
13
C NMR 
(75 MHz, CDCl3) δ 14.4, 22.7 (3C), 41.7, 42.7, 58.8, 59.6, 70.9, 94.2, 
109.7, 118.2, 123.2, 125.1, 125.8, 130.9 (2C), 142.5, 159.6, 167.4, 173.0; 
HRMS-ESI: [M+Na]
+
, calcd for C21H26N2NaO4S
+
 425.1505, found 425.1513. 
Ethyl (E)-2-((S)-1'-benzyl-1-((R)-tert-butylsulfinyl)-5'-methoxy-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙3j). Prepared 
according to GP-B using VI∙1j and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 57 
mg, 81%; pale yellow foam; [α]D25 = - 79.6 (c 0.5, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 1.10 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H), 3.53 (dd, J = 15.9 
and 1.9 Hz, 1H), 3.74 (s, 3H), 3.82 (dd, J = 15.9 and 1.9 Hz, 1H), 4.13 (m, 
2H), 4.81 (d, J = 15.6 Hz, 1H), 4.99 (d, J = 15.6 Hz, 1H), 5.54 (t, J = 1.9 
Hz, 1H), 6.60 (d, br, J = 8.6 Hz, 1H), 6.74 (dd, J = 8.6 and 2.5 Hz, 1H), 
7.09 (d, J = 2.5 Hz, 1H), 7.21-7.35 (m, 5H); 
13
C NMR (101 MHz, CDCl3) δ 
14.4, 22.7 (3C), 41.8, 44.3, 55.9, 58.75, 59.6, 71.3, 94.3, 110.3, 111.9, 
115.5, 127.0, 127.5 (2C), 127.8, 128.8 (2C), 135.2, 135.6, 156.4, 159.4, 
167.35, 173.1; HRMS-ESI: [M+Na]
+
, calcd for C26H30N2NaO5S
+
 505.1768, 
found 505.1757. 
Ethyl (E)-2-((S)-1'-benzyl-1-((R)-tert-butylsulfinyl)-5'-chloro-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙3k). Prepared 
according to GP-B using VI∙1k and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 43 
mg, 59%; pale yellow foam; [α]D25 = - 29.8 (c 0.1, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 1.10 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H), 3.53 (dd, J = 15.9 
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and 1.8 Hz, 1H), 3.82 (dd, J = 15.9 and 1.8 Hz, 1H), 4.12 (m, 2H), 4.81 (d, 
J = 15.6 Hz, 1H), 5.00 (d, J = 15.6 Hz, 1H), 5.52 (t, J = 1.8 Hz, 1H), 6.63 
(d,  J = 8.4 Hz, 1H), 7.19 (dd, J = 8.4 and 2.1 Hz, 1H), 7.23-7.38 (m, 5H), 
7.48 (d, J = 2.1 Hz, 1H); 
13
C NMR (75 MHz, CDCl3) δ 14.4, 22.6 (3C), 
41.7, 44.3, 58.9, 59.7, 71.1, 94.5, 110.9, 125.4, 127.4 (2C), 128.1, 128.8, 
128.9 (2C), 130.6, 134.6, 135.2, 144.3, 158.9, 167.2, 174.8; HRMS-ESI: 
[M+Na]
+
, calcd for C25H27ClN2NaO4S
+
 509.1272, found 509.1279. 
Ethyl (E)-2-((S)-1'-benzyl-1-((R)-tert-butylsulfinyl)-5'-fluoro-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙3l). Prepared 
according to GP-B using VI∙1l and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 33 
mg, 47%; pale yellow foam; [α]D25 = - 82.4 (c 0.4, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 1.14 (s, 9H), 1.28 (t, J = 7.1 Hz, 3H), 3.57 (dd, J = 15.9 
and 1.9 Hz, 1H), 3.86 (dd, J = 15.9 and 1.9 Hz, 1H), 4.18  (m, 2H), 4.87 
(d, J = 15.6 Hz, 1H), 5.04 (d, J = 15.6 Hz, 1H), 5.56 (t, J = 1.9 Hz, 1H), 
6.68 (dd, J = 8.6 and 3.9 Hz, 1H), 6.97 (td, J = 8.8 and 2.6 Hz, 1H), 
7.26-7.41 (m, 6H); 
13
C NMR (101 MHz, CDCl3) δ 14.4, 22.6 (3C), 41.9, 
44.4, 58.9, 59.7, 70.9, 94.4, 110.6 (d, J = 7.7 Hz), 113.1 (d, J = 24.5 Hz), 
117.2 (d, J = 23.0 Hz), 127.5 (2C), 127.6, 128.1, 129.0 (2C), 134.8, 138.2, 
158.2, 159.8 (d, J = 150.3 Hz) , 167.2, 173.2; HRMS-ESI: [M+Na]
+
, calcd 
for C25H27FN2NaO4S
+
 493.1568, found 493.1559. 
Ethyl (E)-2-((S)-1'-benzyl-6'-bromo-1-((R)-tert-butylsulfinyl)-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙3m). Prepared 
according to GP-B using VI∙1m and VI∙2a. FC: CH2Cl2:EtOAc, 49:1; yield: 
56 mg, 71%; pale yellow foam; [α]D25 = - 43.7 (c 0.6, CHCl3); 1H NMR 
(300 MHz, CDCl3) δ 1.08 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H), 3.52 (dd, J = 
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15.9 and 1.9 Hz, 1H), 3.81 (dd, J = 15.9 and 1.9 Hz, 1H), 4.13 (m, 2H), 
4.81 (d, J = 15.6 Hz, 1H), 4.97 (d, J = 15.6 Hz, 1H),  5.52 (t,  J = 1.9 Hz, 
1H), 6.88 (m, br, 1H), 7.21 (dd, J = 8.0 and 1.6 Hz, 1H), 7.24-7.35 (m, 
5H), 7.37 (d, br,  J = 8.0 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 14.4, 22.6 
(3C), 41.8, 44.3, 58.8, 59.6, 70.6, 94.3, 113.2, 124.5, 124.7, 126.2, 126.4, 
127.5 (2C), 128.1, 129.0 (2C), 134.6, 143.6, 159.2, 167.2, 173.3; HRMS-ESI: 
[M+Na]
+
, calcd for C25H27BrN2NaO4S
+
 553.0767, found 553.0772. 
Benzyl (E)-2-((S)-1'-benzyl-1-((R)-tert-butylsulfinyl)-2'-oxospiro[azetidine-
2,3'-indolin]-4-ylidene)acetate (VI∙3n). Prepared according to GP-B using 
VI∙1a and VI∙2b. FC: CH2Cl2:EtOAc, 49:1; yield: 40 mg, 52%; pale orange 
foam;  [α]D25 = - 57.9 (c 0.4, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.11 (s, 
9H), 3.58 (dd, J = 15.9 and 1.9 Hz, 1H), 3.85 (dd, J = 15.9 and 1.9 Hz, 
1H), 4.87 (d, J = 15.6 Hz, 1H), 5.06 (d, J = 15.6 Hz, 1H), 5.17 (s, 2H), 
5.64 (t, J = 1.9 Hz, 1H), 6.76 (d, br, J = 8.1 Hz, 1H), 7.10 (td, J = 8.1 and 
1.0 Hz, 1H), 7.27 (td, J = 8.2 and 1.2 Hz, 1H), 7.28-7.43 (m, 10H), 7.53 
(dd, J = 8.1 and 1.0 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 22.7 (3C), 
41.8, 44.3, 58.8, 65.6, 71.1, 93.9, 109.8, 123.2, 125.2, 125.8, 127.6-128.9 
(10C), 130.8, 135.1, 136.5, 142.5, 160.0, 167.1, 173.3; HRMS-ESI: [M+Na]
+
, 
calcd for C30H30N2NaO4S
+
 537.1818, found 537.1811. 
 
Post-transformation reactions 
Ethyl (S,E)-2-(1'-benzyl-2'-oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate 
(VI∙4). To a solution of compound VI∙3a (0.11 mmol, 1.0 eq) in 1:1 mixture 
of anhydrous 1,4-dioxane and anhydrous MeOH (550 µL), HCl in dioxane 
(4 M solution, 0.44 mmol, 0.4 eq) was added. After the mixture was 
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stirred at room temperature for 1 h, all volatiles were removed under 
reduced pressure, and the residue was dissolved in water (2 mL) and 
extracted with EtOAc (1 x 1 mL). The water layer was basified to pH 8 with 
aqueous concentrated NH4OH and extracted with EtOAc (2 x 2 mL). 
Combined organic extracts were washed with brine, dried over Na2SO4, 
and concentrated under reduced pressure. The crude was purified by FC 
(CH2Cl2:EtOAc, 49:1) affording product VI∙4 as a pale orange foam (25 
mg, yield = 64%); [α]D25 = - 47.4 (c 0.9, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 1.28 (t, J = 7.1 Hz, 3H), 3.21 (d, br,  J = 14.2 Hz, 1H), 3.44 (dd, 
J = 14.1 and 2.8 Hz, 1H), 4.15 (m, 2H), 4.80 (s, br, 1H), 4.90 (d, J = 15.6 
Hz, 1H), 4.95 (d, J = 15.6 Hz, 1H), 6.76 (m, br, 1H), 6.78 (d, br, J = 7.8 
Hz, 1H), 7.11 (t, br, J = 7.7 Hz, 1H), 7.27 (td, J = 7.8 and 1.2 Hz, 1H), 
7.29-7.37 (m, 5H), 7.56 (d, br, J = 7.5 Hz, 1H); 
13
C NMR (101 MHz, 
CDCl3) δ 14.6, 41.6, 44.2, 59.0, 65.6, 83.6, 109.5, 123.4, 124.2, 127.4, 
127.5 (2C), 127.9, 128.9 (2C), 130.4, 135.4, 142.6, 162.7, 169.2, 175.1; 
HRMS-ESI: [M+Na]
+
, calcd for C21H20N2NaO3
+
 371.1366, found 371.1360. 
(S,E)-ethyl 2-(1'-benzyl-1-(tert-butylsulfonyl)-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙5). A solution of compound VI∙3a (0.11 
mmol, 1.0 eq) in anhydrous CH2Cl2 (1.1 mL, 0.1M) was cooled to 0°C, and 
m-CPBA (0.11 mmol, 1.0 eq) was added in small portions. Stirring was 
continued for 15 min, then the solution was diluted with CH2Cl2 (10 mL), 
and washed with a saturated aqueous solution of NaHCO3 (3 x 5 mL) and 
brine. The organic layer was dried over Na2SO4 and concentrated under 
reduced pressure. The crude was purified by FC (CH2Cl2:EtOAc, 49:1) 
affording product VI∙5 as a pale yellow foam (54 mg, yield = 99%); [α]D25 
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= + 20.5 (c 0.7, CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 1.27 (t, J = 7.1 Hz, 
3H), 1.33 (s, 9H), 3.44 (dd, J = 15.6 and 1.9 Hz, 1H), 3.71 (dd, J = 15.6 
and 1.9 Hz, 1H),4.16 (q, J = 7.1 Hz, 2H), 4.83 (d, J = 15.6 Hz, 1H), 5.04 
(d, J = 15.6 Hz, 1H), 5.68 (s, br, 1H), 6.69 (d, br, J = 7.8 Hz, 1H), 7.08 (t, 
br, J = 7.7 Hz, 1H), 7.19-7.38 (m, 6H), 7.50 (d, br, J = 7.8 Hz, 1H); 
13
C 
NMR (101 MHz, CDCl3) δ 14.5, 22.7 (3C), 41.8, 44.4, 58.9, 59.7, 70.6, 
94.3, 113.2, 124.6, 126.2, 126.4, 127.5 (2C), 128.2, 129.0 (3C), 134.6, 
143.6, 159.2, 167.3, 173.3; HRMS-ESI: [M+Na]
+
, calcd for C25H28N2NaO5S
+
 
491.1611, found 491.1604. 
(S)-1'-benzyl-1-((R)-tert-butylsulfinyl)spiro[azetidine-2,3'-indoline]-2',4-dione 
(VI∙6). A solution of compound VI∙3a (0.11 mmol, 1.0 eq) in anhydrous 
CH2Cl2 (13.75mL) was bubbled with ozone at -78°C for 10 minutes. Then 
Me2S (1.21 mmol, 11.0 mmol) was added at the same temperature and the 
reaction was warmed up to room temperature and stirred for 10 minutes. 
The solvent was evaporated under reduced pressure and the residue was 
purified by FC (CH2Cl2:EtOAc, 49:1) to afford compound VI∙6 as a pale 
yellow foam (45 mg, yield = 99%); [α]D25 = - 47.8 (c 0.05, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 1.23 (s, 9H), 3.37 (d, J = 15.1 Hz, 1H), 3.69 (d, 
J = 15.1 Hz, 1H), 4.93 (d, J = 15.6 Hz, 1H), 5.03 (d, J = 15.6 Hz, 1H), 
6.82 (d, br, J = 7.6 Hz, 1H), 7.14 (t, br, J = 7.6 Hz, 1H), 7.23-7.39 (m, 
6H), 7.50 (d, br, J = 7.6 Hz, 1H); 
13
C NMR (101 MHz, CDCl3) δ 22.6 (3C), 
44.4, 49.9, 59.2, 60.9, 109.9, 123.4, 124.3, 125.1, 127.5, 128.0 (2C), 128.9, 
130.6 (2C), 135.0, 142.5, 165.7, 173.4; HRMS-ESI: [M+Na]
+
, calcd for 
C21H22N2NaO3S
+
 405.1243, found 405.1251. 
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General procedure C (GP-C) for the synthesis of N-tert butanesulfonyl ketimines 
VI∙7a-j. To a solution of N-substituted isatin (1.17 mmol, 1.0 eq) in anhydrous 
CH2Cl2 (2.9 mL, 0.4 M), Ti(OiPr)4 (2.34 mmol, 2.0 eq) and 2- methyl-2-
propanesulfinamide (1.4 mmol, 1.2 eq) were added. The solution was refluxed 
until complete disappearance of the starting materials (monitored by TLC). The 
reaction was quenched by adding saturated aq. NaHCO3 (15 mL) and diluted 
with CH2Cl2 (15 mL). The biphasic solution was filtered through a pad of Celite 
and the organic phase washed with water (2 x 15 mL), dried over Na2SO4 and 
the solvent was evaporated under reduced pressure. The crude was purified by 
flash chromatography (FC), using Hexane/EtOAc/CH2Cl2 (gradient from 9:1:10 to 
5/5/10) as eluent. To a solution of the desired sulfinamide in CH2Cl2 (6 mL), m-
CPBA (1.5 equiv) was slowly added at room temperature and the mixture was 
stirred until completion of the reaction (monitored by TLC). The reaction was 
quenched by adding saturated aq. NaHCO3 (15 mL) and diluted with CH2Cl2 (15 
mL). The organic phase was washed with sat. NaHCO3 (2×40 mL), dried 
(Na2SO4), and concentrated. The corresponding sulfonamide was used without 
further purification. 
(E)-2-methyl-N-(2-oxo-1-tritylindolin-3-ylidene)propane-2-sulfonamide (VI∙7c). 
Prepared according to GP-C starting from N-trityl substituted isatin. Red foamy 
solid, yield: 97%.  
1
H NMR (300 MHz, CDCl3) δ 8.42 (d, J = 7.7 Hz, 1H), 7.49 
– 7.37 (m, 6H), 7.37 – 7.19 (m, 9H), 7.11 (t, J = 7.8 Hz, 1H), 6.97 (d, J = 7.8 
Hz, 1H), 6.35 (d, J = 7.8 Hz, 1H), 1.44 (s, 9H); 
13
C NMR (101 MHz, CDCl3) δ 
162.1, 151.5, 144.5, 141.7 (3C), 136.9,  130.1 (6C), 128.6 (6C), 128.0 (3C), 123.9, 
123.8, 117.9, 114.9, 75.9, 60.7, 24.5 (3C); HRMS (ESI): [M+Na]
+
, Calcd for 
C31H28N2NaO3S
+
 531.1716, found 531.1709. 
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(E)-2-methyl-N-(2-oxo-1-propylindolin-3-ylidene)propane-2-sulfonamide (VI∙7d). 
Prepared according to GP-C starting from N-propyl substituted isatin. Red foamy 
solid, yield: 95%. 
1
H NMR (300 MHz, , CDCl3, 7:3 mixture of two rotamers) δ 
8.40 (m, br, 0.3H), 8.06 (d, J = 7.8 Hz, 0.7H), 7.50 (t, J = 7.8 Hz, 0.3H), 7.45 
(t, J = 7.8 Hz, 0.7H), 7.11 (t, J = 7.8 Hz, 0.7H), 7.07 (t, J = 7.8 Hz, 0.3H), 
6.93 (d, J = 7.8 Hz, 0.7H), 6.82 (t, J = 7.8 Hz, 0.3H), 3.74 – 3.62 (m, 2H), 
1.74 (sext, br, J = 6.8 Hz, 2H), 1.62 (s, 6.3H), 1.60 (s, 2.7H), 0.99 (t, br, J = 6.8 
Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 162.6, 150.4, 147.4, 139.0 and 138.5 (1C), 
124.0 (2C), 116.2, 110..4 and 110.3 (1C), 60.6, 43.1 and 42.7 (1C), 24.5 (3C), 21.2 
and 20.8 (1C), 12.0; HRMS (ESI): [M+Na]
+
, Calcd for C15H20N2NaO3S
+
 331.1087, 
found 331.1096. 
(E)-2-(1-isopropyl-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfonamide 
(VI∙7e). Prepared according to GP-C starting from N-isopropyl substituted isatin. 
Red foamy solid, yield: 99%. 
1
H NMR (400 MHz, CDCl3, 17:3 mixture of two 
rotamers) δ 8.19 (dd, J = 7.8 and 1.7 Hz, 0.15H), 8.12 (dd, J = 7.8 and 1.7 Hz, 
0.85H), 7.76 (ddd, J = 8.2, 7.5 and 1.7 Hz, 0.15H), 7.73 (ddd, J = 8.2, 7.5 and 
1.7 Hz, 0.85H), 7.34 – 7.21 (m, 2H), 4.77 (hept, J = 6.8 Hz, 1H), 1.62 (d, J = 
6.9 Hz, 6H), 1.62 (s, 1.35H) 1.57 (s, 7.65H); 
13
C NMR (101 MHz, CDCl3) δ 162.6, 
158.0, 149.9, 138.9 and 138.5 (1C), 124.9 and 124.7 (1C), 124.0 and 123.7 (1C), 
113.3, 112.0 and 111.3 (1C), 60.0, 45.7 and 45.5 (1C), 24.7 and 24.5 (3C), 19.9 
(2C); HRMS (ESI): [M+Na]
+
, Calcd for C15H20N2NaO3S
+
 331.1087, found 
331.1081. 
(E)-2-methyl-N-(2-oxo-1-phenylindolin-3-ylidene)propane-2-sulfonamide (VI∙7f). 
Prepared according to GP-C starting from N-phenyl substituted isatin. Red foamy 
solid, yield: 98%. 
1
H NMR (400 MHz, CDCl3, 7:3 mixture of two rotamers) δ 
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8.21 (dd, J = 7.9 and 1.4 Hz, 0.7H), 8.00 (d, br, J = 7.9 Hz, 0.3H), 7.69 - 7.53 
(m, 4H), 7.44 (t, J = 7.8 Hz, 0.3H), 7.41 – 7.26 (m, 2.7H), 6.58 (d, J = 7.8 Hz, 
1H), 1.47 (s, 9H);
 13
C NMR (101 MHz, CDCl3) δ 162.2, 150.9, 143.1, 138.5 and 
137.5 (1C), 133.7, 130. 6(3C), 129.6 and 129.5 (2C), 127.1, 125.0 and 124.7 (1C), 
115.9, 111.4, 60.8, 24.9-24.5(3C); HRMS (ESI): [M+Na]
+
, Calcd for 
C18H18N2NaO3S
+
 365.0930, found 365.0939. 
(E)-N-(1-benzyl-5-methoxy-2-oxoindolin-3-ylidene)-2-methylpropane-2-
sulfonamide (VI∙7g). Prepared according to GP-C starting from 5-OMe-N-benzyl 
substituted isatin. Red foamy solid, yield: 98%. 
1
H NMR (400 MHz, CDCl3) δ 
7.42 – 7.26 (m, 6H), 6.99 (dd, J = 8.2 and 2.6 Hz, 1H), 6.62 (d, J = 8.3 Hz, 
1H), 4.89 (s, 2H), 3.79 (s, 3H), 1.64 (s, 9H); 
13
C NMR (101 MHz, CDCl3) δ 162.7, 
156.7, 145.2, 144.1, 135.3, 129.7 (2C), 128.8, 128.0 (2C), 126.7, 125.6, 116.7, 
111.9, 60.7, 56.7, 44.9, 24.6 (3C); HRMS (ESI): [M+Na]
+
, Calcd for 
C20H22N2NaO4S
+
 409.1192, found 409.1186. 
(E)-N-(1-benzyl-5-chloro-2-oxoindolin-3-ylidene)-2-methylpropane-2-sulfonamide 
(VI∙7h). Prepared according to GP-C starting from 5-Cl-N-benzyl substituted 
isatin. Red foamy solid, yield: 92%. 
1
H NMR (400 MHz, CDCl3, 4:1 mixture of 
two rotamers) δ 7.42 - 7.26  (m, 7H), 6.76 (d, J = 8.2 Hz, 0.2H), 6.68 (d, J = 
8.2 Hz, 0.8H), 4.93 (s, 2H), 1.67 (s, 1.8H), 1.65 (s, 7.2H); 
13
C NMR (101 MHz, 
CDCl3) δ 161.2, 148.2, 145.6, 138.3 and 137.9 (1C), 134.7, 130.7 and 129.8(2C), 
129.9, 129.0 (2C), 128.0 (2C), 116.9, 112.2, 63.9, 45.5 and 45.0 (1C), 24.6 and 
24.5 (3C); HRMS (ESI): [M+Na]
+
, Calcd for C19H19ClN2NaO3S
+
 413.0697, found 
413.0674. 
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General procedure D (GP-D) for enantioselective formal [2+2] annulation 
reaction for the synthesis of compounds VI∙11a-k. To a solution of the 
proper N-tert butanesulfonyl ketimine VI∙7a-j (0.10 mmol) and catalyst 
VI∙10g (0.02 mmol) in THF (1.5 mL), allenoate VI∙2a (or 2b, for 
spiroazetidine VI∙11k) was added (0.20 mmol). The mixture was stirred at 
room temperature and the conversion was monitored by TLC. The solvent 
was evaporated under reduced pressure and the crude was purified by FC, 
using CH2Cl2/EtOAc 9/1 as eluent. 
(S,E)-ethyl-2-(1'-benzyl-1-(tert-butylsulfonyl)-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙11a). Prepared according to GP-D using imine 
VI∙7a and allenoate VI∙2a. Pale orange foam; yield: 90%. 1H NMR (300 
MHz, CDCl3) δ 7.50 (d, br, J = 7.8 Hz, 1H), 7.19-7.38 (m, 6H), 7.08 (t, br, 
J = 7.7 Hz, 1H), 6.69 (d, br, J = 7.8 Hz, 1H), 5.68 (s, br, 1H), 5.04 (d, J = 
15.6 Hz, 1H), 4.83 (d, J = 15.6 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.71 (dd, 
J = 15.6 and 1.9 Hz, 1H), 3.44 (dd, J = 15.6 and 1.9 Hz, 1H), 1.33 (s, 9H), 
1.27 (t, J = 7.1 Hz, 3H);  
13
C NMR (101 MHz, CDCl3) δ 173.3, 167.3, 159.2, 
143.6, 134.6, 129.0 (3C), 128.2, 127.5 (2C), 126.4, 126.2, 124.6, 113.2, 
94.3, 70.6, 59.7, 58.9, 44.4, 41.8, 22.7 (3C), 14.5; [α]D25= + 12.2 (c 0.90, 
CHCl3); HRMS (ESI): [M+Na]
+
, Calcd for C25H28N2NaO5S
+
 491.1611, found 
491.1604; enantiomeric ratio: 80:20 , determined by HPLC (C-AD, 
Hexane/iPrOH 7:3, flux: 0.7 mL/min, λ = 254 nm): tR =  16.80 min 
(major) tR = 23.38 min (minor). 
(S,E)-ethyl 2-(1-(tert-butylsulfonyl)-1'-methyl-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (6b).  Prepared according to GP-D using imine VI∙7b 
and allenoate VI∙2a. Pale orange foam; yield: 91%. 1H NMR (400 MHz, 
 
Formal [2+2] Annulation Reaction 
- 178 - 
 
CDCl3) δ 7.50 (d, J = 7.5 Hz, 1H), 7.38 (d, J = 7.5 Hz, 1H), 7.12 (t, J = 
7.5 Hz, 1H), 6.86 (d, J = 7.5 Hz, 1H), 5.66 (t, J = 1.9 Hz, 1H), 4.16 (q, J = 
7.1 Hz, 2H), 3.66 (dd, J = 16.0, 1.9 Hz, 1H), 3.41 (dd, J = 16.0, 1.9 Hz, 
1H), 3.24 (s, 3H), 1.32 (s, 9H), 1.23 – 1.30 (m, 3H); 13C NMR (101 MHz, 
CDCl3) δ 173.3, 167.7, 159.4, 144.7, 131.8, 125.9, 125.0, 123.7, 109.5, 95.9, 
71.7, 62.2, 60.5, 39.8, 27.3, 24.5 (3C), 15.0; [α]D25= + 19.3 (c 0.80, 
CHCl3); HRMS (ESI): [M+Na]
+
, Calcd for C19H24N2NaO5S
+
: 415.1298, 
found 415.1303; enantiomeric ratio: 83:17, determined by HPLC (C-AD, 
Hexane/iPrOH 7:3, flux: 0.7 mL/min, λ = 254 nm): tR = 24.96 min 
(major) tR = 29.58 min (minor). 
(S,E)-ethyl 2-(1-(tert-butylsulfonyl)-2'-oxo-1'-tritylspiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙11c). Prepared according to GP-D using imine 
VI∙7c and allenoate VI∙2a. Pale orange foam; yield: 95%. 1H NMR (300 
MHz, CDCl3) δ 7.39 – 7.50 (m, 7H), 7.14 – 7.30 (m, 9H), 6.89 – 7.03 (m, 
2H), 6.28 (d, J = 7.4 Hz, 1H), 5.62 (t, J = 1.9 Hz, 1H), 4.05 – 4.19 (m, 
2H), 3.58 (dd, J = 15.7, 1.9 Hz, 1H), 3.31 (dd, J = 15.7, 1.9 Hz, 1H), 1.34 
(s, 9H), 1.20 – 1.30 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 172.8, 167.1, 
158.9, 143.9, 141.6 (3C), 129.5 (7C), 127.6 (6C), 127.0 (3C), 125.6, 123.9, 
122.5, 116.6, 94.9, 74.9, 71.6, 61.7, 59.8, 40.1, 24.0 (3C), 14.4; [α]D25= - 
0.67 (c 1.5, CHCl3); HRMS (ESI): [M+Na]
+
, Calcd for C37H36N2NaO5S
+
: 
643.2237, found 643.2240; enantiomeric ratio: 71:29, determined by 
HPLC (C-AD, Hexane/iPrOH 7:3, flux: 0.7 mL/min, λ = 254 nm): tR = 
8.00 min (major) tR = 11.84 min (minor). 
(S,E)-ethyl 2-(1-(tert-butylsulfonyl)-2'-oxo-1'-propylspiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙11d). Prepared according to GP-D using imine 
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VI∙7d and allenoate VI∙2a. Pale orange foam; yield: 77%. 1H NMR (300 
MHz, CDCl3) δ 7.49 (d, J = 7.4 Hz, 1H), 7.35 (td, J = 7.4 and 1.1 Hz, 1H), 
7.10 (t, J = 7.4 Hz, 1H), 6.86 (d, J = 7.4 Hz, 1H), 5.65 (t, J = 1.9 Hz, 1H), 
4.15 (q, J = 7.1 Hz, 2H), 3.75 (dt, J = 14.6 and 6.8 Hz, 1H), 3.63 (dd, J = 
15.6 and 1.9 Hz, 1H), 3.58 (dt, J = 14.6 and 6.8 Hz, 1H), 3.39 (dd, J = 
15.6 and 1.9 Hz, 1H), 1.72 (sext, J = 6.8 Hz, 2H), 1.32 (s, 9H), 1.27 – 1.22 
(m, 3H) 0.97 (t, J = 6.8 Hz, 3H);
 13
C NMR (101 MHz, CDCl3) δ 173.1, 
167.8, 159.6, 142.9, 131.6, 126.2, 125.1, 123.5, 109.8, 95.7, 71.8, 60.5, 
42.7, 40.0, 30.4, 24.6 (3C), 21.2, 15.1, 12.0; [α]D25 = + 5.5 (c 1.02, 
CHCl3); HRMS (ESI) calculated for C21H28N2NaO5S
+ 
[M+Na]
+
 443.1611, 
found 443.1617; enantiomeric ratio: 78:22, determined by HPLC (C-AD, 
Hexane/iPrOH 7:3, flux: 0.7 mL/min, λ = 254 nm): tR = 7.73 min (major) 
tR = 9.85 min (minor). 
(S,E)-ethyl 2-(1-(tert-butylsulfonyl)-1'-isopropyl-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙11e). Prepared according to GP-D using imine 
VI∙7e and allenoate VI∙2a. Pale orange foam; yield: 93%. 1H NMR (300 
MHz, CDCl3) δ 7.49 (d, J = 7.7, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.08 (t, J = 
7.7 Hz, 1H), 6.99 (d, J =  7.7 Hz, 1H), 5.64 (t, J = 2.0 Hz, 1H), 4.56 
(hept, J = 6.8 Hz, 1H), 4.15 (q, J = 7.6 Hz, 2H), 3.64 (dd, J = 15.9 and 
2.0 Hz, 1H), 3.40 (dd, J = 15.9, 2.0 Hz, 1H), 1.50 (d, J = 6.8, 3H), 1.48 
(d, J = 6.8, 3H), 1.30 (s, 9H), 1.26 (t, J = 7.6 Hz, 3H); 
13
C NMR (101 
MHz, CDCl3) δ 172.4, 167.2, 159.1, 143.2, 130.9, 125.6, 124.8, 122.5, 
110.4, 95.0, 71.1, 61.5, 59.9, 44.7, 39.1, 23.9 (3C), 19.2 (2C), 14.5; [α]D25 = 
+ 14.7 (c 0.99, CHCl3); HRMS (ESI) calculated for C21H28N2NaO5S
+ 
[M+Na]
+
 443.1611, found 443.1616; enantiomeric ratio 82:18, determined 
 
Formal [2+2] Annulation Reaction 
- 180 - 
 
by HPLC (C-AD, Hexane/iPrOH 7:3, flux: 0.7 mL/min, λ = 254 nm): tR = 
7.32 min (major) tR = 9.33 min (minor). 
(S,E)-ethyl 2-(1-(tert-butylsulfonyl)-2'-oxo-1'-phenylspiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙11f). Prepared according to GP-D using imine 
VI∙7f and allenoate VI∙2a. Pale orange foam; yield: 82%. 1H NMR (300 
MHz, CDCl3) δ 7.64 – 7.39 (m, 6H), 7.30 (t, J = 7.8 Hz, 1H), 7.15 (t, J = 
7.8 Hz, 1H), 6.83 (d, J = 7.8 Hz, 1H), 5.68 (t, J = 2.0 Hz, 1H), 4.17 (q, J 
= 7.2 Hz, 2H), 3.77 (dd, J = 16.0, 2.0 Hz, 1H), 3.52 (dd, J = 16.0, 2.0 
Hz, 1H), 1.33 (s, 9H), 1.27 (t, J = 7.2 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) 
δ 172.3, 167.2, 158.9, 144.6, 134.0, 131.2, 129.8 (2C), 128.5, 126.6 (2C), 
125.8, 124.9, 123.5, 110.2, 95.4, 71.3, 61.6, 60.0, 39.2, 24.0 (3C), 14.5; 
[α]D25 = + 10.3 (c 1.04, CHCl3); HRMS (ESI) calculated for C24H26N2NaO5S+ 
[M+Na]
+
 477.1455, found 447.1460; enantiomeric ratio: 77:23, 
determined by HPLC (C-AD, Hexane/iPrOH 4:1, flux: 0.7 mL/min, λ = 254 
nm): tR = 9.63 min (major) tR = 14.79 min (minor). 
(S,E)-ethyl 2-(1'-benzyl-1-(tert-butylsulfonyl)-5'-methoxy-2'-
oxospiro[azetidine-2,3'-indolin]-4-ylidene)acetate (VI∙11g). Prepared 
according to GP-D using imine VI∙7g and allenoate VI∙2a. Pale orange foam; 
yield: 89%. 
1
H NMR (400 MHz, CDCl3) δ 7.38 – 7.27 (m, 5H), 7.12 (d, J 
= 2.7 Hz, 1H), 6.78 (dd, J = 8.4 and 2.7 Hz, 1H), 6.60 (d, J = 8.4 Hz, 
1H), 5.71 (t, J = 1.9 Hz, 1H), 5.05 (d, J = 15.8 Hz, 1H), 4.81 (d, J = 15.8 
Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 3.78 (s, 3H), 3.75 (dd, J = 15.9 and 1.9 
Hz, 1H), 3.45 (dd, J = 15.9 and 1.9 Hz, 1H), 1.38 (s, 9H), 1.30 (t, J = 7.2 
Hz, 3H); 
13
C NMR (101 MHz, CDCl3) δ 172.5, 167.1, 158.8, 156.4, 136.4, 
135.2, 128.8 (2C), 127.7, 127.3 (2C), 127.0, 115.4, 111.4, 110.5, 95.2, 71.5, 
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61.8, 59.9, 55.9, 44.3, 39.7, 24.0 (3C), 14.4; [α]D25 = + 8.9 (c 0.95, 
CHCl3); HRMS (ESI) calculated for C26H30N2NaO5S
+ 
[M+Na]
+
 521.1717, 
found 521.1720; enantiomeric ratio: 76:24, determined by HPLC (C-AD, 
Hexane/iPrOH 4:1, flux: 0.7 mL/min, λ = 254 nm): tR = 15.00 min (major) 
tR = 20.63 min (minor). 
(S,E)-ethyl 2-(1'-benzyl-1-(tert-butylsulfonyl)-5'-chloro-2'-oxospiro[azetidine-
2,3'-indolin]-4-ylidene)acetate (VI∙11h). Prepared according to GP-D using 
imine VI∙7h and allenoate VI∙2a. Pale orange foam; yield: 26%. 1H NMR 
(400 MHz, CDCl3) δ 7.52 (d, J = 2.1 Hz, 1H), 7.38 – 7.26 (m, 5H), 7.23 
(dd, J = 8.2 and 2.1 Hz, 1H), 6.63 (d, J = 8.2 Hz, 1H), 5.71 (t, J = 2.1 Hz, 
1H), 5.07 (d, J = 16.0 Hz, 1H), 4.82 (d, J = 16.0 Hz, 1H), 4.20 (q, J = 7.1 
Hz, 2H), 3.74 (dd, J = 15.9 and 2.1 Hz, 1H), 3.47 (dd, J = 15.9 and 2.1 
Hz, 1H), 1.39 (s, 9H), 1.31 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 MHz, CDCl3) 
δ 172.4, 166.9, 158.2, 141.6, 136.7, 134.6, 130.8, 129.0 (2C), 128.7, 127.9, 
127.2 (2C), 124.7, 111.0, 95.6, 70.7, 61.8, 60.0, 44.4, 39.5, 23.9 (3C), 
14.4; [α]D25 = + 9.8 (c 1.05 , CHCl3); HRMS (ESI) calculated for 
C25H27ClN2NaO5S
+
 [M+Na]
+
 525.1221, found 525.1229; enantiomeric 
ratio: 72:28, determined by HPLC (C-AD, Hexane/iPrOH 4:1, flux: 0.7 
mL/min, λ = 254 nm): tR = 10.31 min (major) tR = 16.59 (minor). 
(S,E)-Benzyl-2-(1'-benzyl-1-(tert-butylsulfonyl)-2'-oxospiro[azetidine-2,3'-
indolin]-4-ylidene)acetate (VI∙11k). Prepared according to GP-D using imine 
VI∙7a and allenoate VI∙2b. Pale yellow foam; yield: 80%. 1H NMR (400 
MHz, CDCl3) δ 7.53 (d, br, J = 7.8 Hz, 1H), 7.44-7.23 (m, 11H), 7.11 (t, br, 
J = 7.7 Hz, 1H), 6.72 (d, br, J = 7.8 Hz, 1H), 5.78 (s, br, 1H), 5.19 (s, br, 
2H), 5.08 (d, J = 15.8 Hz, 1H), 4.84 (d, J = 15.8 Hz, 1H), 3.74 (d, br, J = 
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16.0 Hz, 1H), 3.47 (d, br, J = 16.0 Hz, 1H), 1.36 (s, 9H); 
13
C NMR (101 
MHz, CDCl3) δ 173.4, 167.5, 160.0, 143.9, 136.9, 135.7, 131.7, 129.5 (3C), 
129.3, 129.0, 128.8, 128.4 128.0 (3C), 126.0, 125.1, 123.8, 110.7, 95.5, 
71.8, 66.6, 62.3, 44.9, 40.3, 24.6 (3C); [α]D25 = + 15.0 (c 0.8, CHCl3); 
HRMS (ESI): [M+Na]
+
, Calcd for C30H30N2NaO5S
+
 553.1768, found 
553.1772; enantiomeric ratio: 78:22, determined by HPLC (C-AD, 
Hexane/iPrOH 7:3, flux: 0.7 mL/min, λ = 254 nm): tR =  16.80 min 
(major) tR = 23.38 min (minor).  
 
Post-transformation reactions 
(S,E)-2-(1'-benzyl-1-(tert-butylsulfonyl)-2'-oxospiro[azetidine-2,3'-indolin]-4-
ylidene)acetic acid (VI∙15). 
To a solution of VI∙11a (0.21 mmol) in water/THF/iPrOH (1:1:1, 1.5 mL), 
LiOH (0.63 mmol) was added and the mixture was stirred at room 
temperature. After the completion of the reaction (monitored by TLC), the 
reaction mixture was quenched with a 1M aqueous solution of HCl and 
extracted with CH2Cl2. The organic layer was collected, dried over 
anhydrous sodium sulfate, and concentrated under reduced pressure 
affording the product as a white foam (quantitative yield). 
1
H NMR (400 
MHz, CDCl3) δ 7.54 (d, J = 7.4 Hz, 1H), 7.41 – 7.23 (m, 6H), 7.12 (t, J = 
7.4 Hz, 1H), 6.73 (d, J = 7.4 Hz, 1H), 5.71 (t, J = 1.9 Hz, 1H), 5.07 (d, J = 
15.8 Hz, 1H), 4.87 (d, J = 15.8 Hz, 1H), 3.76 (dd, J = 16.3 and 2.0 Hz, 
1H), 3.49 (dd, J = 16.3 and 2.0 Hz, 1H), 2.05 (m, br, 1H), 1.37 (s, 9H); 
13
C 
NMR (101 MHz, CDCl3) δ 172.6, 172.5, 161.3, 143.2, 135.0, 131.1, 128.9 
(2C), 127.8, 127.3 (2C), 125.1, 124.4, 123.2, 110.1, 94.4, 71.2, 61.8, 44.3, 
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39.7, 23.9 (3C); [α]D25 = + 5.7 (c 0.79, CHCl3); HRMS (ESI) calculated for 
C23H24N2NaO5S
+
 [M+Na]
+
 463.1298, found 463.1289.  
(S)-Ethyl 1-benzyl-1'-(tert-butylsulfonyl)-2-oxo-1',3'-dihydrospiro[indoline-
3,2'-pyrrole]-4'-carboxylate (VI∙16). To a stirred solution of VI∙11a (0.21 
mmol) in CH2Cl2 (9 mL) at 0 °C, CF3SO3H (0.68 mmol) was added. After 
stirring at 0 °C for 2 h, the mixture was neutralized with 0.1 M NaOH and 
extracted with CH2Cl2 (4 × 15 mL). The combined organic phases were 
dried (MgSO4) and concentrated in vacuo, affording the product as a white 
foam (quantitative yield). 
1
H NMR (400 MHz, CDCl3) δ 7.56 (d, br, J = 
7.8 Hz, 1H), 7.40-7.25 (m, 6H), 7.05 (t, br, J = 7.7 Hz, 1H), 6.79 (d, br, J 
= 7.8 Hz, 1H), 6.15 (s, br, 1H), 4.97 (d, J = 15.5 Hz, 1H), 4.91 (d, J = 15.5 
Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.49 (d, br, J = 16.4 Hz, 1H), 2.63 (d, 
br, J = 16.4 Hz, 1H), 1.46 (s, 9H), 1.38 (t, J = 7.1 Hz, 3H); 
13
C NMR (101 
MHz, CDCl3) δ 171.1, 170.5, 169.7, 142.3, 134.7, 131.6, 129.1 (2C), 128.1, 
127.3 (2C), 126.4, 125.1, 124.0, 81.2, 79.7, 66.6, 58.5, 44.2, 38.4, 24.0 
(3C), 14.2; [α]D25 = + 6.3 (c 0.53, CHCl3); HRMS (ESI): [M+Na]+, Calcd 
for C25H28N2NaO5S
+
 491.1611, found 491.1617.  
(S)-ethyl 4-(1-benzyl-3-(1,1-dimethylethylsulfonamido)-2-oxoindolin-3-yl)-3-
oxobutanoate (VI∙17). To a solution of VI∙11a (0.20 mmol) in trifluoroacetic 
acid (5 mL) and CH2Cl2 (2 mL), anisole (4 mmol) was added, and the 
mixture was stirred for 1h at 60 
o
C. To this saturated Na2CO3 was added 
and organic materials were extracted with EtOAc. Dried and concentrated 
extract was subjected to FC (Hexane/ EtOAc 1/1) to give the product as a 
pale yellow foam (yield: 65%). 
1
H NMR (400 MHz, CDCl3) δ 7.57 (d, br, J 
= 7.8 Hz, 1H), 7.43-7.24 (m, 5H), 7.21 (t, br, J = 7.7 Hz, 1H), 7.04 (t, J = 
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7.7 Hz, 1H), 6.72 (d, br, J = 7.8 Hz, 1H), 5.75 (s, br, 1H), 5.04-4.90 (m, 
2H), 4.15 (q, J = 7.1 Hz, 2H), 3.60 (d, J = 17.4 Hz, 1H), 3.47-3.38 (m, 
2H), 3.07 (d, J = 17.4 Hz, 1H),  1.34 (s, 9H), 1.22 (t, J = 7.1 Hz, 3H); 
13
C 
NMR (101 MHz, CDCl3) δ 201.0, 174.7, 166.1, 142.4, 135.6, 129.7, 128.8 
(2C), 128.7, 127.7, 127.3 (2C), 125.3, 122.9, 109.7, 61.7, 60.6, 60.3, 50.1, 
49.2, 44.4, 24.1 (3C), 14.0; [α]D25 = - 57.4 (c 0.50, CHCl3); HRMS (ESI): 
[M+Na]
+
, Calcd for C25H30N2NaO6S
+
 509.1717, found 509.1711. 
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VII. Conclusion and Future Perspective 
 
In conclusion, I exploited the potentialities of various convergent approaches, 
mostly based on multicomponent reactions (MCRs), for the synthesis of small 
libraries of highly functionalized oxindoles, also taking into particular attention 
the issue of stereochemical induction. 
I successfully applied BINOL-derived phosphoric acids to the vinylogous-Mannich 
reaction between trimethylsiloxyfuran and isatin-derived ketimines, obtaining a 
small library of chiral quaternary 3-aminooxindole butenolides. Unable to obtain 
good crystals for the X-ray analysis, the configurational assignment of the 
obtained compounds was performed by chemical correlation. For this project, a 
computational study of the transition state allowed to rationalize the 
stereochemical outcome, highlighting the possible binding modes of the catalyst-
imine-nucleophile transition complex. 
Still aiming to combine MCRs with asymmetric organocatalysis, I developed the 
first BINOL-derived phosphoric acid catalysed Biginelli-like reaction on a ketone. 
In particular, I achieved the synthesis of a small library of biologically relevant 
enantioenriched spiro[indoline-pyrimidine]-diones derivatives by employing N-
substituted isatins as carbonyl substrates. The assignment of the configuration at 
the new oxindole C-3 stereocenter was assessed through quantum-mechanical 
methods and NMR spectroscopy, while computational studies on the reaction 
transition state allowed to rationalize the enantioselectivity and the 
stereochemical outcome. 
In the context of diversity-oriented synthesis, I focused my attention on the 
possibility of combining two diverse MCRs, namely Asinger and Ugi-type 
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reactions. In particular, I developed the first Asinger reaction involving isatin as 
the oxo component and leading to large a family of spirooxindole-fused 3-
thiazoline derivatives. The resulting thiazolines proved to be optimal substrates 
for Ugi-Joullié 3-CR and azido-Ugi 3-CR reactions leading to spirooxindole-fused 
3-thiazolidine-carboxamide and tetrazole-containing derivatives, respectively. 
These reactions were surprisingly high trans-diasteroselective due to a particular 
envelope-like conformation of the spirothiazoline. The relative stereochemistry 
was confirmed for both classes of products by X-ray analysis and some post-
transformations were also performed, in order to increase the chemical diversity.   
Finally, I explored the synthesis of enantiopure compounds bearing the small-size 
azetidine ring spiro-fused with the oxindole moiety. In this work, I developed the 
first effective application of chiral imines for the preparation of 
methyleneazetidines. In particular the suitability of chiral, isatin-derived tert-
butanesulfinyl ketimines for a diastereoselective [2+2] annulation-based strategy, 
is fully demonstrated for the first time. Considering the importance of asymmetric 
catalytic approaches over chiral auxiliary strategies, I also successfully investigated 
the possibility of carrying out the synthesis of such spirooxindole-fused 4-
methyleneazetidines in an enantioenriched form, by using cinchona-based 
catalysts. 
In my opinion, the results presented here clearly highlight the high potential of 
the multicomponent approach when applied to the synthesis of small libraries of 
oxindole-based products. To this regard, the discovery of novel MCRs, as well as 
their combination with asymmetric organocatalysis, will be the key point in the 
next future of this rapidly growing research area. 
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Most of the compound libraries presented in this thesis have been submitted to a 
preliminary computational and biological evaluation, in collaboration with 
Merck Pharma. 
 
